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Abstract 
Muscarinic acetylcholine receptors (M1-M5) belong to the class A family of 
transmembrane G protein coupled receptors (GPCRs) and mediate various signalling 
processes. M1, M3 and M5 predominantly couple to Gq and promote intracellular calcium 
ion release from the endoplasmic reticulum. M2 and M4 preferentially couple Gi inhibiting 
adenylyl cyclase activity to thus decrease cAMP production and acting to regulate various 
ion channels. There is growing evidence that many GPCRs can exist as dimers or higher-
order oligomers (Milligan, 2013) and muscarinic receptors are no exception (Alvarez-
Curto et al., 2010). Herein, combinations of homomers and heteromers of co-expressed 
human M2 (hM2WT) and a RASSL (Receptor Activated Solely by Synthetic Ligand) form 
of the human M3 receptor (hM3RASSL) (Alvarez-Curto et al., 2011) were demonstrated to 
occur using N-terminal SNAP and CLIP tags in combination with homogeneous time 
resolved FRET (htrFRET).  
Stable Flp-In™ T-REx™ 293 cell lines able to inducibly express each of these receptor 
forms upon addition of doxycycline, and a cell line able to express both the hM3RASSL 
constitutively and hM2WT in a doxycycline inducible manner were generated. In these 
cells both hM3RASSL and hM2WT were detected after treatment with different 
concentrations of doxycycline via Western blots using tag-specific antibodies. Radioligand 
binding using [3H]-QNB indicated that similar amounts of hM2WT and hM3RASSL were 
expressed following induction with 5 ng.ml-1 doxycycline in the cells co-expressing the 
two receptors. Expression of the receptors was observed at the surface of live cells 
following labelling of the expressed receptors with SNAP and CLIP-specific cell 
impermeant substrates. Following induction with doxycycline each of hM2WT and 
hM3RASSL homomers and hM2WT-hM3RASSL heteromers were identified. Detection of 
oligomers was achieved following co-labelling with htrFRET-compatible substrates. 
Occupancy of hM2WT-hM3RASSL heteromers with the hM2WT agonist carbachol 
resulted in a marked, time and concentration-dependent decrease in detected heteromers 
and a concomitant, concentration-dependent increase in hM2WT homomers. The dynamics 
of interchange between heteromers and homomers was investigated by using a multiplex 
labelling approach and htrFRET. This method involved labelling with one energy donor 
and two energy acceptors capable of emitting at distinct wavelengths. Results confirmed 
the hM2WT-hM3RASSL heteromer to hM2WT homomer transition upon selective 
carbachol-mediated activation of hM2WT. A small increase in the hM3RASSL homomer 
was detected upon activation of the hM3RASSL with the selective agonist clozapine-N-
oxide, but this was only observed in the absence of heteromers.  
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 Despite the presence of hM2WT-hM3RASSL heteromers the functional pharmacology of 
hM2WT and hM3RASSL receptor specific agonists was largely unaltered.
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1.1 G protein-coupled receptors 
 
G protein-coupled receptors (GPCRs) are a large and diverse family of plasma membrane 
proteins. They are highly conserved throughout evolution with approximately 1-2% of the 
human genome encoding for GPCRs. The evolution of multicellular organisms was partly 
dependent on the successful evolution of GPCRs, being able to transduce extracellular 
signals to intracellular functions, and thus, enabling cells to communicate with each other 
and with their environment (Bockaert and Pin, 1999). GPCRs are present in insects (Hill et 
al., 2002) and plants (Insel et al., 2012) and thus are considered to be of ancient origin 
(Perez, 2005). They are also present in nematodes with the C.elegans genome encoding 
more than 1000 GPCRs (Bargmann, 1998), in yeast (Versele et al., 2001) and protozoa 
(Vernier et al., 1995). 
GPCRs are recognised by a  vast variety of ligands, including ions, odorants, lipids, 
photons, amino acids, hormones and polypeptides (Kobilka, 2007) and are involved in 
several cell signalling transduction pathways that regulate numerous important cellular 
processes (Lagerstrom and Schioth, 2008), thus possessing a vital role in sensing 
environmental changes (Goddard and Watts, 2012). GPCR function is implicated in the 
regulation of various physiological systems and disease states such as cancer, pain, 
cardiovascular disorders, gastrointestinal disorders and conditions of the central nervous 
system. The complex signalling pathways that are mediated via GPCR activation, the 
generation of cell-based functional assays in combination with traditional radioligand 
binding assays and the novel structural information derived from crystal structures of 
several GPCRs have enabled the translation of fundamental biology into therapeutic 
applications (Milligan and McGrath, 2009). In addition, the cell membrane location of 
GPCRs and the diversity of tissue expression make GPCRs ideal targets for drug 
discovery. Not surprisingly, around 30% of drugs developed target GPCRs and there is still 
growing interest in this type of receptor both within the pharmaceutical industry and 
academia (Hill, 2006). Many diseases and disorders involving non-functional or 
constitutively activated receptors, changes in ligand binding specificity or improper 
receptor processing and cases where G proteins are inactive or constitutively active had 
generated the need for development of therapeutics to target either directly GPCRs or 
molecules that are involved in GPCR signalling pathways.  
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1.2 Structure of GPCRs 
GPCRs possess a characteristic seven trans-membrane (7-TM) architecture and therefore 
they are also known as 7-TM receptors. Each TM domain is composed of 25-30 amino 
acid residues with a relatively high degree of hydrophobicity. Other common features of 
GPCRs include an N-terminal extracellular domain and a C-terminal cytoplasmic domain. 
The seven transmembrane domains are α-helices connected by six loops, three of which 
are intracellular and three extracellular (Perez and Karnik, 2005). Different types of 
GPCRs demonstrate sequence variations and differences in the length and the function of 
N-terminal, C-terminal domains and the intracellular loops (Bockaert and Pin, 1999). The 
common structure of a GPCR is illustrated in Figure 1.1.  
 
 
Figure 1.1 Topographic structure of a GPCR. GPCRs are composed of 7 transmembrane 
domains that consist of α-helices (TM1-TM7), 3 extracellular loops (EL1-EL3), an extracellular 
amino terminus (N-terminus), 3 intracellular loops (IL1-IL3), with IL3 possessing a key role in G 
protein binding and activation, and an intracellular carboxyl domain (C- terminus). 
 
 
The majority of the information on GPCR structure was provided once the 3-D structure of 
rhodopsin was solved, by X-ray crystallography (Palczewski et al., 2000). Rhodopsin is a 
visual pigment located in the photoreceptor cells of retina and is responsible for converting 
photons into chemical signals (Zhou et al., 2012). The crystal structure of rhodopsin has 
served as a template for other GPCRs and the information obtained had greatly enriched 
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the understanding of GPCRs in terms of structure and function (Palczewski, 2006). The 
crystal structures of other GPCRs followed and these included the β1-adrenoceptor (Warne 
et al., 2008), β2-adrenoceptor (Rasmussen et al., 2007), A2A-adenosine receptor (Jaakola et 
al., 2008), the complex of β2-adrenoceptor with its G protein (Rasmussen et al., 2011), the 
human muscarinic M2 receptor (Haga et al., 2012) and the rat M3 receptor (Kruse et al., 
2012). The 7-TM domain of rhodopsin is composed of α-helices arranged in a barrel-
shaped, cylindrical formation connecting the three intracellular and three extracellular 
loops. The N-terminus is composed of a two-stranded β-sheet and it contains glycosylation 
sites (Asn2, Asn15) along with other amino acids that are important in the folding of the 
receptor (Thr4, Asn5, Thr17, Pro23, Asn28). The second extracellular loop (EL2) of 
rhodopsin extends between TM4 and TM5 and is crucial for ligand binding. The EL2 
consists of a two-stranded β-sheet which is positioned at the opening of the ligand binding 
pocket and serves as a ‘lid’ blocking the exit of the bound ligand from the pocket. The 
stability of the β-sheet is enhanced by hydrophobic interactions between certain residues 
(Tyr178, Pro180, Met183, Cys185 and Cys187), by hydrogen bonding network involving 
Glu181, Tyr192 of the sheet and Tyr268 of TM6, and by a disulphide bridge between 
Cys187 of the β-sheet and Cys110 located on TM3. The presence of a salt bridge between 
the two strands of the β-sheet formed by Asp190 and Arg177 further maintains the 
conformational stability of the ‘lid’ structure (Zhou et al., 2012). The ligand binding 
pocket is located on the extracellular part of the 7-TM domain and is surrounded by 
hydrophobic residues (Met207, Phe208, Phe212 on TM5 and Trp265, Tyr268 on TM6) 
stabilising the conformation which only undergoes dynamic changes upon receptor 
activation. Another salt bridge between Arg135 on TM3 and Glu247 on TM6 is formed 
and acts as an ionic lock blocking the G protein binding site of the receptor in its inactive 
conformation. The ionic lock breaks only upon photo-activation, with TM6 shifting away 
from the 7-TM core, thus creating a cavity on the cytoplasmic side of the receptor allowing 
for G protein binding and activation (Palczewski, 2006). A highly conserved NPXXY 
motif that is located on TM7 possesses a vital role in receptor activation through the 
shifting of the tyrosine residue towards TM6 further promoting the breakage of the ionic 
lock. The third intracellular loop (IL3) of rhodopsin is essential for interactions with G 
protein and arrestins. Lys296 acts as Schiff base to covalently link to 11-cis-retinal 
(prosthetic group), while Glu113 is essential for stabilising the interaction with the ligand 
(Palczewski, 2006). Other residues within the binding pocket of rhodopsin enable 11-cis-
retinal to act as an inverse agonist and prevent receptor activation until a photon is 
absorbed and photo-activation occurs (Tsutsui and Shichida, 2010).  Photo-activation 
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causes the isomerisation of 11-cis-retinal to the trans- isomer (trans-reinal), which is the 
full agonist of rhodopsin. The C-terminus of rhodopsin contains palmitoylation sites at 
residues Cys322 and Cys323, several serine and threonine residues that act as 
phosphorylation sites, and a VXPX motif important for receptor transport. Figure 1.2 
shows the crystal structure of rhodopsin.   
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Figure 1.2 Crystal structure of bovine rhodopsin. (A) The 3-D structure of rhodopsin showing 
the 7-TM domain forming a cylindrical structure, the extracellular N-terminus and the intracellular 
C-terminus. Residues that are involved in the binding pocket architecture are shown in yellow. The 
ionic lock and the NPXXY motif are also shown. (B) The 2-D structure of rhodopsin 
demonstrating some of the secondary structural features such as the disulphide bridge connecting 
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the EL2 with TM3. (C) The 3-D structure of the ligand binding pocket with EL2 acting as a ‘lid’ 
for the pocket (Figure taken from Zhou et al., 2012). 
 
 
A lot of the structural features of rhodopsin are conserved in other GPCRs, but some 
differences exist especially in the binding pocket and also in the mechanism of receptor 
activation. Activation of rhodopsin requires that the ligand remains tightly held in the 
pocket and this is achieved by the EL2 domain adopting a conformation forming a tight 
‘lid’ blocking the ligand in the pocket. Other GPCRs have a more flexible EL2 domain 
above the binding pocket (Zhou et al., 2012).  
Most GPCRs contain highly conserved disulphide bridges between cysteine residues in the 
EL2 and EL3, a bond that is essential for folding and packing of the receptor and for 
regulating the ligand binding site by stabilizing receptor conformation (Karnik and 
Khorana, 1990). The orthosteric binding site is often located deep in the pocket created by 
the TM domains. Based on biochemical and mutagenesis studies of the rhodopsin system 
and rhodopsin-like receptors, a switch from inactive to active conformation is associated 
with movement of the TM3 and TM6, upon ligand binding. The conformational changes 
namely the rotation of TM6 and the dissociation from TM3, in turns affect the 
conformation of the IL2 and IL3, making the G protein binding domain visible and 
available for recognition and binding by a G protein (Venkatakrishnan et al., 2013).  
Other ligand binding sites may exist, depending on the receptor and these are usually 
located on the extracellular loops. These differ from the orthosteric binding site and are 
called allosteric binding sites, allowing the binding of distinct ligands to the GPCR. The 
binding of allosteric ligands can influence the binding characteristics of orthosteric ligands 
and it may also induce activation of G-protein dependent pathways via GPCR allosteric 
activation (van der Westhuizen et al., 2015). 
 
               
1.3 Classification of GPCRs  
GPCRs are classified into six groups (A to F) based on sequence homology and are also 
classified according to the endogenous ligands they bind to (Cherezov et al., 2007). The A-
F classification system covers all GPCRs and some of the classes are not found in humans. 
For example D and E represent fungal pheromone receptors and class F includes 
archaebacterial opsins (Fredriksson et al., 2003).  
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The mammalian GPCRs are categorised in three main classes according to sequence 
similarity and these are:  class A (rhodopsin-like receptor family), class B (secretin 
receptor family) and class C (family of metabotropic glutamate receptors) (Emami-Nemini 
et al., 2013).  
The rhodopsin-like (class A) family has more than 700 members that share high sequence 
similarity (Pal et al., 2012) and share several structural characteristics with rhodopsin such 
as an NPXXY motif on TM7 and a DRY motif between TM3 and IL2 (Palczewski et al., 
2000). Ligand binding for most rhodopsin-like receptors takes place within a cavity formed 
between the TM region. Some important GPCRs that belong to class A family include 
muscarinic acetylcholine receptors, dopamine receptors, adrenergic receptors, opioid 
receptors, adenosine receptors and histamine receptors.  
The secretin-like (class B) family consists of several members such as calcitonin receptor, 
corticotropin releasing hormone receptor, glucagon and glucagon-like receptor, growth 
hormone releasing receptor etc. This receptor family is characterised by binding to large 
peptide hormones (Pal et al., 2012). The secretin receptor was the first to be cloned in the 
family and hence the name. The N-terminal domain is 60-80 amino acids long, containing 
cysteine residues that form disulphide bridges that play key roles in ligand binding. The 
secretin receptor and other members of this family play a key role in hormonal homeostasis 
with secretin receptor stimulating secretion of acid-neutralising fluids in pancreas and 
duodenum; growth hormone releasing hormone receptor mediating growth hormone 
secretion; glucagon and calcitonin receptors regulating glucose homeostasis (Pal et al., 
2012). Novel insights into the structure and function of class B receptor family was offered 
by publications of the crystal structures of the glucagon receptor and the corticotropin 
releasing factor receptor 1 (Hollenstein et al., 2014).  
The glutamate-like receptor (class C) family consists of metabotropic glutamate receptors 
(mGlu receptors), Ca+2 sensing receptors, γ-aminobutyric acid B receptors (GABAB), 
sweet and amino acid taste receptors, pheromone receptors and some orphan receptors 
(Chun et al., 2012). The N-terminus of glutamate receptor family members is 280-580 
amino acids long and contains the ligand recognition domain generated by forming two 
lobes separated by a cavity in which glutamate binds to produce the so called ‘Venus fly 
trap’ or VFT domain.  This extracellular domain is common to class C receptors and it is 
responsible for ligand recognition. The VFT domain may also accommodate allosteric 
binding sites and it is connected with the 7-TM core through a cysteine rich domain, which 
also plays a role in receptor activation (Chun et al., 2012). 
 
Chapter 1   
 
25 
 
1.4 Signalling of GPCRs  
GPCRs couple to and activate guanine nucleotide binding proteins (G proteins). G proteins 
are hetero-trimeric proteins that consist of three subunits (α, β and γ) which exist in a 
complex when inactive. The Gα is the largest subunit (40-45 kDa) in the heterotrimeric 
complex. It is composed of two domains (a GTPase domain and an α-helical domain) and 
is capable of forming a complex with one β (35 kDa) and one γ subunit (15 kDa), when in 
GDP-bound form (Malbon, 2005). Upon ligand mediated activation the receptor undergoes 
a conformational change leading to the exchange of GDP for GTP on the Gα subunit, 
which then dissociates from the Gβγ complex. The G protein subunits then act on 
downstream effectors and initiate signalling pathways. The GTPase activity (GTP-
hydrolysing activity) of the Gα subunit hydrolyses GTP into GDP, leading to the 
termination of the G protein mediated downstream signalling and the different subunits re-
associate back into the hetero-trimeric complex (Hamm, 2001). The Gβγ subunits can 
function independently from the Gα and activate a diverse range of effectors initiating 
signal transduction pathways (Sadja et al., 2003). The Gβγ complex can interact with 
phospholipase Cβ (PLCβ) (Lin and Smrcka, 2011), G protein receptor kinase 2 (GRK2) 
(Evron et al., 2012), G protein-regulated inwardly rectifying potassium channels (GIRK) 
(Luscher and Slesinger, 2010), N-type calcium channels (Brown and Sihra, 2008), 
adenylate cyclase (AC) isoforms (Sunahara and Taussig, 2002).  Regulation of G protein 
function is mediated by accessory proteins e.g. activators of G protein signalling (AGS) 
which facilitate the exchange rate of GDP for GTP, and regulators of G protein signalling 
(RGS), that act by accelerating the rate of GTP hydrolysis on the Gα subunit, therefore, 
having a regulatory role in the duration of G protein activation (Traynor and Neubig, 
2005).  
There are four main classes of Gα subunits that have been identified based on sequence 
similarity (Neves et al., 2002). These are: Gs (stimulates an increase in intracellular cyclic 
adenosine monophosphate (cAMP) levels by activating an AC), Gi/o (inhibits AC which 
leads to a decrease in intracellular cAMP levels); Gq/11 (leads to an increase in intracellular 
calcium ion levels through the activation of PLCβ) and G12/13 (regulation of Rho guanine 
nucleotide exchange factors, RhoGEF proteins).  
In more detail, Gαs subunit activates the enzyme AC, which in turns catalyses the 
conversion of ATP into cAMP, resulting in increased cytosolic cAMP levels. Four 
molecules of cAMP are required for binding to the cAMP-dependent protein kinase, also 
known as protein kinase A or PKA. When PKA is activated it interacts with proteins to 
phosphorylate them on specific serine and/or threonine residues. The Gαi/o subunit has the 
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opposite effect compared to the Gαs, since its activation leads to the inhibition of AC 
activity and thus, the reduction in cAMP production levels, which in turns results in a 
decrease in the PKA activity.  
The Gαq/11 subunit, once activated by a GPCR, activates the enzyme PLC. PLC hydrolyses 
phosphatidylinositol 4, 5 -bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 
1,4,5-trisphosphate (IP3).  DAG remains bound to the membrane and acts as a second 
messenger by activating protein kinase C (PKC) which phosphorylates proteins. IP3 
diffuses in the cytosol and acts on IP3 receptors located in the endoplasmic reticulum (ER), 
resulting in an increase in intracellular calcium ion levels. Calcium ions together with 
DAG work towards the activation of PKC.  
The Gα12/13 subunits act by activating Rho guanine nucleotide exchange factors (Rho-
GEFs) which in turn activate the small cytosolic Rho-GTPase. The Rho-GTPase can 
activate numerous proteins such as Rho-kinase that are responsible for regulation of actin 
cytoskeletal remodelling in cells. A brief summary of the different G protein mediated 
pathways is included in Figure 1.3. 
 
                       
                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 G protein coupling patterns. Examples of GPCRs that couple to different G protein 
types and mediate the different signalling pathways. (Figure taken fromWettschureck and 
Offermanns, 2005). 
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1.5 Regulation of GPCR signalling and G protein independent signalling pathways  
Regulation of GPCR signalling occurs during three different processes: 1. Desensitisation, 
2. Internalisation and 3. Down-regulation. The key element that is involved in these 
processes is a cytosolic protein called β-arrestin (Luttrell and Lefkowitz, 2002). Beta 
arrestins are multifunctional proteins acting as signal terminators, as adaptor proteins and 
as signal transducers (DeWire et al., 2007; Shukla et al., 2013). The roles of arrestins are 
listed in the schematic diagram in Figure 1.4. 
The family of arrestins contains four members: two visual arrestins (arrestin 1 and 4) and 
two non-visual arrestins (arrestin2 and 3, also known as β-arrestin1 and β-arrestin2, 
respectively) (Lefkowitz and Shenoy, 2005). The visual arrestins restrict to binding to 
photoreceptors such as rhodopsin (Gurevich and Benovic, 1993). The two β-arrestins (1 
and 2) although structurally similar to visual arrestins, are of broader importance in terms 
of GPCR signalling regulation. Crystal structures of arrestin molecules in their basal state 
have revealed an elongated molecule containing an N- and a C-domain, composed of 
antiparallel β-sheets, which are connected by a linker region made of 12 residues. The 
polar core is a region located between the two domains and is composed of a network of 
charged residues connected with hydrogen bonds (Han et al., 2001). Arrestins bind to the 
ligand activated receptor once it has been phosphorylated at its C-terminal domain or 
intracellular loops by protein kinases such as GRKs (Kovoor et al., 1999).Two types of 
interactions are involved in the binding of β-arrestin to a phosphorylated GPCR. Briefly, a 
phosphate sensor on β-arrestin interacts with the phosphorylated C- terminus or the IL3 of 
the receptor and a conformational sensor on rhodopsin recognises the agonist-induced 
active conformation of the receptor’s core (Shukla et al., 2013). Important information 
obtained from X-ray laser experiments have enabled the production of the first 3-D map of 
a pre-activated form of mouse visual arrestin bound to a constitutively active form of 
human rhodopsin (Kang et al., 2015). According to this model rhodopsin uses TM7 and 
helix 8 to recruit arrestin, while arrestin undergoes conformational changes through 
rotating its N- and C-termini resulting in the opening of a cleft on arrestin allowing 
accommodation of the IL2 domain of rhodopsin (Kang et al., 2015).  
Following receptor stimulation for a prolonged period of time, receptor mediated signalling 
is attenuated i.e. the response to the persistent stimulus is decreased, via a process called 
desensitisation. Desensitisation begins with exposure of the receptor to agonist and it is 
initiated by the phosphorylation of key residues in the C tail and cytoplasmic loops of the 
receptor by protein kinases (e.g. PKA, PKC, GRKs).  
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The interaction between the receptor and β-arrestin that confers a series of conformational 
changes, upon the receptor, leads to dissociation of the receptor-G protein complex (via 
sterically blocking the G protein- receptor coupling) and thus, the termination of G-protein 
mediated signalling cascades. Therefore, β-arrestin possesses a role as signal terminator 
(Luttrell and Lefkowitz, 2002). This interaction initiates the process of receptor 
homologous desensitisation (mediated by agonist stimulation of the receptor and 
subsequent receptor phosphorylation by GRKs). Ligand binding is not always required for 
the process, since an unbound receptor can be desensitised by heterologous desensitisation 
(receptor phosphorylated by second messenger-dependent protein kinases) (Luttrell and 
Lefkowitz, 2002).  
Arrestins also have the ability to act as adaptor proteins by binding to components of the 
endocytic machinery. The high affinity binding of β-arrestin to clathrin, dynamin and β2-
adaptin subunit of the AP-2 adaptor protein results in a multi-complex formation linking 
the receptor-bound arrestin to the clathrin endocytic machinery. This process initiates 
receptor internalisation in clathrin coated pits, and subsequently in clathrin coated vesicles 
(Oakley et al., 2000; Han et al., 2001). Goodman et al., (1996) demonstrated the co-
localisation of β2-AR with β-arrestin and clathrin, by immuno-fluorescence microscopy in 
live cells, suggesting arrestin possesses a role in endocytosis and trafficking of GPCRs 
(Goodman et al., 1996).  
 β-arrestin can act as a multi-protein scaffold and has a role in the recruitment of specific 
signalling molecules to the receptor, thus conferring the role of signal transducer to β-
arrestin, since it can re-direct signalling to alternate pathways (Gurevich and Gurevich, 
2003; Kang et al., 2015). Arrestin can recruit Src family kinases, components of 
extracellular signal regulated kinases ERK1/2, c-Jun N-terminal kinases (JNK3) and p38 
kinases, re-directing the receptor signalling pathway towards mitogen activated protein 
kinase (MAPK) signalling cascades, leading to ERK1/2 phosphorylation, upon receptor 
internalisation (Calebiro et al., 2010; Mundell and Benovic, 2000). MAP kinase pathway is 
regulated by a series of signalling cascades. The pathway is initiated by the activation of 
MAP kinase kinase kinases (MAPKKK) that in turn phosphorylate and activate MAP 
kinase kinases (MAPKK). MAPKK in turns phosphorylate and activate MAP kinases 
(MAPK) such as ERK1/2. Activated ERK1/2 acts by phosphorylating various cytoplasmic, 
nuclear and cytoskeletal components that are involved in cellular processes that regulate 
cell cycle (division and growth), apoptosis, cell differentiation, proliferation (Luttrell and 
Lefkowitz, 2002).   
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Figure 1.4 Roles of β-arrestin in the life cycle of GPCRs.  The activation of a GPCR leads to its 
phosphorylation at specific serine and threonine residues by GRKs, resulting in the recruitment of 
β-arrestins at the cell membrane. 1. Binding of β-arrestin to the phosphorylated GPCR terminates G 
protein coupling, initiating receptor desensitisation process. 2. β-arrestin recruits proteins involved 
in the clathrin dependent internalisation of the receptor, a process that leads to 3. Receptor 
recycling or down-regulation, depending on the strength of interaction between the GPCR and 
arrestin molecules (Figure taken from Luttrell and Lefkowitz, 2002). 
 
 
1.6 Muscarinic acetylcholine receptors 
Muscarinic acetylcholine receptors (mAChRs) are a family of five closely related class A 
GPCRs. The five different sub-types denoted M1-M5 are encoded by CHRM1-CHRM5 and 
are highly conserved throughout evolution from fungi to humans. The mAChRs have been 
cloned, sequenced and studied thoroughly through the years and the muscarinic 
acetylcholine system is considered of great physiological importance with these receptors 
playing important roles in regulating numerous cellular functions. The natural ligand for 
mAChRs is acetylcholine, which is released from cholinergic nerve endings and non-
neuronal cells. Acetylcholine-mediated activation of the receptors is responsible for G 
protein activation and the downstream signalling pathway that follows activation 
(Kurowski et al., 2015).   
The mAChRs may be sub-divided into two groups based on the preference for G protein 
coupling efficiency. M1, M3 and M5 couple predominantly to Gq/11 proteins upon agonist 
activation of the receptor (Bymaster et al., 2002). Activation of the Gq/11 protein is 
followed by activation of PLC and this in turns results in increased intracellular calcium 
ion release (Figure 1.5 A). The βγ subunits of the Gαq protein can regulate the function of 
certain ion channels including potassium or calcium channels (Beech et al., 1992; Hille, 
1992).  
M2 and M4 muscarinic acetylcholine receptors show a preference for Gi/o heterotrimeric G 
protein coupling and this leads to a negative effect on neurotransmitter release (Bymaster 
et al., 2002). Activation of Gi/o pathway is responsible for inhibition of adenylate cyclase 
activity resulting in a decrease of cAMP accumulation (Figure 1.5 B). The βγ subunits of 
the Gi/o protein may also directly regulate potassium channels. This is a key pathway that 
follows activation of M2 receptors in heart muscle (Krejci and Tucek, 2002). The M2 
receptor has also demonstrated the ability to activate alternate G proteins such as Gs 
resulting in a stimulatory effect on cAMP synthesis. This ability was shown to be 
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dependent on the agonist used, the duration of stimulation and the density of the receptors 
at the surface of the cells or tissues being examined. 
Various studies have suggested that muscarinic receptors may also signal through G 
protein- independent pathways (Tobin and Budd, 2003; Billington and Penn, 2002). 
Changes in receptor localisation and trafficking have been reported following receptor 
modification through phosphorylation by protein kinases. The observation that β- arrestin 
recruitment is linked to receptor phosphorylation led to the hypothesis that these two 
functions may be ligand biased. 
 
 
        A. M1/M3/M5                                     B. M2/M4 
  
 
Figure 1.5 G protein mediated signalling of muscarinic acetylcholine receptor subtypes. (A) 
M1, M3 and M5 couple to Gq/11 protein and induce activation of PLC, which catalyses PIP2 into 
DAG and IP3 resulting in the activation of PKC and calcium ion release from the ER. (B) M2 and 
M4 receptor subtypes preferentially couple to Gi/o, inhibiting the activation of AC and thus resulting 
in decreased cAMP levels.  
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1.7  Expression and function of mAChRs  
 
The family of mAChRs plays an important role in the regulation of numerous essential 
functions of the central and peripheral nervous systems. The expression of these receptors 
is widespread in numerous tissues and organs as observed by immunological and immuno-
cytochemical methods (Levey, 1993; Levey et al., 1991), in situ hybridisation 
histochemistry (Weiner et al., 1990) and generation and analysis of muscarinic Chrm1-
Chrm5 knock-out (KO) mice (Wess et al., 2007). The generation of transgenic mAChR 
KO mice has offered insight into numerous muscarinic receptor-related functions (Matsui 
et al., 2000; Wess, 2004). The mAChR KO mice were all viable, fertile and without signs 
of major physiological defects (Wess et al., 2007).  
The Gq/11 coupling group of mAChRs (M1, M3 and M5) is expressed in post-synaptic 
terminals suggesting a role in the modulation of synaptic transmission. M1 receptor is 
widely expressed in the major forebrain areas such as the cerebral cortex, striatum, and 
hippocampus but is also abundant in the periphery e.g. salivary glands and sympathetic 
ganglia. The M1 KO mice demonstrated increased locomotor activity associated with 
memory and learning deficits (Miyakawa et al., 2001). The M1 receptor has been suggested 
to be implicated in Alzheimer’s disease and related cognitive disorders and therefore 
identification or development of M1 selective ligands could be advantageous in the 
treatment of such disorders. Studies in mouse models for Alzheimer’s disease have 
demonstrated that M1 deficiency increased the risk for development of Alzheimer’s (Davis 
et al., 2009) and further enhanced the severity of cognitive decline related with the disease 
(Medeiros et al., 2011). M3 receptor, apart from its wide expression in the CNS, is also 
found in smooth muscle of the gastrointestinal and urinary tracts and in exocrine glands 
and eyes. Activation of M3 promotes smooth muscle contraction, salivary gland secretion 
and is involved in the stimulation of the parasympathetic system (Bubser et al., 2012). The 
physiological role of M3 receptor subtype has been extensively examined, since the 
receptor is widely expressed in CNS and periphery (Wess et al., 2007).  The study of the 
role of M3 receptor was assisted by the generation of whole body M3 receptor KO mice 
(Yamada et al., 2001) and it was proposed that activation of M3 is implicated in 
stimulation of smooth muscle contraction, in the promotion of glandular secretion and 
dilation of peripheral blood vessels. M3 receptor KO mice demonstrated reduced body fat 
mass (Yamada et al., 2001) and the activity of M3 was linked to cancer with a proposed 
role of M3 in tumour formation in the gastrointestinal tract (Raufman et al., 2008). There 
has also been an association of M3 receptor activation in β-pancreatic cells with glucose 
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homeostasis and promotion of insulin release (Gautam et al., 2006; 2007).  In an attempt to 
study this role of M3 receptor, M3 KO mice that lacked the receptor selectively in 
pancreatic β-cells were generated and these demonstrated impaired glucose tolerance and 
reduced insulin secretion (Nakajima et al., 2013). On the other hand, transgenic mice over-
expressing the M3 receptor in β-cells displayed enhanced glucose tolerance and increased 
insulin release (Nakajima et al., 2013). This finding is considered of great therapeutic 
importance offering a potential approach in the treatment of type 2 diabetes with the 
identification of compounds that can selectively activate M3 receptors (Kruse et al., 2014). 
M3 receptor demonstrated an ability to modulate appetite via regulating melatonin-
concentrating hormone (MCH) neurones in hypothalamus, in a study using M3 KO mice 
(Yamada et al., 2001). Exocrine secretion of saliva was also found to be mediated by M3 
(Matsui et al., 2000) as well as M1 (Gautam et al., 2004). The generation of M5 KO mice 
revealed an important role of the M5 receptor in the modulation of drug-addiction and 
drug-seeking behaviours (Wess et al., 2007). M5 expression has been detected in peripheral 
and cerebral blood vessels and also in brain regions including substantia nigra, 
hippocampus, hypothalamus, as well as at distinct midbrain dopamine cell body regions, a 
fact that implies co-localisation with dopamine receptor subtypes. Most neurons in 
substantia nigra especially in the region of ventral tegmental area co-express mRNA 
corresponding to both M5 and D2 receptors (Raffa et al., 2009).  
The Gi/o coupling group of mAChRs (M2 and M4) generally confers an inhibitory effect on 
pre-synaptic terminals resulting in reduced neurotransmitter release. M2 is abundant in the 
CNS, regulating acetylcholine release in the cortex and hippocampus. It is expressed in the 
body periphery, smooth muscle organs and it is the predominant muscarinic receptor in the 
heart. M2 receptor is also abundant in the urinary bladder smooth muscle and activation of 
M2 can cause contraction of the bladder in an indirect manner by reversing 
sympathetically-mediated relaxation (Hedge et al., 1997).  Mice deficient in M2 receptor 
demonstrated decreased responses to cholinergic stimuli (Matsui et al., 2002).Transgenic 
M2 KO mice revealed that M2 receptor has a role in the regulation of body temperature 
(Gomeza et al., 1999) and also in controlling cardiac myocyte contraction (Wess, 2004).  
Although, M3 receptor is thought to have a dominant role in inducing smooth muscle 
contraction, the M2 receptor is suggested to play a modulatory role in the intracellular 
signalling of M3 (Matsui et al., 2002). 
M4 receptor is expressed in high concentrations in the periphery (e.g. lung, salivary glands 
and ileum) and shows similar expression levels as M1 in brain regions (hippocampus, 
cerebral cortex, striatum), while showing low levels of expression in thalamus, cerebellum 
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and brainstem. M4 proposed actions include regulation of locomotor activity, analgesia, 
auto-inhibition of acetylcholine and balancing dopaminergic activity (Bymaster et al., 
2002). M4 KO mice showed an inhibitory effect on the striatal dopamine mediated 
locomotor activity (Bymaster et al., 2002; Wess et al., 2007). 
Muscarinic receptors can modulate the action of ion channels such as K+ and Ca2+ in 
striatal medium spiny neurons, a function that has been attributed to M1 and M4 receptor 
subtypes (Yan et al., 2001). M2 receptor-mediated activation of K
+ channels results in 
decreased heart rate. It is also known that muscarinic receptors can modulate striatal 
dopamine release. More specifically, stimulation of M4 and M5 seems to enhance striatal 
dopamine release, whereas, activation of M3 receptors shows the opposite effect i.e. 
inhibition of dopamine release (Zhang et al., 2002). Lack of M1 and/or M4 muscarinic 
receptors in KO mice resulted in hypersensitivity of dopamine phenotype which is 
associated with psychotic activity and schizophrenia (reviewed in Kruse et al., 2014). A 
better understanding of the function and involvement of mAChRs in pathological 
conditions can enable the development of therapeutics to target diseases and disorders of 
the CNS and periphery.  
 
  
1.8 Structural aspects of ligand binding to mAChRs 
 
A number of muscarinic ligands exist that bind to the orthosteric binding site of mAChRs 
ranging from full (e.g. carbachol, oxotremorine) and partial (e.g. arecoline) agonists to 
antagonists (e.g. atropine, scopolamine) and inverse agonists (e.g. pirenzepine, tiotropium).  
Xanomeline is considered to be a M1 and M4 selective agonist with important advantages 
offered in the improvement of symptoms in Alzheimer’s disease and schizophrenia 
(Bodick et al., 1997; Grant et al., 2010) but it has also demonstrated the ability to bind and 
activate M3 receptor (Christopoulos et al., 2001).  Xanomeline is considered to be an 
orthosteric ligand but it also binds at a secondary site on the M1 receptor (De Lorme et al., 
2007). 
The orthosteric binding site of the muscarinic acetylcholine receptors is the site where the 
endogenous ligand, Ach, binds. The binding site is enclosed deep in a pocket that is formed 
by the TM domains of the receptor. Several models have been suggested and these were 
initially based on mutagenesis and molecular docking studies. Such studies have revealed 
that Ach binding to the receptor’s binding pocket is enabled by amino acid residues in 
TM3, TM4, TM6 and TM7 domains (Jacobson et al., 2010). The crystal structure of 
Chapter 1   
 
35 
 
bovine rhodopsin was used as a template for the generation of a homology model of the M1 
receptor in an attempt to investigate the components of the orthosteric binding site that 
were crucial for Ach binding. This investigation revealed that Asp105 was an essential 
residue for Ach binding, through the formation of a salt bridge with Ach (Hulme et al., 
2003; Jacobson et al., 2010). Other residues in the binding pocket that were considered 
important for the M1 interaction with Ach included: Trp101, Tyr404 andTyr408. Phe77, 
Tyr179 and Phe374 were identified as crucial residues for participating in the allosteric 
binding site for binding to allosteric ligands such as AC-42 and TBPB (Jacobson et al., 
2010). Crystal structures of muscarinic receptors were recently obtained for the human M2 
bound to the antagonist QNB (Haga et al., 2012) and the rat M3 bound to the inverse 
agonist tiotropium (Kruse et al., 2012). The flexibility of the muscarinic receptors’ due to 
the presence of a large and very flexible IL3 was a limiting factor in solving the crystal 
structures (Kow and Nathanson, 2012). This was solved by a modification that involved 
the removal of a large part of IL3, in both receptors, and the replacement with phage T4 
lysozyme that enhanced crystal formation without affecting the receptors’ binding 
properties (Haga et al., 2012; Kruse et al., 2012). The QNB was found to interact with 
Asp103 (TM3) that acts as a counter ion and Asn404 (TM6) forming a hydrogen bond with 
QNB. Both residues serve to orient the ligand into the hydrophobic cavity formed by 
aromatic residues. This aromatic cage engages the amine moiety of QNB and forms a ‘lid’ 
to prevent the ligand dissociating from the binding pocket. The residues important for 
interacting with QNB within the aromatic cage are: Tyr104, Tyr403 and Tyr423 (Haga et 
al., 2012).  Phe181 also interacts with QNB and this is the only amino acid in the 
orthosteric binding pocket of M2 that differs from all the other mAChR sub-types. The rest 
of mAChRs have a leucine residue in the homologous position e.g. Leu225 in M3 (Haga et 
al., 2012; Kruse et al., 2013). The binding pocket of M2 receptor bound to QNB is shown 
in Figure 1.6 A. 
The crystal structure of M3 receptor bound to tiotropium is very similar to that of M2. M3 
receptor also has a large extracellular vestibule, which like in M2 it is a part of a 
hydrophilic channel that contains the orthosteric binding pocket of the receptor. The 
binding site is located deep in the TM domains and is covered by a ‘lid’ composed of 
tyrosine residues e.g. Tyr148, Tyr506 and Tyr529. Asp147 in M3 interacts with the amine 
moiety of the ligand tiotropium and Asn507 forms hydrogen bonds with tiotropium’s 
hydroxyl and carbonyl groups (Kruse et al., 2012). The binding pocket of M3 receptor 
bound to tiotropium is shown in Figure 1.6 B. 
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Figure 1.6 Crystal structures of mAChRs. (A) M2 bound to QNB ( Figure taken from Haga et 
al., 2012) and (B) M3 bound to tiotropium (Figure taken from Kruse et al., 2012). The amino acid 
residues implicated in the interaction between the ligands and the binding pocket of each receptor 
are shown.  
 
The orthosteric binding pocket of the mAChRs is characterised by a high degree of 
sequence homology across the different subtypes. This has been a limiting factor for the 
development of sub-type selective ligands for muscarinic receptors. This has attracted the 
focus on the discovery and development of allosteric modulators for mAChRs.  
The secondary allosteric binding sites show greater divergence in homology among the 
different muscarinic receptor subtypes. The allosteric sites were not subjected to a strong 
evolutionary pressure as the orthosteric sites which were required to accommodate 
endogenous ligands (Smith and Milligan, 2010). Allosteric ligands cause conformational 
changes upon the receptor that either increases (positive allosteric modulator or PAM) or 
decreases (negative allosteric modulator or NAM) the binding and action of the orthosteric 
ligand to the receptor (van der Westhuizen et al., 2015). Two types of allosteric modulators 
have been described for the M1 receptor. These include allosteric agonists (able of 
activating the receptor even in the absence of an orthosteric ligand) and allosteric 
potentiators (require the presence of Ach to exert their function) (Jacobson et al., 2010). 
The first allosteric agonist for the M1 receptor was AC-42 and binding to the allosteric site 
was enabled by Tyr179 and Phe374 of the M1 receptor. Phe77 (TM3) is also thought to be 
critical for maintaining AC-42 functional activity (Jacobson et al., 2010).  
Studies on the crystal structures of M2 (Haga et al., 2012) and M3 (Kruse et al., 2012) 
receptors have led to the identification of a large extracellular vestibule where allosteric 
ligands may bind. This domain is located above the orthosteric binding site and it is 
structurally coupled to the intracellular surface and the orthosteric binding domain and it is 
thought that this interaction allows allosteric ligands to affect the affinity and efficacy of 
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the orthosteric ligands and induce G protein activation (Gregory et al., 2010; May et al., 
2007).  The binding of M2-bound to an orthosteric agonist iperoxo with a PAM, 
LY2119620, at the allosteric site was described by Kruse et al., (2013a).  
An allosteric agent (compound 16) that is able to specifically and selectively activate M3 
but not M2 was identified, using structure-based molecular docking against M2 and M3 
receptors and screening of large numbers of compounds (Kruse et al., 2013 b). The 
identification of compound 16 as a partial agonist at M3 (in a calcium mobilisation assay) 
and the inability to activate M2 receptor (as demonstrated in an adenylyl cyclase inhibition 
assay) was very important as this was the first reported pharmacological agonist that 
showed sub-type selectivity at M3 over M2 receptor. In addition, compound 16 was able to 
stimulate insulin release in pancreatic β-cells (MIN6 insulinoma cells) a function linked to 
M3 receptor activation (Gautam et al., 2010). This could have an important impact in the 
development of novel therapeutics for the treatment of type 2 diabetes (Kruse et al., 2013 
b).  
 
 
1.9 Generation and use of Receptors Activated Solely by Synthetic Ligands (RASSLs) 
 
The importance of GPCRs in terms of therapeutics and their implication for various 
disorders of the periphery and CNS had pointed out the necessity for studying and 
understanding their function both in vitro and in vivo as well as the determination of the 
link between receptor activation and consequent physiological responses. The tools that 
have been employed to investigate receptor or pathway activation included the use of drug-
like exogenous ligands targeting GPCRs and generation of gene knockouts (Conklin, 
2007). Although, these methods were initially very useful in providing some information 
about receptor function, they lacked selectivity in terms of orthologous receptor-ligand 
pairs and showed a poor degree of spatiotemporal control of the GPCR-mediated signalling 
pathways. In addition, in vivo applications in studying GPCR function were problematic 
(Rogan and Roth, 2011). The ability to control GPCR signalling pathways, in order to 
investigate the effects of signalling in vivo, has been greatly complicated due to 
interference of the endogenous ligands with the system to be studied. These difficulties 
were the reason for turning towards a novel approach that involved building new GPCR 
pathways via creation of re-designed GPCRs.  
The first efforts for selective GPCR activation began with the work of Strader et al., 
(1991), which generated a mutated version of the β2-adrenergic receptor, by site directed 
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mutagenesis. This resulted in a receptor unable to respond to natural adrenergic receptor 
ligands but could bind and be activated by a synthetic ligand unable to interact with the 
wild type receptors. Studies on the binding of agonists and antagonists, using this designer 
GPCR, had led to the determination of the role of ionic interactions between receptor and 
ligand in ligand binding specificity. A single amino acid substitution at the binding pocket 
region (i.e. replacement of the β-carboxymethyl side chain of Asp113 with the β-
hydroxymethyl side chain of Ser) resulted in the genetically engineered β2-adrenergic 
receptor able to respond potently and specifically to catechol ester or ketone ligands 
(Strader et al., 1991) but not to adrenergic ligands.  This work had only identified 
compounds with moderate affinities and unknown pharmacokinetics that were not suitable 
for in vivo applications, but had set the road for the new type of designer GPCRs (Rogan 
and Roth, 2011). 
A similar approach to Strader et al., (1991) involving rational design and mutagenesis of 
key amino acid residues involved in the ligand binding process, led to the generation of  
Receptors Activated Solely by Synthetic Ligands (RASSLs) using the human κ-opioid 
receptor as a template (Coward et al., 1998). Two RASSLs were developed, Ro1 that 
contained the second extracellular loop domain from the δ-opioid receptor and Ro2 
chimeric receptor also containing the same modification as Ro1 plus an amino acid 
substitution in the TM6 domain. The modified receptors were chosen based on the ability 
of the synthetic ligands spiradoline and bremazocine to bind and interact with extracellular 
loops of the receptors, and the preference of small molecules to interact with regions closer 
to the TM domains of the receptors. The redesigned receptors Ro1 and 2 were able to 
respond to and signal after activation with the synthetic small molecule ligands spiradoline 
and bremazocine, whilst, showing decreased affinity to natural opioid ligands such as 
dynorphin and enkephalin (Coward et al., 1998). With this study Coward et al., (1998) 
managed to demonstrate that GPCRs can be used as prototypes to generate RASSLs in 
order to selectively activate and investigate GPCR signalling. Ro1 and Ro2 RASSLs were 
the starting point for additional RASSL receptor generation, which showed unique features 
including altered internalisation and perturbed desensitisation properties (Scearse-Levie et 
al., 2001; 2005; Pei et al., 2008). 
Other RASSLs were generated following the same approach. A mutation of Asp115 (a 
highly conserved residue between many GPCRs activated by biogenic amines that is 
critical for ligand binding to the orthosteric site) to glutamate of the Gq coupled serotonin 
receptor 5-HT2A resulted in a RASSL (Kristiansen et al., 2000). Another Gq coupled 
receptor, histamine H1  receptor was made into a RASSL (Bruysters et al., 2005) and the 
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first Gs coupled RASSL based on the melacortin receptor (MC4) (Srinivasan et al., 2003) 
was developed.  Claeysen et al., (2003) used the 5-HT4 receptor as a template to generate a 
family of designer GPCRs that could signal through the main three G proteins (Gq, Gs and 
Gi) (Claeysen et al., 2003).  
The first generation of RASSLs was based on pre-existing synthetic drugs that had known 
pharmacology and the side effects were considered negligible in animals. Some of the 
synthetic ligands show a degree of potency for the WT receptors. For example, spiradoline 
can activate the endogenous κ-opioid receptor (Coward et al., 1998) and the synthetic 
ligand THIQ that targets the Rm1 and Rm2, is more potent at the parent receptor MC4 
(Shrinivasan et al., 2007). This points out the need for increased selectivity in activating 
designer receptors either by working in a KO background or by locally infusing the 
synthetic ligands to the tissue or organ site where only the RASSL is expressed. Another 
limitation of the first generation RASSLs was the lack of external control over the RASSL 
signalling due to constitutive activity of the RASSL. An example is the Ro1 receptor that 
showed no basal activity in tissue culture but had demonstrated a relatively high degree of 
constitutive activity in vivo (Coward et al., 1998). It is not yet clear whether RASSL-linked 
basal activity originates from the RASSL-mediated signalling in the absence of ligand or 
from the over-expression of the receptor. Increased basal activity of a RASSL could be a 
result of the endogenous ligand-mediated activation (Conklin, 2007; Rogan and Roth, 
2011).  
 
The majority of the information on the roles and pharmacology of the mAChRs was 
obtained from studies that involved generation of KO and transgenic animals (Wess, 
2012).  The generation of RASSL variants of mAChRs by directed protein evolution was 
initiated by Armbruster et al., (2007).This work involved the use of rat M3 receptor as a 
template to generate a whole family of designer receptors exclusively activated by designer 
drugs (DREADDs). Repeated rounds of random mutagenesis and screening resulted in the 
identification and isolation of clones that were able to respond to the synthetic ligand 
clozapine-N-oxide (CNO) with increased affinity and potency, but were unable to respond 
to the endogenous muscarinic ligand Ach or related ligands such as carbachol (Cch). A 
mutated version of rat M3 that lacked most of the IL3 (rM3Δ3i) to enhance expression in 
yeast, was used. This receptor was cloned into yeast expression vectors and the positive 
clones were selected based on the displayed desired pharmacological RASSL 
characteristics. The optimal mutation that conferred the RASSL characteristics to the 
receptor was Y148C. This was transferred to the equivalent and conserved residue at the 
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human M3 receptor (Y149C) which was tested in combination with additional mutations. 
The optimal combination of mutations that were identified in the human M3RASSL and 
conferred the ability to the receptor to respond to CNO and also caused loss of 
potency/affinity to Ach and Cch were: Y149C (TM3) and A239G (TM5). The hM3RASSL 
potently enhanced levels of ERK1/2 phosphorylation through activation of MAPK 
proteins, in response to CNO but not acetylcholine (Armbruster et al., 2007). 
In order to investigate the conformational changes at the hM3RASSL compared to the WT 
receptor, upon ligand-mediated activation, a FlAsH-CFP sensor was introduced at the 
receptor key points ( i.e. FlAsH was introduced at IL3 and the CFP was placed at the C-
terminus) to allow detection of conformational changes by intramolecular FRET (Alvarez-
Curto et al., 2011). A mutant containing the Y149C mutation did not respond to either 
CNO or Cch. The mutant containing the A239G mutation only responded to Cch but with 
slower kinetics and reduced potency compared to WT, but did not respond to CNO. The 
mutant containing both mutations was able to display the RASSL characteristics. Both 
Y149C and A239G mutations are required to generate the hM3RASSL, by providing the 
suitable conformation within the receptor’s binding pocket that allows binding to CNO. 
The key residues at the binding pocket that are thought to be interacting with CNO are 
Thr235 and Asp149. The three tyrosine residues in the hM3WT receptor (Y149, Y507 and 
Y530) are thought to form a ‘lid’ structure above the binding pocket that maintains the 
required conformation for Ach binding. The Y149C mutation results in loss of the ‘lid’ 
structure in the hM3RASSL conferring a more loose conformation of the binding pocket 
and thus, allowing CNO (which is more bulky than Ach and Cch) to bind and interact with 
Asp149. The binding of CNO to RASSL and the binding of Ach and Cch to the WT 
receptor result in similar conformational changes within the TM domains of both receptors 
according to the intramolecular FRET experiments described by Alvarez-Curto et al., 
(2011). The molecular models that describe the binding of CNO to hM3WT and to 
hM3RASSL are shown in Figure 1.7. The hM3RASSL elicited a potent calcium release 
through Gq coupling upon activation with CNO, similar to the response demonstrated by 
hM3WT when activated by Ach or Cch. In addition, activation of ERK1/2 was observed 
upon CNO mediated activation of hM3RASSL in a manner similar to that seen by hM3WT 
upon addition of Ach or Cch (Alvarez-Curto et al., 2011) (Figure 1.8).    
The rest of the muscarinic family members (M1, M2, M4 and M5) were made into 
functional RASSL/DREADD receptors using hM3RASSL as a template (Armbruster et al., 
2007). The generation of muscarinic RASSLs or DREADDs was a milestone and the 
validation of those designer receptors as valuable tools with defined ligand specificities 
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enabled studying specific functions of receptor sub-types (e.g. M2 vs M3) or general 
downstream signalling (e.g. Gq vs Gi).  This is of great importance for in vivo and in vitro 
applications, especially for muscarinic receptors that share highly conserved residues in 
their orthosteric binding pocket (Hulme et al., 2003).  In addition, the designer receptors 
activated by CNO proved to be useful in numerous native and artificial cellular 
environments and have offered a novel approach in investigating receptor activation, 
function, signalling (Burstein et al., 1995) and recently in the study of GPCR 
oligomerisation (Alvarez-Curto et al., 2010; Aslanoglou et al., 2015). Variants of the 
hM3DREADD/RASSL receptor, termed hM3Dq and rM3/β1D5 designer receptors were 
expressed in pancreatic β-cells and demonstrated the ability to modulate blood glucose 
levels and to mediate insulin secretion in response to CNO, suggesting clinical usefulness 
of the DREADDs in translational applications (Guettier et al., 2009).  
One of the main advantages of the second generation designer receptors is the lack of 
baseline activity (Armbruster et al., 2007). In addition, the use of pharmacologically inert 
synthetic ligands, based on compounds with known pharmacology, offer the desired 
functional selectivity in the system studied. CNO, which is structurally similar to 
clozapine, is an inert ligand i.e. it does not target endogenous receptors and it is highly 
bioavailable in rodents and humans. Clozapine metabolism in the liver yields two main 
metabolites, CNO and N-desmethylclozapine, both of which show appreciable activation 
of the hM3RASSL receptor (Sur et al., 2003). N-desmethylclozapine was suggested to be a 
potent allosteric partial agonist of M1 receptor (Sur et al., 2003). CNO, despite its many 
advantages in the activation of DREADDs and RASSLs, is metabolised, to a small extent, 
to clozapine in the liver. Clozapine, is able to modulate neuronal activity by activating 
numerous receptors present the CNS, and this back metabolism effect can interfere with 
the selective activation of DREADDs and thus limits the translational application of the 
designer receptors. New evidence on the structure-activity relationship (SAR) between 
CNO and DREADDs was demonstrated by Chen et al., (2015), where the DREADD 
hM3Dq was used for studying the SAR between CNO and the receptor. This work led to 
the discovery of compounds demonstrating potent activation of the DREADD without 
activating the WT receptors. One of these compounds was the drug perlapine. Perlapine 
was proposed to be a novel hM3Dq agonist with more than 10,000 fold selectivity for 
DREADD over the WT (Chen et al., 2015).  
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  A.                                                                   B. 
 
Figure 1.7 Molecular models of the binding mechanism of CNO to (A) hM3WT and (B) 
hM3RASSL. (A) Thr149 in M3WT is essential for the ‘lid’ structure that confers a narrow 
conformation to the binding pocket allowing Ach and Cch, but not CNO to fit (CNO is a bulkier 
molecule than Ach and Cch). CNO thus, cannot interact with Thr235 and Asp149 within the 
binding site of the receptor. (B) The amino acid residues involved in the interaction between CNO 
and hM3RASSL are labelled. The interaction of CNO with the Thr253 of the hM3RASSL via a 
hydrogen bond is shown as a dotted line (Figures taken from Alvarez-Curto et al., 2011). 
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Figure 1.8 hM3RASSL receptor activation in response to CNO. (A) The two point mutations 
(Y149C and A239G) on the hM3WT that led to the generation of hM3RASSL that cannot respond 
to natural muscarinic ligands such as acetylcholine or carbachol but only responds to the synthetic 
ligand CNO.  Calcium mobilisation assay performed using cells stably expressing demonstrated 
that (B) carbachol but not CNO could elevate [Ca2+]i levels via FLAG-hM3WT-Citrine and (C) 
CNO but not carbachol could induce calcium release from ER via myc-hM3RASSL-Cerulean 
(Alvarez-Curto et al., 2010). Selective activation of ERK1/2 phosphorylation was achieved via (D) 
carbachol (but not CNO) mediated activation of VSV-SNAP-hM3WT and (E) CNO (but not 
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carbachol) mediated activation of VSV-SNAP-hM3RASSL (Figures taken fromAlvarez-Curto et 
al., 2011). 
 
 
1.10 Oligomerisation of GPCRs 
1.10.1 Dimers versus monomers 
The formation of biological complexes originating from proteins interacting with each 
other is termed oligomerisation. In an oligomer the interacting partner proteins (protomers) 
can be identical (forming homomers) or different (forming heteromers). The 
oligomerisation process is very common in many biological systems. A vast variety of 
proteins involved in numerous biological functions seem to be forming such complexes 
that are important for cellular function. Single transmembrane protein tyrosine kinase 
receptors, cytokine receptors, B and T cell receptors, various transcription factors, enzymes  
and nuclear hormone receptors are only some examples of protein types that exist and 
function as multimeric complexes or oligomers (Klemm et al., 1998).  
Initial studies on GPCRs proposed that monomeric receptors were able to bind and activate 
their G proteins (Whorton et al., 2007). There is now growing evidence that supports the 
existence of GPCRs as dimers or higher order oligomers (Milligan, 2004, 2009, 2013; 
Javitch, 2004). The initial data suggesting the monomeric profile of GPCRs as functional 
units were the basis for the proposal of  the receptor- G protein interaction/activation 
model (i.e. the 1:1 stoichiometry of receptor: G protein) (Terrillon and Bouvier, 2004). 
This model was re-examined because new evidence proposed a more consistent model, 
where a receptor dimer is capable of binding two ligand molecules and a G protein, 
changing the stoichiometry for ligand/dimer/G protein to 2:1:1 (Herrick-Davis et al., 2005; 
Pellissier et al., 2011). Initial evidence that supported the existence of functional 
monomeric GPCRs was demonstrated by the observation that monomeric rhodopsin in 
solution was able to activate its G protein (Ernst et al., 2007) and to bind to arrestin in a 
1:1 stoichiometry (Tsukamoto et al., 2010; Bayburt et al., 2011). Examples of purified 
receptors that were reconstituted into proteoliposomes capable of accommodating only 
monomers, demonstrated that monomeric GPCRs were able to activate their G proteins 
(Whorton et al., 2007). On the other hand, there was a growing body of evidence clearly 
suggesting the existence of homomeric and heteromeric GPCR complexes and more 
importantly implying that those complexes are functional and potentially providing a 
regulatory role in many cellular processes (Milligan, 2009; Angers et al., 2002; Klemm et 
al., 1998).  
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Atomic force microscopy revealed the dimeric arrangement of rhodopsin in native mouse 
disc membranes (Fotiadis et al., 2003) .The presence of rhodopsin dimers in native retinal 
membranes was demonstrated (Liang et al., 2003), as well as the ability of the rhodopsin 
dimer to interact with a single G protein (Jastrzebska et al., 2013). Crystal structures of the 
extracellular ligand binding regions of mGluR1 receptor in complex with glutamate and 
structures of the inactive state of the receptor showed the presence of receptor homodimers 
(Kunishima et al., 2000). Information collected from crystal structures of chemokine 
CXCR4 receptor (Wu et al., 2010), κ-opioid receptor (Wu et al., 2012) and μ-opioid 
receptor (Manglik et al., 2012) confirmed the ability of receptors to be arranged in a 
dimeric/oligomeric organisation. Different interfaces seemed to be involved in receptor 
oligomerisation. An example is the TM1-TM2-helix 8 interface that is observed in μ-
opioid receptor homodimerisation (Manglik et al., 2012), in κ-opioid receptor dimerisation 
(Wu et al., 2012), in β1-adrenergic receptor dimerisation (Huang et al., 2013), in inactive 
rhodopsin (Park et al., 2008) and rhodopsin bound to 11-cis-retinal (Ruprecht et al., 2004) 
dimer formation. Another potential dimerisation interface that was revealed from studying 
crystal structures of CXCR4 and μ-opioid receptor involved TM5-TM6 interactions (Hiller 
et al., 2013), while the role of TM5 seems to be important in the dimerisation of the 
dopamine D2 receptor, muscarinic acetylcholine M3 receptor and  the 5-HT2C  receptor. 
TM6 domain was suggested to be involved in the homodimerisation interface of the β2-
adrenergic receptor (Hiller et al., 2013).  
Although solving the crystal structures of some GPCRs revealed valuable information 
about the oligomeric arrangement of the receptors, there was not a consensus 
dimeric/oligomeric interface common for all GPCRs or even common for the members of 
a group of GPCRs. In addition, the process of crystallisation is a complex and multi-step 
one, and it is not clear whether dimeric/oligomeric GPCR crystals have physiological 
relevance (Bouvier and Hebert, 2014).  
 
 
1.10.2 Roles of oligomerisation 
One of the initial reports of potential interactions between different GPCRs included 
functional cross-talk between α2- and β2-adrenoceptors demonstrated as an increase in α2-
adrenoceptor binding in cortical tissue after treatment with isoproterenol, a β2-adrenoceptor 
agonist (Maggi et al., 1980; reviewed in Gomez-Soler et al., 2011). Various similar 
examples were reported but were considered as evidence of receptor signalling cross-talk 
rather than strong oligomerisation evidence. The first experiment that had pharmacological 
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significance was carried out by Jordan and Devi, (1999) who suggested the formation of a 
heterodimer between κ- opioid and δ-opioid receptors. Co-expression of both receptors 
resulted in decreased affinity of κ- or δ-opioid receptor selective ligands, when 
administered alone, but the affinity was restored when both ligands were added to the 
assay, suggesting the existence of heteromers, through the occurrence of positive co-
operativity (Jordan and Devi, 1999). Another example whereby the formation of 
oligomeric complex confers pharmacological diversity to the receptor system is the 
observation of stable heteromers between the co-expressed orexin 1 (OX1) and 
cannabinoid 1 (CB1) receptors. The CB1 receptor antagonist, rimonabant, antagonises 
orexin A stimulation of ERK1/2 through OX1, when the two receptors are in a complex. 
The oligomeric profile of both receptors can be regulated by both OX1 and CB1 receptor 
ligands (Ellis et al., 2006). This suggests that receptor heteromerisation can alter receptor 
pharmacology, probably by altering receptor-agonist recognition by the formation of a new 
binding site with unique pharmacology (Gomez-Soler et al., 2011). 
A very important example that attracted attention to GPCR oligomers was described in the 
work of Maggio et al., (1993). This involved the generation of chimeric receptors 
combining features of the muscarinic M3 and adrenergic α2C-AR receptor to study 
oligomerisation using a functional complementation approach. A chimeric M3/α2C-AR was 
generated by combining the first five TM domains of M3 (including the IL3) and the last 
two TM domains of the adrenergic receptor. An equivalent α2C-AR/M3 chimera involved 
the combination of the first 5 TM domains of the adrenergic receptor and the final two TM 
domains of the M3, including the IL3 of M3. The IL3 was included unaltered because it 
was considered to be essential for G protein coupling specificity. Treatment with the 
muscarinic agonist carbachol did not lead to muscarinic receptor-mediated signalling when 
each chimeric receptor was expressed alone. Co-expression of the chimeras resulted in a 
carbachol-mediated response, indicating that the muscarinic receptor function was rescued, 
potentially due to oligomerisation, thus, suggesting a role of receptor oligomerisation in 
receptor function (Maggio et al., 1993; 1998). These examples support the hypothesis of 
class A receptors’ ability to form oligomers (Milligan, 2013; Herrick-Davis, 2013). 
 
Class C GPCRs form constitutive dimers/oligomers, with the GABAB receptor 
demonstrating the functional significance of oligomerisation, being able to activate G 
protein only when in hetero-dimeric form (Jones et al., 1998; Kaupmann et al., 1998). In 
the case of GABAB receptor heteromerisation is required for function (White et al., 1998). 
GABAB consists of two subunits, the GABAB1, that is capable of binding to the GABA 
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ligand, but cannot activate G protein and GABAB2 which is responsible for G protein 
activation but not for binding to G protein (Jones et al., 1998). Heteromerisation of the 
GABAB1 and GABAB2 results in the masking of the ER retention signal sequence of the 
GABAB1 (Margeta-Mitrovic et al., 2000) allowing the complex to reach plasma membrane 
and function. This suggests that oligomerisation possesses roles not just in the function and 
signal transduction but also in the trafficking of receptors (Pin et al., 2007; Calebiro et al., 
2013), since neither of the protomers was able to function nor to travel to the plasma 
membrane alone. Additional evidence of dimer/oligomer formation in early protein 
synthesis was generated using a truncated version of β2-AR where the C-terminal domain 
was replaced with the corresponding region of GABAB1 receptor. This resulted in an ER 
export-deficient mutant that inhibited the cell surface trafficking/delivery of the wild type 
β2-AR, when the two versions were co-expressed (Salahpour et al., 2004). A similar 
approach was followed for co-expressed CXCR1 and CXCR2 receptors. The C-terminal 
domain of the CXCR1 was replaced with the ER retention motif sequence of the β2-AR 
and a CXCR1 ER retention mutant was generated. Co-expression of the mutant with 
CXCR1 or CXCR2 WT prevented cell surface delivery of the WT receptors (Wilson et al., 
2005).This evidence suggests that formation of quaternary structure of GPCRs that leads to 
oligomerisation occurs early in biosynthesis of proteins (Milligan, 2004; Salahpour et al., 
2004). It is important to mention that the role of oligomerisation is also highly regulated in 
terms of protein folding, since misfolded proteins are unable to pass the cellular quality 
control and thus cannot traffic from ER to plasma membrane, but are processed for 
proteosomal degradation (Petaja-Repo et al., 2001).  
A role of oligomerisation in receptor internalisation has also been suggested since agonist 
mediated endocytosis has been documented for many heteromers including somatostatin 
SSTR1/SSTR5 heteromers (Rocheville et al., 2000), α2A/β1-AR heteromers (Xu et al., 
2003) and δ-opioid/β2-AR receptor heteromers, whereby stimulation of only one protomer 
was sufficient to cause co-internalisation of the complex. Homodimers of β2-AR also 
internalised upon agonist binding (Sartania et al., 2007).  
Signalling of the receptors that participate in an oligomeric complex is affected in some 
cases, implying a role of oligomerisation in GPCR signalling cascades.  
Oligomer formation can change G protein coupling preference and specificity, 
subsequently affecting GPCR signalling cascades. Dopamine D1 and D2 receptors signal 
through Gs and Gi, respectively, when in monomeric or homodimeric forms. The formation 
of a D1/D2 heteromer was followed by activation of Gq coupling, suggesting that 
heteromerisation can result in altered G protein coupling than that of the corresponding 
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monomers (Rashid et al., 2007). This finding was opposed by Frederick et al., (2015) who 
challenged the existence of the Gq signalling D1/D2 complex in mutant mouse models 
(behavioural pharmacological approach), in ex vivo analyses involving 
immunocytochemistry for investigating receptor co-localisation and proximity ligation 
assay (PLA) to assess proximity of receptors in brain slices and, finally, by BRET-based in 
vitro work (Frederick et al., 2015). 
Interestingly, heteromerisation between muscarinic receptors M3 and M5, in cells co-
expressing the receptors, demonstrated a negative regulatory role in receptor function. A 
peptide derived from the IL3 of M5 that specifically targets heteromer formation without 
affecting receptor function, inhibited carbachol-mediated ERK1/2 activation and reduced 
the levels of heteromer formation between M3 and M5 (Borroto-Escuela et al., 2010).  
Dimers of GPCRs are considered as more appropriate scaffolds for binding to single 
arrestin molecules (Han et al., 2001) resulting in the desensitisation of the GPCR dimer 
and leading to clathrin-mediated internalisation of the dimer (Milligan, 2004). It has been 
demonstrated that oligomerisation may alter the β-arrestin subtype -receptor interactions. 
Co-expressed thyroptropin releasing hormone TRH1 and TRH2 receptors demonstrated 
alternative patterns of β-arrestin subtype recruitment than that seen when each receptor was 
expressed alone (Hanyaloglu et al., 2002). Co-expressed vasopressin V2 and V1α receptors 
were reported to behave in a similar manner in terms of β-arrestin recruitment (Terrillon et 
al., 2004). Formation of oligomers in early stages of biosynthesis, was reported for 
vasopressin V2 receptor (Morello et al., 2000) and oxytocin receptors, using BRET 
(Terrillon et al., 2003), as well as homomerisation and heteromerisation of opioid receptor 
subtypes (Wang et al., 2005; Gomes et al., 2013).  
Oligomerisation of GPCRs can change the behaviour of the receptors and affect the plasma 
membrane diffusion, which may in turn affect the receptors’ interactions with other 
cellular components including cytoskeletal, scaffolding proteins or the lipid molecules of 
the membrane (Gomes-Soler et al., 2011). Receptor oligomerisation facilitates the 
proximity between two or more receptors, resulting in increased interaction probability but 
also in enhanced binding specificity through the formation of an enlarged interaction 
surface area (Klemm et al., 1998) bringing potential stability to the complex. 
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1.10.3 Evidence of GPCR oligomers in vivo 
Expression of receptors in heterologous cellular systems has been very useful in the 
investigation of GPCR oligomerisation, but it has been suggested that certain parameters 
such as the level of receptor expression may affect the interpretation of data and may lead 
to false conclusions about the oligomerisation of a receptor. Even if all the experimental 
conditions are controlled and all the assay controls are used, there are a number of factors 
that can affect the integrity of the results. Therefore, it is of great importance that 
experiments should be directed to in vivo studies in native tissues or even whole 
organisms, so that the functional relevance of GPCR oligomerisation can be validated.  
Some initial attempts to confirm the existence of oligomers in native tissues have been 
performed.  
Homodimers of oxytocin receptors were identified using an htrFRET-based approach with 
fluorescently labelled antagonists, in mammary gland tissue of lactating rats (Albizu et al., 
2010). Functional complementation experiments using mutated receptors in the absence of 
functional LH receptors in mice confirmed the presence of LH receptor oligomers in vivo 
(Rivero-Muller et al., 2010; Vassart, 2010).  
Melatonin receptors MT1 and MT2 in rod photoreceptors were demonstrated to function as 
heterodimers. In a KO mouse study, the loss of either MT1 or MT2 receptors, or over-
expression of a non-functional version of MT2 receptor resulted in the inhibition of 
melatonin mediated signalling (Bouvier and Hebert, 2014).  
Detection of constitutive serotonin 5-HT2C receptor homomers in choroid plexus epithelial 
cells was achieved by employing a combination of fluorescence correlation spectroscopy 
(FCS) and photon counting histogram (PCH), using an anti-5-HT2C fragment antigen 
binding protein to label native receptors in their native cellular environment (Herrick-
Davis et al., 2015).  
A better understanding of the receptor expression and co-expression patterns in 
combination with the development of techniques that will enhance in vivo study of 
oligomerisation in native tissues would be advantageous in solving questions of GPCR 
oligomerisation and the physiological relevance and implications to disease. 
 
 
1.10.4 Evidence of mAChRs oligomerisation 
Following the observation of protein-protein interactions between the chimeric M3/α2C-AR 
and α2C-AR/M3 receptors that were attributed to the ability of muscarinic receptors to 
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dimerise via a domain swapping mechanism (Maggio et al., 1993, 1998), other data 
emerged supporting oligomerisation of mAChRs.  
The ability of mAChRs to form oligomers has been confirmed by various RET-based 
methods. For example, the use of two differentially tagged hM1 receptors (hM1-Rluc and 
hM1-EYFP) generated BRET signal that was consistent with the formation of constitutive 
hM1 homomeric complexes (Marquer et al., 2010). Many variations of FRET have been 
utilised to study GPCR oligomerisation. Intra-molecular FRET has been used to study 
conformational changes within the receptor molecule (Vilardaga et al., 2003). Inter-
molecular FRET has been employed to study receptor dimerisation and also interactions 
between the M1 receptor and ligand molecules (Ilien et al., 2009). The stability and size of 
oligomers cannot be easily determined by conventional BRET and FRET-based 
approaches; hence a more specialised approach is required. For example, the dynamic 
interchange between M1 monomers and dimers at the surface of live cells was determined 
using two-colour total internal reflection fluorescence imaging (TIRFM), which utilised a 
fluorescently labelled form of the muscarinic antagonist telenzepine. The results from this 
work were consistent with the presence of both M1 dimers and monomers and it was 
proposed that, at steady state about 30% of the M1 receptor population exists in a dimeric 
form (Hern et al., 2010). 
The oligomeric arrangement of M2 receptor into homo-tetramers has been demonstrated in 
live cells by quantitative FRET (Pisterzi et al., 2010) with the M2 receptor tendency to 
form tetramers being confirmed by pharmacological studies (Redka et al., 2014). 
Zeng and Wess, (1999) had demonstrated the existence of M3 in monomeric, dimeric and 
oligomeric forms, by subjecting lysates from COS-7 cells expressing the rat M3 receptor to 
Western blot analysis under non-reducing conditions. Site directed mutagenesis using rat 
M3 receptor as a template generated cysteine substituted M3 mutants. This indicated two 
important cysteine residues (Cys140 and Cys220) with a key role in M3 dimer formation. 
The results were confirmed by co-immunoprecipitation and immunological studies (Zeng 
and Wess, 1999). Disulphide cross-linking experiments under non-reducing conditions 
using these cysteine substituted mutants of the rat M3 receptor led to the identification of 
some variants that exclusively existed in a constitutive dimeric form (Hu et al., 2011). 
Results from these studies were consistent with the existence of two possible dimeric M3 
interfaces (e.g. TM4-TM5-IL2 through IL2-IL2 contacts and TM1-TM2-helix 8 through 
H8-H8 interactions) (Hu et al., 2013). The formation of M3 dimers or higher order 
oligomers has also been demonstrated by McMillin et al., (2011) by saturation BRET 
experiments using Venus and luciferase tagged M3 receptors (McMillin et al., 2011). 
Chapter 1   
 
51 
 
Molecular modelling assisted by BRET data and mutagenesis of M3 receptor’s TM 
domains revealed the existence of four different dimeric arrangements characterised by 
four distinct interfaces involving: TM5-TM5, TM6-TM7, TM4-TM5 and TM1-TM2. The 
lowest energy model involved the TM5-TM5 interface and predicted that Tyr255 on a 
monomer of M3 is responsible for interactions with Arg253, Lys256 and Lys260 residues 
on the adjacent M3 monomer (McMillin et al., 2011).  A variant of FRET called 
homogeneous time-resolved FRET (htrFRET) has been used in combination with SNAP- 
and CLIP tagging of the N-terminus of receptors and labelling with SNAP and CLIP 
epitope specific fluorescent substrates (described in section 1.12), in the detection of 
homomers of the M3 receptor (Alvarez-Curto et al., 2010) and similarly in the detection of 
M2 and M3 homomers and heteromers in live cells (Aslanoglou et al., 2015). The 
rhomboidal arrangement of M3 tetramers was documented using quantitative FRET 
spectrometry and mathematical analysis of the FRET efficiencies obtained from spectral 
deconvolution (Patowary et al., 2013). The above examples are shown in Figures 1.9 and 
Figure 1.10. In order to understand the basis of M3 tetrameric interactions, a combination 
of site-directed mutagenesis and htrFRET was used (Varela Liste et al., 2015). Molecular 
modelling studies assisted by alanine mutagenesis at residues within the TM domains of 
the VSV-SNAP-hM3WT have pointed out the involvement of several TM domains of M3 
in the organisation of a tetramer. The TM domains involved were: TM1, TM4, TM5, TM6, 
TM7 and helix 8. Multiple residues on the TM domains were identified to play a role in the 
formation of oligomers and the molecular model generated was consistent with a dimer: 
dimer interface involving TM1-TM2-helix 8 interactions, with the presence of cholesterol 
molecules between the dimers of the receptor (Varela Liste et al., 2015). 
The ability of M1, M2 and M3 receptors to form constitutive homomers was detected by 
quantitative BRET analysis using live HEK 293 cells expressing fluorescently tagged 
receptors. The presence of homomers of muscarinic receptors was demonstrated along with 
the existence of  heteromers (M1/M2, M2/M3, M1/M3) by saturation BRET assays, 
suggesting that the dimer was the predominant receptor form (Goin and Nathanson, 2006).  
Maggio et al., (1999) examined binding of two antagonists, pirenzepine and tripitramine, 
to M2 and M3 muscarinic receptors. The results revealed the existence of distinct receptor 
populations; the first corresponding to individual M2 or M3 receptors while the second 
population was consistent with heteromeric formation between M2/M3 (Maggio et al., 
1999). Biochemical data using co-immunoprecipitation and fluorescence microscopy 
experiments confirmed the M2/M3 heteromerisation and homomerisation of M2 and M3 and 
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suggested that β-arrestin 1 recruitment to M3 required the paired activation of both receptor 
protomers that constitute the dimer (Novi et al., 2005).   
Saturation BRET in combination with co-immunoprecipitation experiments was carried 
out in order to study oligomerisation of M3 and M5 receptors (Borroto-Escuela et al., 
2010). This study suggested that M3 and M5 exist as constitutive homo-dimers and can also 
hetero-dimerise when expressed in the same cells. There is also evidence that suggest a key 
role of IL3 of M5 in the modulation of dimerisation by possibly affecting the 
conformational rearrangement of M3-M5 hetero-dimer, in a G-protein independent fashion 
(Borroto-Escuela et al., 2010).  
 
 
Figure 1.9 Muscarinic receptor oligomers. (A) A saturation BRET-based assay using transfected 
mammalian cells demonstrated the presence of homomers of M1, M2 and M3 receptors (Figure 
taken from Goin and Nathanson, 2006). (B) Total internal reflection fluorescence microscopy 
carried out at single cell resolution utilising fluorescently tagged telenzepine successfully 
demonstrated the presence of M1 dimers at the surface of live cells and proposed the dynamic 
interchange between monomers and dimers of M1 receptor (Figure taken from Hern et al., 2010). 
(C) Homogeneous time-resolved FRET signals that corresponded to the existence of VSV-SNAP-
hM3WT and VSV-SNAP-hM3RASSL oligomers at the surface of live Flp-In™ T-REx™ 293 cells, 
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were obtained following labelling with SNAP-Lumi4 Tb and SNAP-Red substrates, acting as 
energy donor and acceptor, respectively (Figure taken from Alvarez-Curto et al., 2010). 
   
 
Figure 1.10 M3 receptor is a tetramer of rhomboidal arrangement. FRET-based analysis of 
Flp-In™ T-REx™ 293 cells co-expressing myc-hM3RASSL-Cerulean (inducible) and FLAG-
hM3WT-Citrine (constitutive) in combination with analysis within a theoretical framework of 
distributions of FRET efficiencies and spectral deconvolution of these efficiencies, suggested that 
the homomeric population of M3 receptors is a mixture of dimers and rhombic tetramers (Figure 
taken from Patowary et al., 2013).   
 
Despite the growing evidence supporting GPCR oligomerisation, no general consensus on 
the mechanism that underlies this has been reached that could include all GPCRs. This 
could be due to structural differences between receptors, potentially requiring different 
dimer/oligomer interfaces. Many different methods have been used to investigate the 
oligomerisation of receptors. The different methods used provided a great degree of 
variation in the obtained outcomes in terms of oligomerisation and have not offered 
definitive answers on size, stability and regulation of receptor oligomerisation. This points 
out the importance for further investigation in the field of receptor oligomerisation in order 
to try and provide answers to questions regarding the size of the complexes formed, the 
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manner oligomerisation affects signalling and pharmacology of receptors and the nature of 
oligomerisation (constitutive or ligand-mediated). 
 
 
1.11 Ligand regulation of oligomerisation 
 
Several questions still remain unanswered about the size and stability of oligomeric 
complexes formed between GPCRs. In addition, ligand-mediated regulation of GPCR 
oligomerisation is still an area of great scientific debate.  There is no consensus mechanism 
in terms of regulation of oligomerisation by ligands, but different observations have been 
encountered suggesting three possibilities. Firstly, if the receptor exists in a 
dimeric/oligomeric arrangement, it is possible that any ligand-mediated receptor activation 
may alter the conformation of the receptor and this can result in a change in the oligomeric 
profile of the receptor in question. Secondly, it is possible that no changes will be observed 
in receptor oligomerisation upon ligand binding. Finally, ligand activation may be a 
prerequisite for dimer/oligomer formation (Angers et al., 2002).  
Investigation of β2-AR dimerisation suggested the dynamic interchange between 
monomeric and dimeric forms of the receptor upon ligand addition. More specifically, 
agonist (isoproterenol) stimulation of β2-AR stabilised the dimeric formation whereas, 
inverse agonist (timolol) favoured the reversal of dimer formation into monomers (Hebert 
et al., 1996). BRET-based assays that involved the stimulation of β2-AR with a selective 
agonist, isoproterenol, resulted in an increase in the level of energy transfer consistent with 
either an increase in dimer formation or an intramolecular conformational change that 
altered the orientation of the energy donor and acceptor or their proximity (Angers et al., 
2000). More recent BRET-based experiments demonstrated physical and functional 
interactions between CB1 cannabinoid receptors and β2-AR in transfected cells and also in 
tissues co-expressing the receptors. Ligand regulation of oligomerisation affected the 
signalling and trafficking of the two receptors. The CB1 receptor inverse agonist AM251 
inhibited β2-AR induced pERK signalling in cells co-expressing the receptors, while the 
CB1 receptor neutral antagonist, O-2050, had no effect on the β2-AR-related signalling 
pathways (Hudson et al., 2010). Opioid agonists were documented to lead to a decrease in 
the dimer concentration of δ-opioid receptors (Cvejic and Devi, 1997). By contrast, 
constitutive BRET signal was observed indicating the dimerisation of δ-opioid receptor, 
but the oligomeric profile of the receptor was insensitive to agonist treatment (McVey et 
al., 2001). The constitutive homomeric status of gonadotropin releasing hormone receptor, 
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as detected by FRET signal between the GFP and RFP tagged receptors, was increased 
upon agonist (buserelin) treatment in a concentration-dependent manner (Cornea et al., 
2000). However the heteromerisation between dopamine D2 and somatostatin SST5 
receptors was promoted by antagonists rather than agonists (Rocheville et al., 2000).  
The dynamic interplay between CXCR1 and CXCR2 heteromers and their corresponding 
homomers was affected by the addition of the agonist CXCL8, which binds to both 
receptors, but shows greater affinity for CXCR2. Changes in FRET signal were detected 
corresponding to a decrease of heteromers and increase in both CXCR1 and CXCR2 
homomers. In addition, the expression of CXCR1 interfered with the formation CXCR2 
homomers suggesting that receptor expression also plays a role in regulation of 
oligomerisation (Martinez-Munoz et al., 2009).   
A BRET-based approach to investigate the heteromerisation between α1-AR and CXCR2 
receptors demonstrated that the constitutive heteromers formed were not affected by 
ligands (Mustafa et al., 2012).  
A combination of SNAP tag technology and TIRFM approach to detect individual 
receptors and oligomers of β1-AR and β2-AR receptors at the cell surface, allowed for 
single molecule tracking of individual GPCRs (Calebiro et al., 2013). In addition, the 
detection and analysis of oligomers showed that β1-AR was predominantly in a monomeric 
form at low receptor densities, but dimer formation was enhanced when receptor density 
increased. On the contrary, the β2-AR showed a higher tendency towards forming dimers 
or higher order oligomers even at low receptor densities. The transient nature of the β1/β2-
AR interaction was also demonstrated (Calebiro et al., 2013). The method employed by 
Calebiro et al., (2013) allowed for the dynamics and size of receptor complexes to be 
estimated, and enabled the monitoring of receptor mobility and finally was useful in 
assessing ligand regulation upon agonist binding (Calebiro et al., 2013). 
 
The issue of ligand regulation of muscarinic receptor oligomerisation is not yet clear. A 
series of contradicting results exists, with some indicating ligand-mediated regulation of 
the oligomeric status of muscarinic receptors and others supporting the inability of ligands 
to confer changes in the homomeric and/or heteromeric profile of muscarinic receptors. 
Some muscarinic ligands were documented to affect the oligomeric organisation of 
muscarinic receptors. Namely, pirenzepine induced M1 dimerisation (Ilien et al., 2009) and 
the orthosteric antagonist QNB stabilised pre-existing M2 dimers (Park and Wells, 2003).  
The muscarinic toxin 7 (MT7), a highly M1 selective allosteric peptide that is isolated from 
snake venom, seems to have the ability to bind and stabilise pre-existing dimeric forms of 
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M1, probably by inducing conformational changes within the oligomer, without promoting 
new M1 dimer formation. This was demonstrated by BRET-based assays, monitoring the 
BRET signal, indicative of the M1-Rluc and M1-EYFP interactions (Marquer et al., 2010).  
Early biochemical data using mutants of the rat M3 receptor lacking most of the IL3 
resulted in non-significant changes in the muscarinic receptor oligomerisation upon 
treatment with carbachol (Zeng and Wess, 1999). On the other hand, Hu et al., (2013) 
identified some cysteine substituted mutants of rat M3 receptor where carbachol treatment 
resulted in a reduction of M3 monomers and a simultaneous increase in dimeric form of 
M3, in a concentration dependent manner (Figure 1.11) (Hu et al., 2013).  
 
                 
Figure 1.11 Carbachol regulates M3 receptor dimerisation. Cysteine substituted rat M3 receptor 
mutant (R260C) was used to perform cross linking experiments, assisted by incubation with copper 
phenanthroline (CuPhen). M3 dimerisation increased in response to carbachol treatment (arrow) 
while at the same time there was a decrease in the monomeric form of the M3 receptor (star) 
(Figure taken from Hu et al., 2011).  
 
Another BRET-based approach followed by Goin and Nathanson, (2006), demonstrated 
the existence of M1, M2, M3 homomers and heteromers by quantitative saturation BRET 
analysis, but failed to show that short term carbachol treatment could regulate the 
oligomeric status of either homo- and hetero-mers between muscarinic receptors (Goin and 
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Nathanson, 2006). The ability of carbachol and atropine to regulate the homomeric 
arrangement of M3WT receptor was demonstrated by htrFRET-based assays in 
combination with SNAP-tag technology, while the synthetic ligand CNO enhanced the 
dimerisation of the RASSL version of M3, as described by Alvarez-Curto et al., 2010 
(Figure 1.12).  
 
 
Figure 1.12 Agonists promote hM3 receptor oligomerisation. Flp-In™ T-REx™ 293 cells 
inducibly expressing either the VSV-SNAP-hM3RASSL (A and B) or the VSV-SNAP-hM3W 
receptors were subjected to SNAP-Lumi4 Tb (donor) and SNAP-Red (acceptor) labelling and 
htrFRET was monitored upon ligand addition. (A) The synthetic ligand CNO induced an increase 
in homomerisation of VSV-SNAP-hM3RASSL in a concentration dependent manner; (B) while 
Cch and atropine had no effect on the homomeric organisation of the receptor. (C) The agonist 
carbachol significantly increased the homomerisation of VSV-SNAP-hM3WT, as demonstrated by 
an increase in htrFRET, while CNO had no effect on the homomeric profile of VSV-SNAP-
hM3WT (Figure taken from Alvarez-Curto et al., 2010).  
 
Recent data propose the ability of carbachol to induce changes in heteromerisation between 
M2WT and M3RASSL receptors in cells co-expressing both receptors. The heteromeric 
arrangement of M2/M3 was reduced upon carbachol treatment while at the same time the 
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M2/M2 homomerisation was increased, as detected by htrFRET. Although changes in 
M2/M3 heteromers and M2 homomers were detected, the M3 homomers seemed to remain 
unaffected by agonist treatment (Aslanoglou et al., 2015).   
The lack of a common theme for ligand-mediated regulation of GPCR oligomerisation may 
suggest that each receptor behaves in a unique manner in terms of interacting with other 
receptors. In addition, the experimental approach followed and the interpretation of the 
data obtained may be crucial for determining the role of ligands in regulating the 
oligomeric profile of receptors. Therefore, methods that offer enhanced resolution, high 
sensitivity and the appropriate controls (positive and negative) to ensure good quality data 
could be extremely advantageous.  
Understanding and clarifying the role of ligands in the regulation of oligomeric state of 
GPCRs could contribute in the understanding of the actual role of oligomerisation. 
 
 
1.12 Resonance energy transfer (RET) methods used to study GPCR 
oligomerisation  
 
Novel advances in RET methods have revolutionised the development of htrFRET, a 
relatively new method that has been used for investigating protein-protein interactions, in 
live cell-based assay formats. htrFRET is based on the same principles of resonance energy 
transfer, as described by Theodor Förster in 1948 (that is the non-radiative energy transfer 
that occurs between two energy partners, one donor and one acceptor). The requirements 
for FRET energy donor and acceptor partners are: (A) energy compatibility; donor 
emission spectrum must overlap with the excitation spectrum of the acceptor, (B) 
compatible orientation of both donor and acceptor and (C) non-radiative energy transfer 
can occur only when the two energy partners (donor and acceptor) are in close proximity. 
The efficiency (E) of the transfer may be calculated using the equation below. Efficiency is 
inversely proportional to the sixth power of the distance (r): 
 
𝐸 =
𝑅𝑜6
𝑅𝑜6 + 𝑟6
 
 
Where, E is the energy transfer efficiency and Ro is the Forster distance between donor 
and acceptor when the transfer efficiency is 50% (Förster, 1948).  
Standard FRET experiments involve the fusion of fluorescent proteins to the receptor in 
question.  Very popular combinations of fluorescent proteins for FRET experiments 
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includes variants of the GFP (CFP and YFP) incorporated into the receptor of interest by 
genetic engineering (Vilagarda et al., 2009) (see Figure 1.13). Alternatives included a 
combination of CFP and FlAsH FRET sensor (Alvarez-Curto et al., 2010). A conceptually 
similar RET-based method utilises the combination of a fluorescent protein and a 
luciferase has been extensively used to detect protein-protein interactions by monitoring 
BRET (Goin and Nathanson, 2006). 
 
 
Figure 1.13 FRET between two GPCRs fused to CFP and YFP. Two spectrally compatible 
fluorescent proteins, such as CFP and YFP, can be fused at the C- or the N-terminus of two 
different GPCRs to investigate dimeric/oligomeric interactions between them. The FRET signal 
corresponds to the formation of a dimeric/oligomeric interaction between two GPCRs, as this 
brings the CFP and YFP into proximity.  
 
htrFRET in combination with SNAP/CLIP tag fusions and TagLite® technology is based 
on the generation of protein fusions with epitope tags preferably at the extracellular N-
terminus of the receptor expressed at the surface of live cells and labelled with FRET 
compatible fluorescent substrates. The SNAP tag is 20 kDa and is derived from O6-guanine 
nucleotide alkyltransferase, an enzyme that is involved in the DNA repair mechanism in 
eukaryotic organisms. The SNAP tag can be specifically bound to any fluorophore that 
contains benzyl guanine (BG), resulting in a covalent interaction. A variant of SNAP tag, 
the CLIP tag can also be used. CLIP tag is of similar size and can also be fused at the 
receptor/protein of interest, without interfering with receptor function and it can be 
covalently labelled with benzyl cytosine conjugated fluorophore (Figure 1.14).   
The main element in the htrFRET approach is the combination of energy donor and 
acceptor. Energy donors that can be used are either Europium cryptate (Eu3+ cryptate) or 
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Lumi4 terbium (Tb2+ cryptate). The rare earth cryptates belong to the family of lanthanides 
and they possess long fluorescent lifetime, a feature that is central to htrFRET. The long 
fluorescence lifetime allows the elimination of the background noise (non-specific signal 
originating from either auto-fluorescence or fluorescence coming from any remaining 
serum contained in the cell medium), by leaving a gap between the time of excitation and 
the time of FRET measurement, usually in the micro second scale. This allows for the 
specific FRET signal to be measured in a time-resolved manner. It is not necessary to 
separate free from bound and thus it is a homogeneous assay where washing steps are 
eliminated or limited.  
Homogeneous time-resolved FRET offers flexibility and increased sensitivity, allowing for 
robust and reliable assays with high throughput potential and fewer false positive or 
negative results. SNAP and/or CLIP htrFRET compatible substrates allow measurement of 
emissions at two different and distinguishable wavelengths e.g. 620 nm donor and 665 nm 
acceptor (htrFRET signal) (Degorce et al., 2009).  
 
 
Figure 1.14 SNAP and CLIP tag labelling. The protein/receptor of interest can be tagged with a 
SNAP or CLIP tag by genetic engineering and once the fusion is expressed and trafficked to the 
cell surface, SNAP specific benzylguanine and CLIP specific benzylcytosine substrates can be used 
to label the tagged receptors. The SNAP and CLIP tags act as suicide enzymes by reacting with 
benzylguanine and benzylcytosine linked labels, to covalently bond the tags via a thio-ester 
linkage. The labelled SNAP or CLIP fusion protein, once labelled can be excited at a certain 
wavelength and then emits at a longer wavelength. (Figure from New England Biolabs 
https://www.neb.com/tools-and-resources/feature-articles/snap-tag-technologies-novel-tools-to-
study-protein-function ).  
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The first time that htrFRET methodology was used in combination with SNAP tag 
technology in detecting and analysing GPCR oligomers was described by Maurel et al., 
(2008). This approach included generation of SNAP tagged GABAB1 and FLAG tagged 
GABAB2 receptors. The fused receptors were expressed at the surface of live HEK 293 
cells and the SNAP-GABAB1 was labelled with europium cryptate donor (BG-K) and the 
FLAG-GABAB2 was labelled using anti-flag antibodies conjugated with d2 (acceptor), 
allowing the detection of TR-FRET signal consistent with the existence of receptor 
heterodimers at the surface of the cells. The maximal FRET signal was detected once the 
labelling conditions were optimised. Optimisation ensured equivalent labelling of SNAP 
tags with each fluorophore. The TR-FRET efficacy (ratio between the acceptor emission 
and amount of donor) was constant over a range of receptor density suggesting that the 
signal was due to actual protein-protein interactions rather than due to random collisions. 
Evidence demonstrating the existence of dimer of dimers organisation for GABAB 
receptors was also presented and this study constituted a very important contribution to the 
investigation of GPCR dimerisation (Maurel et al., 2008).   
Traditional approaches used for investigating GPCR oligomerisation such as ligand 
binding, co-immunoprecipitation and functional complementation  have provided 
supporting evidence for the oligomerisation theory but cannot provide definitive proof of 
direct protein-protein interactions. In addition, such techniques cannot give answers about 
the size, the stability, regulation and more importantly about the role of oligomeric 
complexes (Cottet et al., 2012).  Other resonance energy transfer methods such as classical 
FRET using fluorescent proteins or BRET using luciferase and fluorescent protein fusions 
often require over-expression of the receptors in transfected cells. This often leads to 
difficulties in distinguishing RET signal corresponding to real protein interactions from 
signal obtained due to random collisions. In addition, the low noise-to-signal ratio that 
results from intrinsic fluorescence originating from the cells and/or the overlap between 
emission spectra of RET donor and acceptor is considered a drawback of these techniques.  
Although, RET-based methods present adequate spatial resolution that allows detection of 
interactions between proteins with relative precision, it is difficult to make conclusions on 
the amount or the order of oligomeric complexes e.g. dimer, trimer, tetramer or higher 
order oligomer. 
The htrFRET approach offers great signal resolution and high signal-to-noise ratio.  
htrFRET does not demonstrate any dependence to the relative orientation of the 
fluorophore, since lanthanide emission is polarised, unlike in BRET or standard FRET.  
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The unique spectral properties of terbium cryptates (Lumi4 Tb) allow for multiplex 
labelling of the receptors using more than two fluorescent substrates that follow the rule of 
spectral compatibility, without any interference of their emission channels.  
 
Fluorescently labelled ligands can be used in an htrFRET experimental design (Albizu et 
al., 2010) and this may transfer the study of GPCR oligomerisation from heterologous 
expression systems to native tissues, which may potentially unravel the in vivo role of 
GPCR oligomers and establish the functional relevance of oligomers in native tissues. The 
use of ligands labelled with htrFRET compatible fluorophores may be a very useful 
alternative to fluorescently labelled antibodies used for studying receptors in native tissues. 
Antibodies can be target-specific but their size is a limiting factor since they generate steric 
hindrance in the vicinity of the receptors which can affect the binding of receptors. In 
addition, antibody binding to the epitope may be affected by possible conformational 
changes mediated by ligand induced receptor activation.  
The combination of htrFRET with SNAP/CLIP tagging of receptors is a useful tool in 
detecting GPCR oligomers (Alvarez-Curto et al., 2011; Pou et al., 2012) at the surface of 
live cells (Figure 1.15), but it has also provided a novel approach in studying the dynamics 
of oligomerisation. One of the main disadvantages of any RET-based technique is the 
difficulty in reaching definitive conclusions about the order of oligomerisation i.e. the 
inability to distinguish dimers from higher order oligomers. Another drawback of the RET-
based approaches is the inability to distinguish between cell-surface and intracellular 
receptors. In the case of htrFRET, this important issue was overcome, with the 
development of cell impermeant and cell permeable labelling substrates that allowed the 
specific labelling of either cell surface receptors or whole cell receptor population. 
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Figure 1.15 htrFRET based detection of GPCR homomers and heteromers. (A) Homomers 
between two N-terminally SNAP or CLIP tagged receptors can be detected at the cell surface, 
following labelling with SNAP or CLIP specific substrates. The SNAP/CLIP-Lumi4 Tb may be 
used as energy donor, emitting at 620 nm, and the SNAP/CLIP-Red as energy acceptor, emitting at 
665 nm following transfer of energy from the donor. (B) Heteromers between SNAP and CLIP 
tagged receptors may be detected, following labelling with SNAP or CLIP Lumi4 Tb donor and 
CLIP or SNAP Red acceptor, respectively.  
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1.13 Aims of the project 
The scope of this PhD project was to shed light into the field of muscarinic acetylcholine 
receptor oligomerisation and more specifically to look into the formation of homomers and 
heteromers between the human M2WT (hM2WT) and a genetically engineered variant of 
the human M3WT, called hM3RASSL, able to respond only to the synthetic ligand 
clozapine N-oxide (CNO). The debated topic of ligand regulation of receptor 
oligomerisation was another important topic to be tackled, since various observations have 
been reported on the subject, using different technical methods and various cellular 
expression systems. The aim was to investigate potential ligand-mediated regulation of 
hM2WT and hM3RASSL receptor oligomerisation. This employed an htrFRET approach in 
combination with SNAP-tag technology and heterologous expression of the receptors in 
Flp-In™ T-REx™-293 cells. An important aim was to assess the stability of any 
oligomeric complexes and the possible interchange between homomers and heteromers.   
An understanding of oligomerisation of M2 and M3 receptors and ligand regulation of the 
oligomerisation profile would be advantageous in the study of the muscarinic receptors 
behaviour and in understanding of possible pathophysiology in tissues where the two 
receptors are co-expressed and co-localised (e.g. gastrointestinal and airway smooth 
muscle). In the long term, understanding of M2/M3 heteromer formation could lead to 
novel therapeutic approaches via the development of oligomer specific ligands that could 
modulate the pharmacology of the receptors in a complex and provide treatments with 
reduced side effects and increased selectivity and specificity.
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2.1 Materials 
2.1.1 General reagents and kits 
Agarose (Flowgen Biosciences, Nottingham, UK) 
Bicinchoninic acid (BCA) reagent (Pierce, Tattenhall, UK) 
Broad range Rainbow molecular weight protein marker (Life Technologies, Paisley, UK) 
cAMP dynamic 2 kit (Cisbio Bioassays, Codolet, France) 
Fluorescent dyes: SNAP-Surface 549, SNAP-Surface 488, CLIP-Surface 488, CLIP-
Surface 547 (New England Biolabs, UK) 
GF/C filters (Brandel Inc. Gaithersburg, MD) 
Hank’s Balanced Salt Solution (HBSS) (Life Technologies, Paisley, UK) 
IP-One Tb kit (Cisbio Bioassays, Codolet, France) 
NativePAGE™ Novex® 3-12% Bis-Tris Protein Gels (Life Technologies, Paisley, UK) 
NuPAGE® Novex® 4-12% Bis-Tris Protein Gels (Life Technologies, Paisley, UK) 
NuPAGE® MOPS SDS Running Buffer (20X) (Life Technologies, Paisley, UK) 
Oligonucleotides for PCR reactions (Thermo Fisher Scientific, Ulm, Germany) 
Polyethylenimine (PEI) (Sigma Aldrich, Poole, Dorset, UK)  
Poly-D-Lysine (Sigma Aldrich, Poole, Dorset, UK) 
Platinum® Pfx DNA polymerase (Life Technologies, Paisley, UK) 
QIAfilter Plasmid Maxi kit (Qiagen, Crawley, UK) 
QiaQuick gel extraction kit (Qiagen, Crawley, UK) 
ReBlot Plus solution (Chemicon Europe Ltd., Chandlers Ford, UK) 
Restriction endonucleases from Roche Applied Science (Lewes, East Sussex, UK), 
Promega, UK Ltd., (Southampton, UK), and New England Biolabs, UK) 
SNAP/CLIP-Lumi4 Tb, SNAP/CLIP-Red and SNAP-Green (Cisbio Bioassays, Codolet, 
France) 
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Supersignal West Pico chemiluminescent substrate (Pierce, Perbio Science UK Ltd., 
Tattenhall, Cheshire, UK) 
SYBR® Safe DNA Gel Stain (Life Technologies, Paisley, UK) 
Tunicamycin (Sigma Aldrich, Poole, Dorset, UK) 
Wizard Plus SV Miniprep kit (Promega, Southampton, UK) 
X-ray film (Konika Europe, Hohenbrunn, Germany) 
 
2.1.2 Tissue culture reagents  
Dulbecco′s Modified Eagle′s Medium (DMEM), L-glutamine, 0.25% trypsin-EDTA, 
doxycycline- Sigma-Aldrich Company Ltd. (Poole, Dorset, UK) 
Geneticin G418 and foetal bovine serum - Invitrogen (Paisley, UK) 
Hygromycin B-Roche Applied Science (Lewes, East Sussex, UK) 
Trypan Blue stain (0.4%) -Life Technologies (UK) 
 
2.1.3 Ligands  
Atropine methyl nitrate Sigma-Aldrich Company Ltd. (Poole, Dorset, UK) 
Carbachol (Tocris Bioscience, UK) 
Clozapine-N-Oxide (CNO) (Enzo Life Sciences, UK) 
 
2.1.4 Radioligands  
[3H]-Quinuclidinyl benzilate (QNB) (Perkin-Elmer Life and Analytical Sciences, 
Beaconsfield, Buckinghamshire, UK) 
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2.1.5 Antisera 
Rat anti-HA (Roche, UK)  
Rabbit anti-VSV (in house) 
Rabbit anti-SNAP (New England Biolabs, MA, USA) 
Mouse anti-M3 (Gift from Professor A. Tobin, University of Leicester)  
Monoclonal anti-VSV-G agarose conjugate (Sigma Aldrich, UK) 
Goat anti-mouse IgG HRP conjugate (GE Healthcare, UK) 
Donkey anti-rabbit IgG HRP conjugate (GE Healthcare, UK) 
Goat Anti-rat IgG HRP conjugate(GE Healthcare, UK) 
Anti-goat IgG HRP conjugate (Sigma Aldrich, UK) 
 
2.1.6 General buffers  
Phosphate Buffered Saline – PBS (1X) 
 137 mM NaCl 
 2.7 mM KCl 
 1.5 mM KH2PO4 
 8 mM Na2HPO4 
pH 7.4 
 
Tris Buffered Saline –TBS (1X) 
 20 mM Tris-Base 
 150 mM NaCl 
pH 7.4 
 
Tris Buffered Saline-Tween 20 (TBS-T)  
 TBS (1X) 
 0.1 % (v/v) Tween-20  
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Tris-EDTA (TE) buffer (1X) 
 10 mM Tris 
 1 mM EDTA 
pH 7.4 
 
 
Radioligand binding assay buffer (1X) 
 20 mM HEPES 
 100 mM NaCl 
 10 mM MgCl2 
pH 7.4 
 
Radioimmune precipitation assay (RIPA) buffer (1X) 
 50 mM HEPES 
 150 mM NaCl 
 1% (v/v) Triton X-100  
 0.5% sodium deoxycholate 
 10 mM NaF 
 5 mM EDTA 
 10 mM Na2HPO4 
 5% (v/v) ethylene glycol 
pH 7.4 
Supplemented with Complete protease inhibitors mixture  
Stored at 4 ˚C  
 
Cell lysis buffer 1X (used for lysate preparation for Blue Native PAGE) 
 150 mM NaCl 
 0.01 mM Na2HPO4 
 2 mM EDTA 
 0.5%  n-Dodecyl β-D-maltoside (DDM) 
 5% glycerol 
Supplemented with Complete protease inhibitors mixture  
Stored at 4 ˚C  
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Laemmli buffer (5X) 
 10% w/v sodium dodecyl sulphate (SDS) 
 10 mM dithiothreitol (DTT) 
 20% glycerol 
 0.2 M Tris-HCl 
 0.05% bromophenol blue 
pH 6.8 
 
 
2.1.7 Molecular biology solutions 
TAE buffer (50X) 
 40 mM Tris-Base 
 5 mM EDTA 
 5.71 % (v/v) glacial acetic acid 
Diluted 1:50 prior to use  
 
DNA loading buffer (5X) 
 0.25 % (w/v) bromophenol blue 
 40 % (w/v) sucrose  
 In water 
 
Luria-Bertani (LB) broth 
 1% (w/v) bactotryptone 
 0.5% (w/v) yeast extract 
 1% NaCl 
Dissolved in water and adjusted pH at 7.4 
Sterilised by autoclaving 
Ampicillin (100 μg∙ml-1) was added for the preparation of LB ampicillin media, after the 
media was cooled down to 50˚C. 
 
Luria-Bertani (LB) agar  
 1.5% (w/v) agar into LB broth 
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Ampicillin (100 μg∙ml-1) was added for the preparation of LB ampicillin agar plates, after 
the media was cooled down to 50˚C. After gentle mixing, the agar was poured onto 10 cm2 
petri dishes and was left on bench to set before storing at 4˚C. 
 
 
Solutions for generation of competent bacteria  
Solution 1: 
 0.03 M (CH3COOK) 
 0.1 M RbCl2 
 0.01 M CaCl2 
 0.05 M MnCl2 
 15% glycerol 
Adjusted pH at 5.8 with acetic acid and filter sterilised. Stored at 4˚C. 
 
Solution 2: 
 10 mM MOPS (pH 6.5) 
 0.075 M CaCl2 
 0.01 M RbCl2 
 15% glycerol 
Adjusted pH at 6.5 with HCl and filter sterilised. Stored at 4˚C.  
 
2.2 Molecular Biology Methods 
2.2.1 XL1 Blue Competent bacterial cells preparation  
XL1-Blue cells were streaked onto an LB-agar plate that was incubated overnight at 37˚C. 
A single colony was used to inoculate 5 ml LB broth at 37˚C overnight. The overnight 
bacterial culture was used to inoculate 100 ml of LB broth and cells were allowed to grow 
until the optical density measured at 550 nm reached 0.45- 0.48. The culture was 
transferred into two 50 ml Falcon tubes, placed on ice for 5 minutes and subsequently 
centrifuged for 10 minutes at 4˚C at 2500 rpm. Cell pellets in each tube were gently 
resuspended in 10 ml Solution 1. The cell suspensions were incubated on ice for 5 minutes 
and then centrifuged for 10 minutes at 4˚C at 2500 rpm. The pellet was then resuspended 
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in 2 ml Solution 2 and incubated on ice for 15 minutes before aliquoting 220 μl cell 
suspension per tube and storing at -80˚C. 
 
2.2.2 Transformation of competent bacterial cells 
For the transformation of competent bacterial cells, XL1-Blue cells were thawed on ice. 
The DNA constructs (50-100 ng) or the ligation reaction (5 μl) was added to 50 μl of the 
competent cells and incubated on ice for 20 minutes. The bacteria were subjected to heat 
shock by incubating samples at 42 ˚C for 90 seconds. After the heat shock, cells were 
placed on ice for a further minute, before 1 ml of LB medium was added. The cells were 
allowed to recover at 37 ˚C in a shaking incubator for 1 h and then centrifuged for 1 minute 
at 14,000 rpm. The cell pellet was resuspended in 100 μl of LB and this was spread onto 
LB agar plates containing ampicillin (100 μg∙ml-1). Plates were then incubated at 37 ˚C 
overnight to allow for selection of transformants.  
 
2.2.3 Isolation and purification of plasmid DNA 
For the extraction of the plasmid DNA from bacterial cells, the Wizard Plus SV Miniprep 
kit (Promega) was used. The QIAfilter Plasmid Maxi kit (Qiagen) was used to isolate and 
purify larger amounts of plasmid DNA. The kits were used according to manufacturer’s 
instructions.  
 
2.2.4 Quantification of DNA  
Quantification of DNA was performed by measuring the absorbance of a DNA sample 
(1:100 dilution) at 260 nm using a spectrophotometer. Absorbance at 280 nm was also 
measured to assess the purity of the sample. This was carried out by calculating the ratio 
A260 / A280. Samples with a ratio between 1.7 and 2 were considered pure enough for use. 
DNA samples used in ligation reactions were quantified by running the DNA samples on a 
1% agarose gel, alongside with 5 μl of the DNA molecular marker (HyperLadder TM) and 
the sizes of the DNA fragments in question were compared to the molecular marker’s 
fragments with known sizes.  
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2.2.5 Digestion of DNA with restriction endonucleases  
30 μl final volume digestion reactions were performed by mixing up to 1μg DNA, 1-2 
units of the selected restriction enzyme or combination of two compatible enzymes, 3 μl of 
the appropriate 10X restriction buffer, and sterile water. The digestion reactions were 
incubated at 37˚C for 1-4 hours depending on the amount of the DNA.  
 
2.2.6 DNA gel electrophoresis 
DNA constructs, PCR reaction products and digested DNA samples were analysed using 
1% agarose gel electrophoresis. The samples were diluted in 5X DNA loading buffer and 
made up to 10 μl with water. The gel was prepared by adding 0.3 mg agarose to 30 ml 1x 
TAE buffer that was heated in the microwave until the agarose was melted. 3 μl SYBR® 
Safe DNA Gel Stain was added (1:1000 dilution) and the gel was gently mixed before it 
was poured onto the gel tank, left to set and then immersed in 1x TAE buffer. After 
loading of DNA samples gels were allowed to run at 50-100 mA for 30 minutes. The DNA 
fragments were visualised using ultraviolet (UV) light. The sizes of the DNA fragments 
were compared to the fragments on the DNA molecular marker (HyperLadder TM).  
 
2.2.7 DNA purification from agarose gels 
For cloning purposes, the DNA fragments that were required for the generation of 
constructs were excised from the gel and were purified using the QiaQuick gel extraction 
kit according to the manufacturer’s instructions. The DNA was eluted in 30-50 μl sterile 
water and the concentration of DNA was measured using a spectrophotometer (section 
2.2.4).  
 
2.2.8 Ligation of DNA  
The generation of constructs was carried out by ligating the appropriate plasmid vector 
with the desired DNA insert using T4 DNA ligase. Once the concentrations of the vector 
and insert DNA were determined by spectrophotometer or by agarose gel electrophoresis, 
various vector: insert ratios were tested, in order to identify the optimum ratio for each 
particular vector- insert pair. The vector: insert ratios mostly used were 6:1 and 4:1 and 
were calculated according the following formula: 
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𝑛𝑔 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡 = 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜
𝑖𝑛𝑠𝑒𝑟𝑡
𝑣𝑒𝑐𝑡𝑜𝑟
 𝑋 
𝑙𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡 (𝑘𝑏)
𝑙𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 (𝑘𝑏)
 
Ligation reaction  
 1 μl T4 DNA ligase 
 1 μl T4 DNA ligase buffer 
 X μl Vector 
 Y μl insert  
 Water up to 10 μl 
The reaction was incubated overnight on ice. Ice was placed in a 5 L beaker and was 
gradually allowed to melt to create a temperature gradient. After incubation, 5 μl of the 
reaction was used for bacterial transformation. 
 
2.2.9 Polymerase chain reaction (PCR) 
PCR was used to amplify the target fragments of DNA and to introduce restriction sites for 
the generation of fusion proteins. The high fidelity Platinum® Pfx DNA polymerase was 
used. 
50 μl Reaction components   
 
 Template DNA: 50 ng/μl                                                                               1 μl 
 Primer (sense and antisense): 25 pmol/μl each                                     1.5 μl each 
 Platinum® Pfx DNA polymerase: 1 U                                                          1 μl 
 Pfx polymerase buffer (10x)                                                                         5 μl 
 Enhancer buffer (10x)                                                                                   5 μl 
 Mg2SO4:  50 mM                                                                                           6 μl 
 dNTP mix: 0.25 mM each dNTP (dTTP, dATP, dGTP, dCTP)                1.5 μl 
 water                                                                                                         27.5 μl 
 
PCR protocol 
 94˚C for 5 minutes to activate the Pfx polymerase 
 Denaturing step: 94˚C for 30 seconds 
 Annealing step: 55˚C for 30 seconds 
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 Extending step: 68˚C for 1.5 minutes 
Repeat 30 cycles 
 
2.2.10 DNA sequencing  
DNA sequencing was performed at the Sequencing Service, School of Life Sciences, 
University of Dundee, Scotland. The amount of DNA sent was 20 ng/μl and the primer’s 
concentration was 3.2 μM per reaction as instructed by the sequencing service.  
 
2.2.11 Cloning- Generation of VSV-SNAP-hM2WT, HA-CLIP-hM3RASSL, VSV-
SNAP-hM3RASSL fusion constructs 
The plasmids pSEMS1-26m (SNAP tag) and pCEMS1-CLIP10m (CLIP tag), supplied by 
Covalys Biosciences AG (Witterswil, Switzerland), were modified by the addition of a 
small linker region encoding for the metabotropic glutamate receptor 5 (mGluR5) signal 
sequence. An epitope tag, either HA or VSV-G, was also incorporated between the ClaI 
and EcoRI restriction sites of the multiple cloning site upstream of SNAP or CLIP tags.  
The linker was made by annealing two complementary primers containing the sequences 
described above with the addition of a Kozak sequence, start codon, and appropriate 
nucleotides to generate ClaI and EcoRI “sticky” ends. The primers were annealed by 
combining 1 ng of each with 1 X “multicore” buffer (Promega Corp.) in a final volume of 
50 μl. This was then heated to 100 °C in a boiling water bath for 5 min, after which the 
bath was then turned off and allowed to cool overnight. The annealed fragment was then 
purified by gel extraction and ligated into the plasmid by standard techniques. The receptor 
sequences were PCR-amplified using primers designed to add BamHI (5’-
CGCGGATCCGCCACCATGACCTTGCACAATAACAGT-3’) and NotI (5’-
TTTTCCTTTTGCGGCCGCCTACAAGGCCTGCTCGGGTGC-3’) sites to the fragment 
termini. These were then ligated into the multiple cloning site downstream of SNAP or 
CLIP tags of the modified plasmids described above. To create constructs that could be 
used to make Flp-In™ T-Rex™ 293-inducible stable cell lines of these constructs, the 
entire insert from the ClaI site to the NotI site was cut out and ligated into a modified 
version of pcDNA5/FRT/TO (Invitrogen) with a ClaI site added to the multiple cloning 
site using a linker formed from two annealed primers as described previously (Alvarez-
Curto et al., 2010). This work was previously carried out by Dr. Elisa Alvarez-Curto. 
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2.3 Cell culture Methods 
2.3.1 Cell maintenance  
All cells were maintained in an incubator at 37˚C in a humidified atmosphere with 5% 
CO2. 
 
2.3.2 HEK 293 cells  
HEK 293 cells were maintained in Dulbecco’s modified Eagle’s medium-DMEM 
supplemented with 10 % foetal bovine serum (FBS), 2 mM L-glutamine, 1% antibiotic 
mixture (100 U∙ml-1 penicillin and 0.1 mg∙ml-1 streptomycin). 
 
2.3.3 Flp-In™ T-REx™-293 cells 
This cell line may be used as a host for the generation of stable cell lines expressing the 
gene of interest (GOI); it expresses the tetracycline repressor protein (tet repressor) and 
contains an FRT integration site.  
Flp-In™ T-REx™-293 cells were maintained in DMEM supplemented with 10 % FBS, 
1% antibiotic mixture (100 U∙ml-1 penicillin and 0.1 mg∙ml-1 streptomycin) and 100 μg∙ml-
1 zeocin.  
Single stable Flp-In™ T-REx™-293 cells lines were maintained  in DMEM with high 
glucose, supplemented with 10 % FBS, 1% antibiotic mixture (100 U∙ml-1 penicillin and 
0.1 mg∙ml-1 streptomycin), 10 μg∙ml-1 blasticidin and 200 μg∙ml-1 hygromycin, which from 
now on will be referred to as complete DMEM. Double stable cell lines were maintained in 
complete DMEM supplemented with 1 mg∙ml-1 geneticin (G-418).  
 
2.3.4 Passaging of cells 
Cells were passaged when 80-90% confluence was reached. Medium was removed and 
cells were washed once with sterile 1x PBS to remove any traces of growth medium. 0.25 
% Trypsin-EDTA was then added to the cells for 2-3 minutes and the flask was shaken by 
hand until the cells were detached from the flask surface. Cells were then harvested in 
growth medium and centrifuged for 5 minutes at 1,300 rpm. The cell pellet was 
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resuspended in fresh growth medium and the suspension was added into flasks, dishes, 
plates or cover-slips, at the required dilution.  
 
2.3.5 Transient transfection of HEK 293 cells using Polyethylenimine (PEI) 
HEK 293 cells were plated in 10 cm dishes (2.5 x106 cells per dish) and grown to 70% 
confluence before they were ready for transfection with PEI. 250 μl of 150 mM NaCl 
sterile solution containing 5 μg of the DNA construct was mixed with 250 μl of solution 
containing 30 μl of PEI (at 1μg∙μl-1) and 220 μl 150 mM NaCl. The PEI: DNA ratio used 
for all the transfections was 6:1. The final solution was then incubated for 10 minutes at 
room temperature, allowing the PEI to coat the DNA with positively charged particles to 
enable introduction through the cell surface via endocytosis. The solution was then 
carefully pipetted onto the cells and incubated for 24 hours.  
 
2.3.6 Generation of Flp-In™ T-REx™-293 cell lines expressing the receptor of 
interest 
Flp-In™ T-REx™-293 cells were used as hosts for the generation of single stable cell lines 
expressing the receptor of interest in a doxycycline inducible manner. Flp-In™ T-REx™-
293 cells stably express a tetracycline repressor protein and also contain an FRT (flippase 
recognition target) integration site. The GOI was sub-cloned into pcDNA5/FRT/TO 
(confers resistance to hygromycin). Flp-In™ T-REx™-293 cells were co transfected with 
pcDNA/FRT/TO-GOI construct and the pOG44 vector expressing the Flp recombinase. 
The resulting cells, with the integrated pcDNA5/FRT/TO GOI into the FRT site, were 
hygromycin resistant and sensitive to zeocin. The expression of the GOI was regulated by 
the tetracycline repressor (tet repressor) protein which in the presence of tetracycline or 
doxycycline (tetracycline analogue) was released from the operator sequence allowing the 
transcription and translation of the GOI.   
Steps followed for the generation of Flp-In™ T-REx™-293 cells stably expressing VSV-
SNAP-hM2-WT or HA-CLIP-hM3-RASSL receptors: 
1. The GOI was sub-cloned into the pcDNA5/FRT/TO vector 
2. pcDNA5/FRT/TO GOI was co-transfected with pOG44 vector into parental Flp-
In™ T-REx™-293 host cells. A ratio of 9:1 (w/w) pOG44: pcDNA5/FRT/TO GOI 
was used for the transfections with a total of 5 μg of DNA per transfection. 
Chapter 2   
 
78 
 
3. Transfected cells were maintained in DMEM supplemented with 10 % FBS, 1% 
antibiotic mixture (100 U∙ml-1 penicillin and 0.1 mg∙ml-1 streptomycin) and 10 
μg∙ml-1 blasticidin.  
4. 24 hours post transfection the medium was replaced with fresh DMEM for another 
24 hours.  
5. 48 hours post transfection the cells were split into separate 100 mm dishes using 
1:500 and 1:1000 dilutions and maintained in complete DMEM containing 10 % 
FBS, 1% antibiotic mixture (100 U∙ml-1 penicillin and 0.1 mg∙ml-1 streptomycin), 
10 μg∙ml-1 blasticidin and 200 μg∙ml-1 hygromycin. Hygromycin allows for the 
selection of cells that have successfully integrated the GOI into their genome.  
6. The medium was replaced with fresh every 2-3 days until colonies (foci) of cells 
started to appear.  
7. Once the colonies started to grow, the complete population of cells was pooled. 
8. The pooled isogenic population of single stable cells was then screened for 
tetracycline/doxycycline dependent expression of the protein of interest.   
9. Doxycycline-dependent inducibility of receptor expression was screened either by 
western blotting or by fluorescence measurement, when a fluorescent tag was fused 
to the receptor of interest.  
Generation of the cell lines described above was carried out by Dr. Elisa Alvarez-Curto. 
 
 
2.3.7 Generation of Flp-In™ T-REx™-293 cell lines co-expressing two receptors 
Generation of a double stable cell line expressing one receptor in a doxycycline inducible 
manner and the second receptor in a constitutive manner, involves the use of a single stable 
cell line with the receptor expression being regulated by the tet repressor, as a host cell 
line. The host cell line was used for the introduction of a second cDNA construct encoding 
the second receptor of interest that would be constitutively expressed allowing the 
generation of a double stable cell line.  
The steps followed for the generation of a double stable cell line included: 
1. The cDNA encoding the receptor to be expressed constitutively of interest was 
sub-cloned into pcDNA3. 
2. The pcDNA3 containing the GOI was transfected into the host cells which were 
maintained in complete DMEM.  
3. 24 hours post transfection the medium was replaced with fresh complete DMEM. 
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4. 48 hours post transfection, the cells were split (1:500 and 1:1000 dilutions) into 
separate dishes and were maintained in complete DMEM for another 24 hours, 
until the cells were attached to the dish’s surface. 
5. The medium was then replaced with complete DMEM supplemented with 1 
mg∙ml-1 G-418 (geneticin) for selection. 
6. Medium was replaced every 2-3 days until individual colonies were seen. 
7. Individual colonies were picked (using a cloning ring) and each colony was plated 
per well in a 24-well plate and cells were grown until ready for screening. 
8. The clones were then screened for constitutive expression of the second receptor 
and for doxycycline dependent expression of the first receptor. Screening of the 
clones was carried out by Western blotting or by fluorescence measurement (when 
a fluorescent tag was fused to the receptor(s) of interest).  
Generation of the cell lines described above was carried out by Dr. Elisa Alvarez-
Curto. 
2.3.8 Induction of receptor expression with doxycycline  
Single or double stable Flp-In™ T-REx™-293 cells were plated in 96- well plates, 10 cm 
dishes, or flasks and were grown to 70-80% confluence in DMEM. In order to initiate the 
expression of the receptor(s), the medium was replaced with DMEM containing the 
antibiotic doxycycline and incubated for 24 hours (unless otherwise stated, depending on 
the requirements of the experiments) at 37˚C/ 5% CO2. After optimisation experiments and 
receptor expression determination the concentrations of doxycycline for the different cell 
lines were defined.   The double stable Flp-In™ T-REx™-293 cells constitutively 
expressing the HA-CLIP-hM3RASSL receptor required 5 ng∙ml-1 of doxycycline to express 
the VSV-SNAP-hM2WT receptor at the desired amount. The single stable cell line 
expressing HA-CLIP-hM3RASSL receptor required 10 ng∙ml-1 doxycycline and the cell 
line expressing the VSV-SNAP-hM2WT was treated with 5 ng∙ml-1 of the antibiotic.  
 
2.3.9 Cell number determination 
Cells were trypsinised as described in section 2.3.4 and harvested in growth medium by 
centrifugation at 1300 rpm for 5 minutes. The cell pellet was the resuspended in the growth 
medium.  Cell suspension (10 μl) was mixed in a tube with 10 μl of trypan blue stain 
(0.4%) to be analysed in a Countess® Automated cell counter. 10 μl of the mixture of 
stained cells was then loaded onto a cell counting chamber and the cells were counted 
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using the Countess® Automated cell counter (Life Technologies, UK) or a 
hemocytometer, manually counting the cells under a microscope.  
 
2.3.10 Cell harvesting 
After treatment of live cells with doxycycline or PEI transfection, to allow expression of 
the desired receptor, cells were washed twice in ice cold PBS and then harvested by 
centrifugation, for 5 minutes at 4 ˚C, at 4000 rpm. The cell pellet was stored for at least 45 
min at -80 ˚C and then used for lysate or membrane preparation or was kept frozen until 
needed.  
 
2.3.11 Treatment of cells with tunicamycin  
Cells were plated in 10 cm dishes and when 70-80% confluence was reached, tunicamycin 
was added at a final concentration of 6 μM. Treatment with doxycycline, to allow for 
receptor expression, was carried out simultaneously. Incubation with tunicamycin was 
routinely carried out for 16 h (or a maximum of 24 h for time course experiments). After 
the treatment, the cells were washed and harvested in ice cold PBS. 
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2.4 Membrane and protein isolation, detection and 
quantification methods 
 
2.4.1 Membrane preparation  
Cells were grown to confluence, after appropriate manipulation to allow expression of the 
desired receptor i.e. PEI transfection of HEK 293 cells or doxycycline induction of Flp-
In™ T-REx™-293 stable cells. Cells were harvested after 24 h of treatment (Section 
2.3.10), in ice-cold 1X PBS and pelleted by centrifugation. Pellets were frozen at -80 ⁰C 
for a minimum of 1 h. Pellets were thawed and resuspended in ice-cold TE buffer 
supplemented with Complete protease inhibitor mixture. Cells were passed through 25-
gauge needle (5-10 times) and then homogenised on ice, by 50 strokes on a glass Teflon 
homogeniser. Homogenised cells were centrifuged at 1000 x g for 5 minutes at 4 ⁰C. The 
supernatant fraction was removed and transferred to microcentrifuge tubes and subjected to 
further centrifugation at 50,000 x g for 45 minutes at 4 ⁰C. The pellets were resuspended in 
TE buffer and protein concentration was assessed by BCA assay (section 2.4.3) Membrane 
preparations were either used directly or kept at -80 ⁰C until required. 
 
2.4.2 Cell lysates preparation 
Cells were grown to confluence after treatment to allow expression of the receptor(s). The 
cells were then harvested and washed twice in ice cold 1X PBS, by centrifugation (section 
2.3.10). The pellets were resuspended in 1X RIPA buffer supplemented with Complete 
protease inhibitors mixture or cell lysis buffer for the preparation of lysates for Blue Native 
PAGE. Resuspended cells were then placed on a rotating wheel for 30-45 minutes at 4 ⁰C, 
to allow further lysis, and then were centrifuged at 14,000 x g, for 15 minutes at 4 ⁰C. The 
supernatant was then transferred to a clean tube and the protein concentration of the lysate 
was determined by BCA assay (section 2.4.3). Lysate preparations were either used 
directly or kept at -20⁰C until required.  
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2.4.3 Determination of protein concentration using BCA assay 
The BCA assay was used to determine the protein concentration of protein samples, from 
either lysates or membrane preparations. Two solutions were mixed for the assay. Solution 
A: bicinchoninc acid (BCA) and solution B: 4% copper sulphate solution in 50:1 ratio. 
Proteins reduce the Cu(II) to Cu(I) in a concentration-dependent manner and then the Cu(I) 
binds to BCA causing a colour change with an absorption of 562 nm. A standard curve was 
plotted using samples of bovine serum albumin (BSA) with known amount, allowing the 
determination of the concentrations of the protein samples in question. In a 96-well ELISA 
plate, 10 μl of the BSA samples and the protein samples with unknown concentration were 
plated and 200 μl of the mixed reagents A and B were added per well. The plate was 
incubated for 15-30 minutes at 37˚C. The absorbance at 562 nm was then read on a 
PheraStar FS plate reader and the protein concentration of the samples was calculated 
using Graph Pad software.  
 
2.4.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein lysate samples or membrane preparation samples were heated at 60-65 ⁰C in 5 x 
Laemmli buffer (10% w/v SDS, 10 mM DTT, 20% v/v glycerol, 0.2 M Tris-HCl at pH 6.8, 
0.05% w/v bromophenol blue) for 5 minutes. The required amount of protein lysate or 
membrane preparation (usually 10-20 μg protein per well) was loaded on NuPAGE® 
Novex® 4-12% Bis-Tris Protein Gels (Life Technologies, UK) and run in 1x NuPAGE® 
MOPS SDS Running Buffer (Life Technologies, Paisley, UK). Proteins were then 
electrophoretically transferred onto a nitrocellulose membrane, and then were blocked for 
1 h in 5% fat-free milk in 1 x TBST (2 mM Tris-Base, 15 mM NaCl, pH7.4 and 0.1% (v/v) 
Tween 20)  and subsequently incubated with the primary antibody in 5% fat-free milk 
TBST at 4 ⁰C, overnight. After 5 x 5 minutes washing steps with TBST, the appropriate 
horse radish peroxidase-conjugated IgG secondary antibody was incubated with the 
membrane at room temperature for 1 h. Immunoblots were developed using enhanced 
chemiluminescence solution (Pierce, UK).    
 
2.4.5 Blue Native Polyacrylamide gel electrophoresis (BN-PAGE) 
Cells were harvested and washed twice in ice-cold PBS (section 2.3.10) and the pellets 
were resuspended in lysis buffer: 150 mM NaCl, 2 mM EDTA, 0.01 mM Na2HPO4, 0.5% 
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DDM, 5% glycerol, supplemented with Complete protease inhibitors mixture, as described 
in section 2.4.2 on the preparation of lysates for Blue Native PAGE. Lysates were prepared 
and protein was quantified by BCA assay. Samples were prepared by adding 3 x G-250, 
Native PAGE sample buffer (Native PAGE Sample prep kit, Life Technologies). Some 
samples were also treated with 1% SDS, for 10 minutes at room temperature, and were run 
alongside with the un-treated samples. The samples were loaded on 10 well 
NativePAGE™ Novex® 3-12% Bis-Tris Protein Gels, 1.0 mm (Novex, Life Technologies, 
UK). The Native PAGETM Running Buffer (20X) was used to prepare the (anode) 1x 
running buffer, placed in the outer chamber of the gel tank, and the two cathode running 
buffers. The dark blue- cathode running buffer was prepared by adding 0.2% (v/v) of the 
Native PAGETM Cathode buffer additive (20X) in the 1x running buffer. The light blue- 
cathode buffer was prepared by adding 0.02% of the Native PAGETM Cathode buffer 
additive (20X). The gels were run in the dark blue cathode buffer for 30 minutes and then 
the dark blue cathode buffer was replaced with the light blue cathode buffer and gels were 
run for another 1 hour at 250 mV, while the gel tank was transferred on ice.  
 Proteins were then transferred onto PVDF membranes and were subsequently fixed by 
incubating with 8% acetic acid for 15 minutes at room temperature. PVDF membranes 
were subsequently processed with the appropriate antibodies and developed as described in 
the section 2.4.4. 
 
2.4.6 Co-immunoprecipitation 
Cells were harvested (section 2.3.10) and were lysed in cell lysis buffer (section 2.4.2). 
The cell pellet in lysis buffer was placed on a rotating wheel for 45 minutes at 4˚C and then 
centrifuged for 30 minutes at 100,000 g at 4˚C and the supernatant-clear lysate was 
transferred to a clean tube. The protein concentration was determined by BCA assay. The 
lysate was incubated with anti-VSV agarose beads or anti-HA beads in 1:1 v/v, at 4˚C, 
rotating overnight. Samples were then washed four times in lysis buffer by centrifugation 
at maximum speed for 1 minute and the supernatant was discarded. The bound receptors 
were then eluted with 2 mg/ml VSV-peptide or HA-peptide by rotating on a wheel for 1 
hour at 4˚C and the eluates were then collected by spinning at maximum speed for 1 
minute at 4˚C. The protein concentration was calculated again to determine the recovery of 
the protein after the immunoprecipitation. Eluates were then prepared for separation on an 
SDS-PAGE or a Blue Native PAGE as described before (sections 2.4.4 and 2.4.5 
respectively).  
Chapter 2   
 
84 
 
2.5 Radioligand Binding 
 
2.5.1 Radioligand saturation binding experiments 
Saturation binding data was determined by adding varying concentrations of the 
radioligand to 5 μg protein. A working stock of [3H]-quinuclidinyl benzilate (QNB) was 
used to prepare the 10x dilutions at different concentrations to be added to the assay (100 
μl per reaction). Atropine at a final concentration of 10 μM was used to determine non-
specific binding. The final volume was 1 ml per reaction. The reactions were incubated at 
30˚C for 2 hours before the bound ligand was separated from free by vacuum filtration 
through GF/C filters (Brandel Inc. Gaithersburg, MD) after two steps of washing with ice 
cold radioligand binding assay buffer. Bound ligand was estimated by liquid scintillation 
spectrometry.  
 
2.5.2 Radioligand single point binding experiments 
Single point binding using a single close to saturating concentration of [3H]-QNB was 
carried out using 5 µg membrane protein per reaction in radioligand binding assay buffer, 
reaching up to 1 ml of final concentration. The concentration of the radioligand was 
dependent on the receptor being examined. The muscarinic ligand QNB has a lower 
affinity for the hM3RASSL receptor with a KD=2.44 nM (Alvarez-Curto et al., 2011) 
therefore, higher concentrations of radioligand were required (up to 20 nM). The KD of 
QNB for the hM2WT was found to be around 0.4 nM, so lower radioligand concentrations 
were used (up to 3 nM). Atropine was used to define the non-specific binding at a final 
concentration of 10 μM.  Reactions were incubated for 2 h at 30 ⁰C. Bound ligand was 
separated from free by vacuum filtration through GF/C filters (Brandel Inc. Gaithersburg, 
MD). The filters were washed twice with assay buffer and bound ligand was estimated by 
liquid scintillation spectrometry. 
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2.5.3 Competition binding experiments 
Competition binding assays were carried out by adding varying concentrations of the 
ligands to be tested e.g. acetylcholine, carbachol, clozapine-N-oxide or atropine in the 
presence of a single concentration of [3H]-QNB. Non-specific binding was determined in 
the presence of 10 µM atropine. Reactions were incubated for 2 h at 30 ⁰C. Bound ligand 
was separated from free by vacuum filtration through GF/C filters (Brandel Inc. 
Gaithersburg, MD). The filters were washed twice with assay buffer and bound ligand was 
estimated by liquid scintillation spectrometry. 
 
 
2.6 Resonance Energy Transfer (RET) Methods 
 
2.6.1 Detection of cell surface receptor expression and oligomerisation by htrFRET 
Cells were grown to 100,000 per well on poly-D-lysine pre-treated 96-well solid black 
bottom plates (Greiner Bio-one, UK). Cells were induced with doxycycline at the stated 
concentrations (see Results) for 24 h to express the receptor of interest. After doxycycline 
induction, cell surface receptor expression was monitored by adding 10 nM SNAP-Lumi4 
Tb or 20 nM CLIP-Lumi4 Tb. After incubation at 37 ˚C/ 5 % CO2 for 1 h, cells were 
washed three times with 1 x FRET labelling media (Cisbio Bioassays, France) and the 
fluorescence was read at 620 nm on  a PheraStar FS. 
For the htrFRET experiments, a combination of donor: acceptor pair was used to detect 
either homomers or heteromers. Detection of VSV-SNAP-hM2WT homomers was carried 
out by labelling with 5 nM SNAP-Lumi4 Tb with varying concentrations of SNAP-Red. 
The HA-CLIP-hM3RASSL homomers were detected by labelling with 10 nM CLIP-Lumi4 
Tb and varying concentrations of CLIP-Red. Heteromeric interactions between VSV-
SNAP-hM2WT and HA-CLIP-hM3RASSL were detected using 5 nM SNAP-Lumi4 Tb 
and varying concentrations of CLIP-Red, or the reverse combination, 10 nM CLIP-Lumi4 
Tb with varying concentrations of SNAP-Red. The substrates were prepared to the 
appropriate concentrations in 1 x FRET labelling media (Cisbio Bioassays, France) and the 
labelling reaction was carried out for 1 h at 37 ⁰C, 5% CO2. Cells were then washed three 
times with 100 µl per well 1 x labelling media and plates were either read directly (once or 
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repeatedly for the requirements of the kinetic htrFRET experiments)  after this or further 
processed to test the effect of receptor ligands. For the kinetic htrFRET experiment, 
ligands were added to the plates, dissolved in 1x FRET labelling medium; they were 
subsequently incubated at set temperatures and times and read out on a PheraStar FS 
HTRF compatible reader. Both the emission signal from the SNAP-Lumi4-Tb or CLIP-
Lumi4 Tb (620 nm) and the FRET signal resulting from the acceptor SNAP-Red or CLIP-
Red (665nm) were recorded. Finally, the specific fluorescent signal was calculated by 
subtracting from the total 665 nm signal that was obtained from cells labelled but not 
expressing the receptor (non-induced cells), and calculating the 665:620 ratio. 
 
2.6.2 Monitoring ligand regulation of receptor oligomerisation by triple labelling 
htrFRET 
Triple labelling experiments involved the simultaneous labelling of the cells with three 
different but spectrally compatible substrates. The substrate used as donor e.g. Lumi4 Tb, 
possesses certain spectral properties, demonstrating four distinct emission peaks upon 
excitation at 337 nm one of which (495 nm) is able to excite green region-emitting 
substrates/acceptors, whilst, the 620 nm emission peak can excite red region-emitting 
substrates/acceptors. It was this property that was utilised in the multiplex labelling (or 
multi-labelling) of the receptors, using one donor (Lumi4 Tb) and two acceptors able to 
emit at different and distinguishable wavelengths (i.e. red emitting at 665 nm and green 
emitting at 520 nm). 
Cells were grown to 100,000 per well on poly-D-lysine pre-treated 96-well solid black 
bottom plates (Greiner Bio-one, UK) and then receptor expression was induced by the 
addition of the appropriate concentration of doxycycline. After 24 hour of induction, cells 
were labelled with the three different substrates by incubating at 37˚C, 5% CO2 for 1 hour. 
One set of experiments involved addition of 5 nM SNAP-Lumi4 Tb as donor and 100 nM 
CLIP-Red and 100 nM SNAP-Green as acceptors. The other set of experiments utilised 
CLIP-Lumi4 Tb at final concentration of 10 nM as a donor and 100 nM of SNAP-Green 
and 100 nM of CLIP-Red as acceptors. After the labelling step, cells were washed three 
times in 1x HBSS and 100 μl of 1x FRET labelling medium was added per well for the 
analysis. Two different protocols were used for the each utilising a different set of dichroic 
filters for the measurement of the three different wavelengths (620 nm, 665 nm and 520 
nm). 
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 The specific fluorescent signal was calculated by subtracting from the total FRET 665 nm 
or 520 nm signal that was obtained from cells labelled but not expressing the receptor 
(non-induced cells) and calculating the 665:620 ratio or the 520: 620 ratio. 
 
2.6.3 Tag-Lite® internalisation assay 
Cells were plated in a black-bottom 96-well plate and induced with doxycycline for 24 
hours. Cells were labelled with 100 nM SNAP-Lumi4 Tb (for SNAP tagged receptors) and 
200 nM CLIP-Lumi4 Tb (for CLIP tagged receptors). After 1 hour labelling at 37˚C, 5% 
CO2 the plates were washed three times with 1x HBSS. Ligands were prepared at the final 
concentrations in Tag-lite® internalisation assay buffer (Cisbio Biosciences, France) and 
100 μl of the ligand preparations were added per well. The Tag-lite® internalisation assay 
buffer may act as a FRET acceptor, when excited by one of the four emission peaks (490 
nm) of the Lumi4 Tb donor. The assay buffer, once excited, emits at 520 nm. FRET 
measurements, using PheraStar FS, were carried out at set time points to allow kinetic 
determination of receptor internalisation in response to ligand mediated activation. The 
FRET ratio was calculated as a ratio of 620/520 and that was plotted over time, using 
Graph Pad software.  
 
 
2.7 Functional assays 
 
2.7.1 Calcium mobilisation assay 
Cells (50,000 per well) were seeded in a pre-coated with poly-D-lysine clear bottom black 
96-well plate. Receptor expression was induced by adding doxycycline and incubating for 
at least 16 hours. After induction of receptor expression, the cells were incubated with 
Fura-2 AM for 45 minutes at 37˚C. After the labelling step was completed the Fura-2 AM 
was removed from the wells, and the cells were washed twice with 1x HBSS buffer and 
finally incubated in 100 μl 1x HBSS per well for 15 minutes. The compound serial 
dilutions were prepared in a separate 96-well ELISA plate. The plate containing the 
labelled cells and the plate with compound serial dilutions were then transferred to the Flex 
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Station (Molecular Devices) and the calcium concentration was measured. The data were 
plotted using Graph Pad software.  
 
2.7.2 Inositol monophosphate (IP-1) accumulation 
Cells were plated in 10 cm dishes and when 70-80% confluence was reached they were 
treated with doxycycline to induce receptor expression. A suspension of 10,000 cells per 
assay point was prepared in stimulation buffer and incubated with ligands for 1 hr at 37 ˚C, 
5 % CO2 in a white Proxiplate-384 Plus (PerkinElmer, Inc. USA). After ligand stimulation, 
cells were lysed in a mixture of detection reagents prepared in lysis buffer according to the 
manufacturer’s instructions (IP-One Tb kit, Cisbio Bioassays, France) and subsequently 
incubated for a further 1 h at room temperature. FRET signal was then measured using a 
PheraStar FS and final IP1 concentrations were calculated as ratio of 665/620 nm. 
 
2.7.3 Cyclic adenosine monophosphate (cAMP) detection 
Cells were plated in 10 cm dishes and when 70-80% confluence was reached, they were 
treated with doxycycline to induce receptor expression.  A suspension of 4,000 cells per 
assay point was prepared in 1x HBSS. The cells were co-incubated with the optimal 
concentration of forskolin (1 µM) and with ligands for 30 minutes in white, 384-well 
Proxiplate. This step was followed by lysis of cells using a mixture of detection reagents 
prepared in lysis buffer according to manufacturer’s instructions (cAMP dynamic 2 kit, 
Cisbio Bioassays, France) and incubation for 1 h at room temperature. FRET signal was 
measured on a PheraStar FS and the inhibition of cAMP levels was calculated as ratio of 
665/620 nm. 
 
 
2.8 Epi-fluorescence imaging of live cells 
Live cells (300,000 per well) were plated in a 6-well plate, on poly-D-lysine pre-coated 
cover-slips (0.0 mm thickness) and they were incubated overnight in complete DMEM. 
The medium was removed the next day and fresh medium containing the appropriate 
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concentration of doxycycline was added for 24 hours. Labelling was performed 24 h post-
induction, using the appropriate cell impermeable fluorescent dyes.  
HA-CLIP-hM3RASSL receptor was labelled with 5 µM CLIP- Surface 488 and the VSV-
SNAP-hM2WT was labelled with 5 µM SNAP-Surface 549.  For the visualization of 
receptors in cells expressing both receptors, both dyes were added simultaneously.   
Cells were incubated with the fluorescent dye for 30 min at 37 °C, 5% CO2. After three 
washes with DMEM, fresh medium was added and the cells were further incubated for 30 
min. Cells on cover-slips were then washed with 1x HBSS. Cover-slips were then 
transferred to a microscope chamber where they were imaged using an inverted Nikon 
TE2000-E microscope (Nikon Instruments, Melville, NY) equipped with a 40x (numerical 
aperture-1.3) oil-immersion Pan Fluor lens and a cooled digital photometrics Cool Snap-
HQ charge-coupled device camera (Roper Scientific, Trenton, NJ). Ligands diluted in 1x 
HBSS were used for studying receptor internalisation upon agonist-induced receptor 
activation.  
 
2.9 Statistical analysis 
Data analysis and curve fitting were carried out using Graph Pad Prism 5 Software. The 
results were presented as means ± SEM of three independent replicates, unless otherwise 
stated, or as means ± range of two independent replicates (n=2). Statistical significances 
were tested using a two-paired t-test at P<0.05, as specified for each experiment. 
Concentration response curves were fitted to a non-linear regression equation using the 
three parameter fit. All graphs were created using GraphPad Prism 5 Software.  
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3.1 Introduction 
 
The tools used for studying receptor oligomerisation are very important as they may 
determine the effectiveness of the approach followed as well as the quality of the outcome. 
In order to study the homomerisation and heteromerisation of the human M2WT and 
M3RASSL an htrFRET approach was used in combination with Tag-lite® technology. The 
htrFRET technique in combination with Tb3+ cryptate energy donors, utilised by Tag-lite® 
technology, has been helpful in probing molecular interactions (Bazin et al., 2001) and has 
been used as a strategy to study receptor oligomerisation (Cottet et al., 2012). Similar live 
cell-based htrFRET methods have been previously used to study heteromerisation between 
D2 and D3 dopamine receptors (Pou et al., 2012) and the oligomerisation between 
metabotropic glutamate receptors (Doumazane et al., 2011), as well as M3 muscarinic 
receptor homomerisation (Alvarez-Curto et al., 2010). This experimental approach requires 
the combination of three different parameters. Firstly, the fusion of the receptors with 
SNAP or CLIP epitope tags, preferably at the N-terminal domain of the receptor to allow 
extracellular labelling and detection. Secondly, use of the Tag-lite® labelling of the tagged 
receptors using htrFRET compatible substrates to specifically label the SNAP and/or 
CLIP-tagged receptors. Finally, a cellular expression system based on the generation of 
Flp-In™ T-REx™-293 stable cell lines can ensure consistent receptor expression at the 
cell surface.  
The initial steps of the project involved the fusion of SNAP and CLIP epitope tags to the 
extracellular N-terminus of the hM2WT and hM3RASSL receptors, respectively. The 
additional HA and VSV-G epitope tags were also fused at the N-terminus of the receptors, 
upstream of the SNAP and CLIP tags, respectively. This allowed the use of tag specific 
antisera to detect the expressed receptors by immunoblotting and also to enable detection 
of receptor-receptor interactions via co-immuno-precipitation. In addition, the mGluR5 
signal sequence was included in the fusion construct and it was cloned upstream of the 
receptor and the tag sequences, to enhance cell surface delivery of the expressed fusions 
(Figure 3.1). 
The SNAP tag is a small (about 20 kDa) protein, based on O6-alkylguanine DNA 
alkyltransferase that has the ability to be modified upon binding to fluorescent labels based 
on O6-benzylguanine derivatives (Maurel et al., 2008). The CLIP tag is a modified version 
of the SNAP tag that specifically reacts with O6-benzylcytosine derivatives (Maurel et al., 
2008). A variety of substrates are available for specific SNAP or CLIP-tag labelling. These 
substrates allow covalent epitope tag to substrate labelling in a 1:1 ratio. The substrates 
used for htrFRET assays are cell impermeant, allowing the detection of cell surface 
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receptor expression and receptor-receptor interactions. The htrFRET donor/acceptor 
partners must fulfill the spectral compatibility criteria i.e. the emission spectrum of the 
donor must overlap with the excitation spectrum of the acceptor and additionally, the 
emission spectra of donor and acceptor must not overlap. The long half-time emission 
fluorescence of terbium cryptate in combination with the time-resolved FRET i.e. 
introducing a time delay between excitation and measurement, allows the elimination of 
short lived background fluorescence and offers a high signal-to-noise ratio. Labelling 
substrates such as SNAP-Lumi4 Tb and CLIP-Lumi4 Tb may be used as energy donors.  
The Lumi4 Tb donors emit at four different wavelengths upon excitation at 337 nm. The 
emission at 620 nm may in turns excite a nearby red energy acceptor, which will 
sequentially emit at 665 nm. This FRET signal, if detected, would suggest an interaction 
between the donor and acceptor species and could correspond to a possible protein-protein 
interaction.  In the absence of a FRET acceptor partner, the fluorescence emission at 620 
nm corresponds to the expression of the cell surface labelled receptor (Figure 3.2 A, B). 
The spectral properties of the htrFRET reagents are shown in Figure 3.2 C, demonstrating 
the overlap of the donor’s emission and the acceptor’s excitation spectra.  
 
A cellular expression system that would allow the heterologous expression of the receptors 
at levels close to the physiological ones and that would enable the study of the receptors at 
the surface of live cells was required. This led to the generation of cell lines based on the 
Flp-In™ T-REx™-293 cells that allowed the expression of each of the VSV-SNAP-
hM2WT or HA-CLIP-hM3RASSL receptors individually. The Flp-In™ T-REx™ -293 
cells stably express the protein of interest in an isogenic and inducible manner. The level of 
expression of the protein of interest can be regulated by varying concentrations of 
doxycycline. A Flp-In™ T-REx™-293 cell line was also developed allowing the co-
expression of both receptors, with the HA-CLIP-hM3RASSL being expressed 
constitutively, while the VSV-SNAP-hM2WT being expressed in a doxycycline inducible 
manner. Once the cell lines were established they were fully characterised in terms of 
receptor expression, cell surface delivery and function. 
 
The high structural homology of the orthosteric binding site shared by all five muscarinic 
sub-types is responsible for the lack of selective muscarinic ligands (Wess, 2004). For this 
reason, a chemically engineered version of the M3 receptor described as Receptor 
Activated Solely by Synthetic Ligand or RASSL that is not able to respond to 
acetylcholine or other muscarinic agonists, but is activated by the synthetic ligand CNO, 
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was developed (Armbruster et al., 2007) and used instead of the wild type M3 receptor 
(Alvarez-Curto et al., 2011). This allowed the differential activation of the two receptors, 
hM2WT and hM3RASSL, when these were co-expressed.  
The necessity of studying GPCR signalling in vivo without the complicating effects of 
endogenous ligands was one of the reasons that had led to the development of RASSLs and 
DREADDs (Coward et al., 1998). The first RASSL that was generated was a mutant 
version of the β2- adrenergic receptor that was unable to respond to its native ligands but 
was activated by non-natural ligands with low potency (Strader et al., 1991). Generation of 
more RASSLs followed, such as the human κ opioid RASSL receptors (Coward et al., 
1998). Additional RASSLs were created that contained fluorescent tags or ones that 
demonstrated different internalisation and desensitisation properties (Scearce-Levie et al., 
2001, 2005; Pei et al., 2008; Rogan and Roth, 2011). Muscarinic RASSLs were developed 
by Armbruster et al., (2007) by selecting between libraries of randomly mutated M3 
receptors in yeast cells, during directed molecular evolution for the synthetic ligand CNO 
(Armbruster et al., 2007). The hM3RASSL contains two single mutations at the third 
(Y149C) and fifth (A239G) transmembrane domains. The hM3RASSL binds to and 
responds to CNO with nanomolar potency, but is unresponsive to carbachol. Once 
activated by CNO, the M3RASSL activates the Gq protein dependent pathway in a similar 
way as the hM3WT, resulting in calcium ion release from the ER, activation of ERK1/2 
phosphorylation pathway, β-arrestin recruitment and subsequent internalisation of the 
receptor (Alvarez-Curto et al., 2011).  
 
 
Aims of this chapter 
 
 Determination of the total and cell surface expression levels of VSV-SNAP-
hM2WT and HA-CLIP-hM3RASSL, in cells expressing each receptor individually 
and in cells co-expressing both receptors. 
 Identification of the doxycycline concentrations that allow for similar expression 
levels of the receptors in cells expressing each of the receptor individually and in 
cells co-expressing the receptors. 
 Investigation of the localisation, functionality and pharmacology of the expressed 
receptors. 
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3.2 Flp-In™ T-REx™-293 cell lines express each of the receptors, VSV-SNAP-
hM2WT or HA-CLIP-hM3RASSL, at the cell surface in a doxycycline-dependent 
manner. 
 
The doxycycline-dependent regulation of receptor expression in Flp-In™ T-REx™-293 
cell lines was assessed by three different approaches. The first approach involved immuno-
detection with anti-SNAP/CLIP antibody (able to recognise both SNAP and CLIP tags) 
against lysates of cells treated with different doxycycline concentrations. The anti-
SNAP/CLIP antiserum was able to detect the HA-CLIP-hM3RASSL at the regions of 100 
kDa corresponding to the un-glycosylated version of the receptor and just above the 100 
kDa (around 120 kDa) corresponding to the glycosylated version of the same receptor 
(Figure 3.3 A). The anti-HA antibody was able to detect only the un-glycosylated HA-
CLIP-hM3RASSL at 100 kDa (Figure 3.3 B).  In a similar manner, the VSV-SNAP-
hM2WT was detected using the anti-SNAP/CLIP antibody and its molecular mass was 
identified at above 70 kDa (Figure 3.4). There was no receptor expression detected in the 
samples prepared using cells not treated with doxycycline, or in the samples prepared from 
non-transfected parental Flp-In™ T-REx™-293 cells. Therefore, it can be suggested that 
the polypeptides detected were specific and they corresponded to the receptors in question.  
In both cell lines expressing each receptor individually, receptor expression was increased 
with increasing doxycycline concentrations. Using the anti-SNAP/CLIP antibody in 
immuno-blotting experiments, it was demonstrated that two different forms of the 
receptors were detected, the glycosylated and non-glycosylated that appeared as slightly 
lower molecular mass polypeptides. To further explore this, cells expressing each of the 
receptors upon doxycycline induction were treated with tunicamycin and the lysates 
prepared were resolved on SDS-PAGE (Figure 3.5). Tunicamycin is a mixture of 
antibiotics that inhibit N-linked glycosylation by blocking GlcNAc phosphotransferase 
(GTP), in early stages of protein synthesis, thus leading to cell cycle arrest in G1 phase, 
which in turns results in apoptosis (Wheatley and Hawtin, 1999). Cells that were 
simultaneously treated with doxycycline to induce receptor expression and tunicamycin to 
block N-linked glycosylation appeared to express only the non-glycosylated version of the 
receptor, with lower molecular mass compared to the glycosylated form (Figure 3.5).  
Glycosylation of a protein confers an increase in the protein’s molecular mass and in the 
case of the two receptors studied here, the molecular masses of the glycosylated HA-CLIP-
hM3RASSL and VSV-SNAP-hM2WT were above 100 kDa and 70 kDa, respectively, as 
opposed to the lower molecular masses detected for each receptor i.e. 80-85 kDa for HA-
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CLIP-hM3RASSL (Figure3.3) and 60-65 kDa for VSV-SNAP-hM2WT (Figure 3.4), when 
non-glycosylated. The treatments with tunicamycin were carried out for 16 hours, in order 
to maintain the levels of cell death due to apoptosis as low as possible, and inhibition of 
glycosylation effective enough.   
 
In order to confirm the doxycycline-dependent inducible expression of receptors, but also 
the successful cell surface delivery of the expressed receptors, labelling of live cells was 
performed using cell impermeant substrates. HA-CLIP-hM3RASSL was labelled with 20 
nM CLIP-Lumi4 Tb and VSV-SNAP-hM2WT was labelled with 10 nM SNAP-Lumi4 Tb 
in intact cells. Fluorescence emission at 620 nm was monitored following excitation at 337 
nm (Figure 3.6 A and B). Receptors were only labelled with the energy donors (as 
described in Figure 3.2 B) in the absence of an energy acceptor, therefore, the fluorescence 
at 620 nm corresponded to the total expression of the cell surface labelled receptors at that 
particular concentration of doxycycline and Lumi4 Tb. Increasing the receptor expression 
with varying concentrations of doxycycline resulted in an increase in the 620 nm 
fluorescence. The increase in 620 nm signal for both receptors HA-CLIP-hM3RASSL 
(Figure 3.6 A) and VSV-G-SNAP-hM2WT (Figure 3.6 B) were in agreement with the 
results observed in the immunoblotting experiments (Figures 3.3 and 3.4, respectively). 
Addition of increasing concentrations up to 30 nM of CLIP-Lumi4 Tb (Figure 3.6 C) or 40 
nM of SNAP-Lumi4 Tb (Figure 3.6 D), did not lead to saturation of the corresponding cell 
surface receptors, suggesting that the range of substrate concentrations used in the 
experiments were not sufficient to label the totality of the cell surface receptors, but only a 
fraction. The concentrations of Lumi4 Tb required to achieve receptor saturation lie within 
the micromolar range (Doumazane et al., 2011). However, using sub-saturating Lumi4 Tb 
concentrations (in the nanomolar range) has been shown to be sufficient to study cell 
surface receptor expression and oligomerisation (Pou et al., 2010; Alvarez-Curto et al., 
2010) without achieving full coverage of the expressed receptors.  
Cell surface delivery of the receptors was also monitored by epi-fluorescence microscopy. 
This involved labelling of intact cells with cell impermeant SNAP or CLIP specific 
fluorescent dyes (Figure 3.7). The SNAP-Surface 488 (green) was used for detecting the 
VSV-SNAP-hM2WT receptor (Figure 3.7 A) and the CLIP-Surface 547 (red) was used for 
detecting the HA-CLIP-hM3RASSL at the cell surface (Figure 3.7 B). Receptor expression 
was detected at the surface of doxycycline treated cells. No fluorescence was detected in 
cells that were maintained in medium without doxycycline, although background 
fluorescence was observed, probably corresponding to non-specific binding of the 
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fluorescent dyes or to auto-fluorescence background (noise) due to any remaining serum 
contained in the growth medium that cells were maintained in.  
 
 
3.3 Pharmacological profile of receptors expressed individually in Flp-In™ T-REx™-
293 cells. 
 
In an attempt to quantify total receptor expression, binding of near saturating 
concentrations of the muscarinic antagonist [3H]-QNB to membranes prepared from 
doxycycline treated cells was carried out. Radioligand binding data showed a pattern of 
receptor expression similar to that detected with the fluorescent measurement at 620 nm 
and a comparable profile (increased receptor expression levels with increasing doxycycline 
concentrations) to the immunoblotting experiments (see Figures 3.3 and 3.4).  Saturating 
concentrations of the radioligand were used in an attempt to achieve maximal coverage of 
the receptor/binding sites. The radioligand concentrations used were determined by the 
previously reported KD values of the radioligand for each of the receptors. The reported 
affinity of [3H]-QNB for the hM3RASSL receptor according to Alvarez-Curto et al., (2011) 
was kD=2.44 nM, lower than that for the hM2WT, which was in the range of 0.16-0.2 nM 
(Peralta et al., 1987; Norman et al., 1989; Burstein et al., 1996).  
The HA-CLIP-hM3RASSL receptor expression was determined using membranes prepared 
from cells treated with 10 ng∙ml-1 doxycycline, for 24 hours and the Bmax at 1.46 ± 0.66 
pmol∙mg-1 protein was calculated. The range of radioligand concentration used for this set 
of experiments was between 14-20 nM (Figure 3.8 A). This measurement is not absolutely 
precise as the radioligand concentration used did not saturate the receptor according to the 
saturation binding experiments carried out (see example in Figure 3.8 C).  
The VSV-SNAP-hM2WT was expressed with a Bmax at 1.8 ± 0.35 pmol∙mg-1 protein, in 
membranes prepared from cells treated with 5 ng∙ml-1 doxycycline for 24 hours, and the 
range of radioligand concentration used was between 0.16-0.45 nM (Figure 3.8 B).  
 
The hM3RASSL receptor was engineered by introducing two single point mutations in the 
orthosteric binding site and resulted in the inability of the receptor to bind to the 
muscarinic ligand [3H]-QNB as efficiently as the wild type receptor. Consequently, that 
had resulted in a significantly lower affinity of the radioligand for the receptor. The 
previously reported KD value for the hM3RASSL receptor was reported to be higher 
(KD=2.44 nM) than that of the wild type hM3 receptor (KD= 35± 0.9 pM) (Alvarez-Curto et 
Chapter 3   
 
97 
 
al., 2011). This had caused a lot of difficulties in carrying out radioligand saturation 
experiments using HA-CLIP-hM3RASSL enriched membrane preparations. The 
radioligand binding experiment conditions involving exceptionally high concentrations of 
[3H]-QNB (20-40 nM) and the cost of the experiments were limiting factors for succeeding 
in the generation of saturation isotherms of HA-CLIP-hM3RASSL and had led to failure in 
confirming the KD of [
3H]-QNB for the hM3RASSL receptor. A representative example 
shown in Figure 3.8 C corresponds to one experiment that failed to demonstrate saturation 
of the HA-CLIP-hM3RASSL by the radioligand. VSV-SNAP-hM2WT enriched 
membranes, prepared from single cells treated with 5 ng∙ml-1 doxycycline, were used to 
measure the specific binding of varying concentrations of [3H]-QNB, ranging from 0.05-
0.5 nM.  This resulted in the generation of a saturation isotherm (Figure 3.8 D) with a KD 
obtained at 0.32 ± 0.07 nM. The expression level of the VSV-SNAP-hM2WT receptor was 
also determined with Bmax= 3.07 ± 0.52 pmol∙mg-1 protein.  
 
Competition binding assays were carried out to test the affinity of carbachol, atropine and 
CNO for VSV-SNAP-hM2WT. For these experiments, concentrations of [
3H]-QNB 
sufficient to give 90% receptor occupancy were used. The competition binding curves 
shown in Figure 3.9 A, B and C are representative experiments using 5 μg of membrane 
protein preparations from cells treated with 5 ng∙ml-1 doxycycline to express VSV-SNAP-
hM2WT. Carbachol could bind to the orthosteric site of the VSV-SNAP-hM2WT receptor 
(pKi = 6.37 ± 0.13) displacing the radioligand (Figure 3.9 A), whereas, the synthetic ligand 
CNO did not demonstrate binding to the receptor (Figure 3.9 B). The antagonist atropine 
outcompeted the radioligand (pKi = 8.74 ± 0.05) (Figure 3.9 C). The pKi values shown in 
Figure 3.9 were obtained from individual experiments. However, the pKi values from four 
different experiments were pooled and shown in Table 3.1. 
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Table 3.1 Calculated pKi values for carbachol and atropine as a measure of affinity 
for the VSV-SNAP-hM2WT receptor. Pooled data from four experiments, carried out in 
triplicates (presented as Means ± SEM, n=4). 
 
 
 
The competition binding experiments using membranes enriched with HA-CLIP-
hM3RASSL receptor prepared from cells treated with 10 ng∙ml-1 doxycycline, failed to 
provide the pKi values of the ligands for the receptor, therefore, no conclusions could be 
made on the affinity of the ligands to bind the receptor (data not shown). Information on 
CNO and atropine affinity for the hM3RASSL was based on previous studies on the 
hM3RASSL receptor (Alvarez-Curto et al., 2011).  A similar approach to perform 
competition binding experiments was followed using cells able to express both receptors, 
the HA-CLIP-hM3RASSL in a constitutive manner and the VSV-SNAP-hM2WT in a 
doxycycline inducible manner, and this is described in detail in section 3.9 of this chapter.  
 
 
3.4 Functionality of receptors expressed individually in Flp-In™ T-REx™-293 cells. 
 
Receptor function and the ability to activate the corresponding G protein were assessed. 
The hM3RASSL binds to Gq/11 proteins in a similar way as the hM3WT, activating the 
enzyme PLCβ which in turns catalyses the production of IP3 and DAG from PIP2. IP3 then 
diffuses in the cytoplasm and binds to IP3 receptors, triggering release of calcium ions from 
the ER. The hM2WT receptor, upon activation with agonist, binds to and activates Gi/0 
proteins. This results in the inhibition of adenylate cyclase and in turns reduction in cAMP 
production (Figure 3.10). 
VSV-SNAP-hM2WT                           pKi (n=4) 
Carbachol (Cch) 6.0 ± 0.2 
Atropine (Atr) 8.6 ± 0.1 
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Flp-In™ T-REx™-293 cells treated with doxycycline for 24 hours, to express the HA-
CLIP-hM3RASSL receptor, were employed in IP-One assays to assess whether the 
receptor was able to stimulate production of inositol monophosphate (IP1), through  
coupling to Gq/11 proteins in response to the synthetic ligand CNO. CNO mediated 
activation of HA-CLIP-hM3RASSL and initiated the accumulation of IP1 with a potency 
described by a pEC50 value of 7.7 ± 0.18. The receptor did not respond to the muscarinic 
ligand carbachol (Figure 3.11). Addition of a monophosphatase inhibitor (lithium chloride) 
prevented the degradation of IP1 and allowed the accumulation of the IP1 molecule.  
The carbachol mediated coupling of the VSV-SNAP-hM2WT receptor to Gi/0 proteins was 
demonstrated by monitoring the inhibition of adenylate cyclase demonstrated as a decrease 
in forskolin-induced levels of cAMP (pEC50= 5.6 ± 0.46) (Figure 3.12). CNO did not 
demonstrate hM2WT receptor activation.  
 
 
3.5 Screening of cell lines co-expressing HA-CLIP-hM3RASSL and VSV-SNAP-
hM2WT receptors. 
 
To explore the potential co-existence between M2 and M3 homomers but also M2-M3 
heteromers, a cellular system that allowed the co-expression of both receptors was 
generated, based on the Flp-In™ T-REx™-293 cell lines. The cell line inducibly 
expressing the VSV-SNAP-hM2WT receptor was transfected with a construct encoding for 
the HA-CLIP-hM3RASSL receptor. This resulted in constitutive expression of the HA-
CLIP-hM3RASSL receptor. The process of generating a cell line able of co-expressing 
HA-CLIP-hM3RASSL in a constitutive manner and VSV-SNAP-hM2WT upon 
doxycycline treatment is fully described in section 2.3.7.  
Several clones were selected and were primarily screened by immuno-blotting, to assess 
total receptor expression, using the anti-SNAP/CLIP antiserum (Figure 3.13). Lysate 
preparations from four different clonal cell lines (clones 8, 10, 15 and 20), grown in the 
absence and presence of doxycycline, were subjected to immuno-blotting against the anti-
SNAP/CLIP antiserum. Clone 8 seemed to express the constitutive HA-CLIP-hM3RASSL 
in lower levels compared to the rest of the clones (Figure 3.13 A) according to the intensity 
measurements of the polypeptide bands (Figure 3.13 B). Clone 10 seemed to express the 
VSV-SNAP-hM2WT in the absence of doxycycline, and it was therefore excluded as a 
potential cell line to study receptor oligomerisation, as it would be impossible to 
manipulate the co-expression of receptors. Clones 15 and 20 demonstrated a similar 
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expression profile for both the constitutive and the inducible receptors, with the total 
expression of the constitutive receptor HA-CLIP-hM3RASSL being higher compared to 
clone 8. The expression of the inducible VSV-SNAP-hM2WT, upon addition of 5 ng∙ml-1 
doxycycline for 24 hour, was similar between clones 15 and 20, but higher than that seen 
in clone 8, under the same doxycycline treatment conditions. A representative example is 
shown in Figure 3.13.  
In an attempt to quantify the total expression of each receptor, and compare between the 
different clones, binding of near saturating concentrations (16 nM) of the muscarinic 
antagonist [3H]-QNB to membranes prepared from doxycycline treated cells showed a 
similar pattern of receptor expression between clones 8 and 10, whereas, clones 15 and 20 
demonstrated a slightly lower expression for both receptors, contradicting the Western blot 
analysis (Figure 3.14).  
 
The next step included assessing cell surface expression of the constitutive HA-CLIP-
hM3RASSL, by monitoring fluorescence at 620 nm, using cells treated or not with 
doxycycline. Cells were labelled with 20 nM CLIP-Lumi4 Tb. The expression of the 
constitutive HA-CLIP-hM3RASSL was unaffected by the presence of VSV-SNAP-
hM2WT, in all cell lines examined (Figure 3.15 A). Expression of VSV-SNAP-hM2WT at 
the cell surface was measured by monitoring fluorescence at 620 nm after labelling with 10 
nM SNAP-Lumi4. There was no fluorescence detected in the absence of doxycycline 
treatment, but when cells were treated with 5 ng∙ml-1 doxycycline fluorescence at 620 nm 
was detected corresponding to the cell surface expression of VSV-SNAP-hM2WT (Figure 
3.15 B).  
Clone 8 was selected for further characterisation and was employed for investigating 
oligomerisation between hM2WT and hM3RASSL. There were various reasons that clone 8 
was considered more suitable compared to the rest of cell lines. One of the reasons 
included the observation of VSV-SNAP-hM2WT receptor expression in the absence of 
doxycycline in clone 10 according to the Western blot analysis. This would complicate 
further characterisation and would potentially interfere with oligomerisation studies. 
Therefore, clone 10 was excluded. Although, clones 15 and 20 demonstrated lower HA-
CLIP-hM3RASSL expression, compared to clone 8, according to radioligand binding 
experiments and fluorescence readings at 620 nm, they had to be excluded because their 
growth pattern was very slow and there were inconsistencies in the morphology of the cells 
which also demonstrated low degree of viability. In addition, the expression levels of the 
constitutive receptor in clone 8 were not very different to the ones observed in clones 15 
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and 20 and the expression of VSV-SNAP-hM2WT could be manipulated by addition of 
doxycycline.  
 
3.6 Characterisation of the selected cell line able of co-expressing HA-CLIP-
hM3RASSL and VSV-SNAP-hM2WT. 
 
The selection of the most suitable cell line able of expressing the HA-CLIP-hM3RASSL in 
a constitutive fashion and the VSV-SNAP-hM2WT only upon doxycycline treatment was 
further characterised. The initial aim was focused on identifying the doxycycline 
concentration at which the inducible VSV-SNAP-hM2WT receptor was produced in 
amounts close to the constitutively expressed HA-CLIP-hM3RASSL, to ideally reach a 1:1 
receptor ratio. This was initially approached by immuno-blotting of lysate preparations 
against the anti-SNAP/CLIP antiserum, as well as the anti-HA and anti-VSV anti-sera 
detecting the HA- and VSV-G- epitope tags, respectively (Figure 3.16). According to the 
results obtained from the immuno-detection and Western blot analysis the HA-CLIP-
hM3RASSL was expressed in the absence of doxycycline, as expected and its expression 
levels were unaffected by doxycycline addition. In addition, the expression of the VSV-
SNAP-hM2WT was doxycycline dependent, while, no polypeptide corresponding to the 
VSV-SNAP-hM2WT was detected by anti-SNAP and anti-VSV antibodies in the absence 
of doxycycline. VSV-SNAP-hM2WT was visible in lysates from cells treated with 2 ng∙ml-
1 doxycycline (as detected using the anti-SNAP antibody) and 5 ng∙ml-1 doxycycline (as 
detected with anti-VSV antibody). The expression of VSV-SNAP-hM2WT was increased 
with increasing concentrations of doxycycline (Figure 3.16). 
 
Cell surface delivery of both receptors was assessed by monitoring the fluorescence at 620 
nm, following labelling with SNAP and CLIP specific substrates (Figure 3.17). Labelling 
with 20 nM CLIP-Lumi4 Tb enabled the detection of the constitutively expressed HA-
CLIP-hM3RASSL which did not seem to be affected by addition of increasing 
concentrations of doxycycline. On the other hand, labelling with 10 nM SNAP-Lumi4 Tb 
of cells treated with increasing concentrations of doxycycline, resulted in a linear increase 
of the 620 nm signal corresponding to the increase in the expression of the inducible VSV-
SNAP-hM2WT (Figure 3.17). 
 
Cell surface VSV-SNAP-hM2WT and HA-CLIP-hM3RASSL were imaged individually 
following co-labelling with the cell impermeant fluorescent dyes CLIP-Surface 488 (green) 
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and SNAP-Surface 549 (red) (Figure 3.18). The constitutively expressed HA-CLIP-
hM3RASSL was present in cells treated or not treated with doxycycline but the VSV-
SNAP-hM2WT receptor was only detected at the surface of cells treated with doxycycline. 
Merging the images resulted in a clear demonstration of co-localisation of the two 
receptors at the surface of live cells, at the resolution of light microscopy.  
 
 
3.7 Pharmacological profile of co-expressed receptors.  
 
In an attempt to quantify the total expression of HA-CLIP-hM3RASSL and VSV-SNAP-
hM2WT in cells that co-express the two receptors, receptor enriched membrane 
preparations from cells treated with varying concentrations of doxycycline were assessed 
using a single [3H]-QNB concentration. Total receptor expression was determined by 
calculation of the Bmax value that corresponded to the expression levels of the 
constitutively expressed HA-CLIP-hM3RASSL in membranes from cells not treated with 
doxycycline (Bmax= 1.6 ± 0.65 pmol∙mg-1 protein).  Membranes from cells treated with 5 
ng∙ml-1 doxycycline demonstrated an increase in total protein expression with a Bmax 
obtained at 4.7 ± 1.5 pmol∙mg-1 protein. The difference in Bmax values corresponds to the 
expression of VSV-SNAP-hM2WT upon doxycycline treatment (Figure 3.19).  
 
Competition binding assays using [3H]-QNB concentrations sufficient to give 90% 
receptor occupancy, were used to assess the affinity of carbachol, CNO and atropine for 
the receptors. The data presented in Figure 3.20 were obtained from individual experiments 
representative of the competition assays carried out using cells that are able of co-
expressing both the receptors. The pKi values shown on each graph in Figure 3.20 are for 
n=1. The counts from different assays could not be pooled together due to variation in the 
added radioactivity between the experiments. The pKi values obtained from four different 
experiments were pooled together and the means are shown in Table 3.2.  
Membranes prepared from cells treated or not with doxycycline were employed against a 
single near saturating concentration of [3H]-QNB and varying concentrations of the non-
labelled ligands were added as competitors. The synthetic ligand CNO successfully 
outcompeted the radioligand with a pKi= 6.70± 0.17 in membranes where only the HA-
CLIP-hM3RASSL was expressed (-Dox conditions) (Table 3.2). The pKi= 6.12 ± 0.21 was 
obtained from one individual experiment (Figure 3.20 A). CNO showed a slightly different 
affinity (pKi= 6.24 ± 0.31) in the presence of the doxycycline inducible VSV-SNAP-
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hM2WT (+ Dox) (Table 3.2). The pKi value from one individual experiment was found to 
be 5.68 ± 0.39 (Figure 3.20 B). Carbachol did not bind HA-CLIP-hM3RASSL in 
membranes prepared from cells not treated with doxycycline (Table 3.2 and Figure 3.20 C 
for a representative example), but successfully outcompeted the radioligand when 
membranes enriched in VSV-SNAP-hM2WT were used, with a pKi= 6.10 ± 0.70 (Table 
3.2). The pKi from one individual experiment was calculated at 6.38 ± 0.27 (Figure 3.20 
D). The antagonist atropine bound to the HA-CLIP-hM3RASSL successfully outcompeting 
the radioligand with pKi (-Dox) = 8.20 ± 0.14 (Table 3.2) and pKi (+Dox) = 7.65 ± 0.10 
(Table 3.2). The affinity of atropine for HA-CLIP-hM3RASSL from one individual 
experiment was determined with pKi (-Dox) = 8.13 ± 0.12 (Figure 3.20 E) and pKi (+Dox) 
=7.68 ± 0.05 (Figure 3.20 F). A second affinity measurement for atropine was recorded, 
which corresponded to the VSV-SNAP-hM2WT receptor, in membranes prepared from 
cells treated with doxycycline, with pKi = 8.53 ± 0.10 (Table 3.2). The affinity of atropine 
for VSV-SNAP-hM2WT from one individual experiment was determined with pKi= 8.56 ± 
0.05 (Figure 3.20 F). 
 
Ligands / pKi VSV-SNAP-
hM2WT (+Dox) 
HA-CLIP-
hM3RASSL (-Dox) 
HA-CLIP-
hM3RASSL (+Dox) 
Carbachol 6.10 ± 0.70 - - 
CNO - 6.70 ± 0.17 6.24 ± 0.31 
Atropine 8.53 ± 0.10 8.20 ± 0.14 7.65 ± 0.10 
 
Table 3.2 pKi values for carbachol, CNO and atropine obtained from competition 
binding experiments. Carbachol only binds to VSV-SNAP-hM2WT receptor and the 
synthetic ligand CNO only binds to the HA-CLIP-hM3RASSL. The antagonist atropine 
was able to bind to both receptors with nanomolar affinities. Data presented as Means ± 
SEM, n=3, experiments carried out in triplicates.  
 
 
3.8 Assessing the function of receptors when these are co-expressed in the same cell 
line. 
 
The function of the doxycycline inducible VSV-SNAP-hM2WT and the constitutive HA-
CLIP-hM3RASSL was assessed, when both receptors were co-expressed in the same cell 
line. The ability of the HA-CLIP-hM3RASSL to bind to and activate the Gq/11 protein was 
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confirmed by assessing the accumulation of IP1 and intracellular calcium ion release, in 
response to CNO (Figure 3.21). The CNO-mediated activation of the HA-CLIP-
hM3RASSL resulted in a potent increase in IP1 levels, in the absence of VSV-SNAP-
hM2WT with a pEC50 = 8.2 ± 0.3. The potency of CNO remained unaltered in the presence 
of both receptors with pEC50 = 8.2 ± 0.27. There was a trend towards an increase in the 
efficacy of CNO, when both receptors were co-expressed, suggesting a possible synergistic 
effect of the hM2WT receptor on the function of hM3RASSL or simply implying possible 
cross-talk between the two receptors’ signalling pathways (Hornigold et al., 2003), but this 
increase was not statistically significant (P>0.05). The HA-CLIP-hM3RASSL was 
unresponsive to carbachol, as expected.  
The possibility of a synergistic effect between the hM2WT and hM3RASSL, in response to 
CNO, was not detected in calcium mobilisation experiments (Figure 3.22). Cells 
expressing the HA-CLIP-hM3RASSL receptor responded robustly to CNO in the absence 
or presence of the doxycycline inducible VSV-SNAP-hM2WT, with pEC50 (-Dox) = 8.4± 
0.08 and pEC50 (+Dox) = 8.3 ± 0.06, respectively. Carbachol did not activate the 
hM3RASSL receptor.  
The VSV-SNAP-hM2WT mediated Gi/o coupling, upon stimulation with carbachol, was 
assessed by measuring the inhibition of adenylate cyclase activity. This was carried out by 
monitoring the levels of cAMP, in response to agonist (Figure 3.23). Cells expressing the 
VSV-SNAP-hM2WT along with the constitutively expressed HA-CLIP-hM3RASSL, 
showed a potent inhibition of the forskolin-induced levels of cAMP in the presence of 
varying concentrations of carbachol (pEC50= 6.9 ± 0.1). The synthetic ligand CNO did not 
inhibit adenylate cyclase activity and in turn had no effect on cAMP levels, and thus we 
can conclude an inability of CNO to bind to and activate the hM2WT receptor.  
 
 
3.9 Discussion  
 
The choice of the Flp-In™ T-REx™-293 cellular system for expressing the receptors of 
interest at the cell surface and further on for studying receptor oligomerisation was an 
important step for the initiation of the project. There are many advantages of Flp-In™ T-
REx™-293 cells stably expressing the receptor(s) of interest over transiently transfected 
HEK 293 cells. For example, Flp-In™ T-REx™-293 cells express receptors in an isogenic 
and inducible manner offering consistency of expression between different experiments.  
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Here, cell lines able to express HA-CLIP-hM3RASSL or VSV-SNAP-hM2WT receptors 
individually, upon treatment with doxycycline, were generated and characterised. An 
additional cell line capable of expressing both receptors was selected from a number of 
clonal cell lines and was also characterised. In the selected cell line the HA-CLIP-
hM3RASSL receptor was constitutively expressed, while, expression of VSV-SNAP-
hM2WT was initiated only upon doxycycline addition. The Flp-In™ T-REx™-293 cell-
based expression system assured the successful delivery of the receptors at the cell surface 
with the addition of the mGluR5 signal sequence to the fusion constructs. Incorporation of 
the SNAP and CLIP tags allowed the detection of the expressed constructs at the cell 
surface of live cells and constituted a key element in studying oligomeric interactions 
between the receptors (see Chapters 4 and 5). Despite the relatively large size of the SNAP 
and CLIP tags (about 20 kDa) their introduction at the N-terminal domain of the receptors 
did not affect receptor pharmacology and signalling, as demonstrated by the radioligand 
binding experiments and by the functional assays.  
The chemical biology approach that involved the use of a mutated version of the hM3 
receptor, called hM3RASSL, allowed for the differential activation of each receptor 
subtype. The hM3RASSL receptor is only activated by the synthetic ligand CNO and the 
hM2WT receptor is only activated by classical muscarinic agonists such as acetylcholine or 
carbachol. A limitation that arose from the use of hM3RASSL receptor involved the 
reduced affinity of the radiolabelled ligand [3H]-QNB for the receptor that led to difficulty 
in saturating the hM3RASSL receptor population and thus, resulting in the inability to 
confirm the previously reported affinity of [3H]-QNB for the hM3RASSL.  
The radioligand binding using saturating concentrations of the muscarinic radioligand 
[3H]-QNB allowed the quantification of the total receptor expression in cells expressing 
each of the receptor alone and in cells co-expressing both receptors.  
An important step involved the identification of the doxycycline concentration required to 
treat the cells able of co-expressing both receptors, which would lead to equal expression, 
ideally to 1:1 ratio, between the constitutively expressed HA-CLIP-hM3RASSL and the 
doxycycline inducible VSV-SNAP-hM2WT. That was achieved by determining the total 
expression of both receptors by using a single concentration of [3H]-QNB which would 
theoretically be enough to saturate both the receptors.  
Competition radioligand binding experiments, using concentrations of [3H]-QNB sufficient 
to give a 90% receptor occupancy were carried out to assess the binding of ligands to the 
expressed receptors. Those experiments confirmed binding of CNO to the hM3RASSL 
receptor and binding of carbachol to the hM2WT receptor with nanomolar affinities. The 
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muscarinic antagonist atropine demonstrated the ability to bind both receptors with similar 
affinity.  
The cell surface expression of the two co-expressed receptors in cells that co-expressed 
both receptors was monitored by measuring fluorescence at 620 nm, following labelling of 
cells with Lumi4 Tb donors. Cell surface delivery of the receptors was confirmed by epi-
fluorescence microscopy.  
The doxycycline concentrations used for each cell line were determined according to total 
and cell surface receptor expression profiles of the receptors. The aim was to identify the 
concentration of doxycycline at which VSV-SNAP-hM2WT and HA-CLIP-hM3RASSL 
would be expressed at similar levels in cells expressing each of the receptors. In addition, 
doxycycline concentration which would allow similar expression of both receptors in cells 
co-expressing VSV-SNAP-hM2WT and HA-CLIP-hM3RASSL was also identified.  
 
Function of the expressed receptors was also assessed.  HA-CLIP-hM3RASSL-mediated 
activation of Gq/11 protein pathways was monitored by measuring IP1 accumulation levels 
and calcium ion release from the ER upon agonist stimulation. Activation of the Gq/11 
pathway is traditionally measured by detection of intracellular calcium using fluorescent 
calcium indicator dyes. Although, monitoring calcium mobilisation is easy, calcium flux is 
very rapid and transient and this limits the sensitivity of the assay. An alternative approach 
was used that involved measurement of IP1 production. The use of lithium chloride to 
inhibit IP1 degradation allowed for an accurate and robust measurement of IP1 
accumulation enabling the determination of potency and efficacy of CNO for HA-CLIP-
hM3RASSL. IP-One is a cell-based, htrFRET-based, competition immunoassay. The IP1 
produced by cells after agonist-induced receptor activation competes with an IP1 analog 
coupled to d2 fluorophore (acting as energy acceptor), for binding to an anti-IP1 
monoclonal antibody labelled with Eu2+ cryptate (acting as energy donor). The resulting 
signal is inversely proportional to the IP1 concentration in the cells.  
Activation of Gi/o protein is traditionally monitored by [
35S]-GTPγ assay. This approach 
only assesses direct activation of the G protein without providing information about the 
downstream signalling cascade. An alternative approach was utilised to monitor the 
agonist-mediated hM2WT activation through Gi/o protein coupling and the subsequent 
negative regulation of adenylate cyclase that results in a decrease in cAMP levels. The 
cAMP assay is a cell-based, htrFRET-based method for monitoring cellular cAMP levels. 
The assay requires pre-stimulation of adenylate cyclase with forskolin. Addition of 
phosphodiesterase inhibitors is also required to inhibit the degradation of cAMP to AMP. 
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Measurement of cAMP levels is carried out using a competition assay in which cellular 
cAMP competes with an introduced cAMP analog conjugated to d2 fluorophore (energy 
acceptor) for binding to an anti-cAMP monoclonal antibody conjugated to Eu2+ cryptate 
(energy donor). The Gi/o mediated decrease in intracellular cAMP levels is expressed as an 
increase in the htrFRET signal. This assay is simple and robust, allowing the determination 
of agonist potency and efficacy for the receptor. In addition, the signal-to-noise ratio is 
greatly enhanced due to signal amplification achieved by moving down the signal 
transduction pathway, in contrast to the [35S]-GTPγS assay that is not subjected to signal 
amplification. 
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A.                                                    B. 
 
                                                                    
 
 
 
 
Figure 3.1 Schematic diagrams of the tagged receptors. (A) The N-terminal of the 
hM3RASSL was fused with the CLIP tag and the HA epitope tag. (B) The VSV-G epitope 
tag was fused upstream the SNAP tag at the N-terminal sequence of the hM2WT receptor. 
The mGluR5 signal sequence was also added to ensure cell surface delivery of the 
expressed receptors.  
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Figure 3.2 Tag-lite® technology to detect protein-protein interations by measuring 
htrFRET and to determine cell surface expression by measuring fluorescence at 620 
nm. (A) When a terbium based htrFRET compatible donor (Lumi4) is excited at 337 nm, it 
emits at a higher wavelength, 620 nm, and given that the htrFRET compatible acceptor 
(d2-Red) is in close proximity, the emitted energy from the donor will excite the acceptor 
that will emit at 665 nm. This represents the FRET emission signal, and it is indicative of  
the close proximity of the donor/acceptor species. (B) In the absence of an acceptor, once 
the receptor labelled with a donor molecule is excited at 337 nm, energy is not trasferred  
but instead the donor emits at 620 nm. This fluorescence measurement can be used as a 
measurement of the total cell surface of expression levels of labelled receptors. (C) 
Diagram showing the spectral properties of htrFRET substrates. The emission spectra of 
the donor Europium cryptate (blue line) and the red acceptor (pink line) are the key 
elements allowing for the spectral selectivity between the acceptor fluorescence emission 
(665 nm) and the donor fluorescence emission (620 nm) (Diagram taken from Trinquet and 
Mathis, 2006). 
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Figure 3.3 Immuno-detection of HA-CLIP-hM3RASSL. Lysates were prepared from 
cells treated with the indicated concentrations of doxycycline to allow expression of the 
receptor. Samples (10μg protein per well) were immuno-blotted against (A) rabbit anti-
SNAP antiserum and the polypeptides seen with molecular mass just below 140 kDa 
correspond to glycosylated HA-CLIP-hM3RASSL receptor (arrow) and the polypeptides 
seen at 100 kDa correspond to the un-glycosylated receptor (star). The bands seen between 
50-70 kDa correspond to non-specific binding. (B) Rat anti-HA antiserum was used 
against the same lysate sample preparations and the same specific polypeptide bands were 
detected corresponding to the un-glycosylated version of the receptor with molecular mass 
of 100 kDa (star).   Samples prepared from cells not treated with doxycycline did not 
demonstrate receptor expression.   
 
 
 
 
 
 
 
 
 
 
 
                 
 
* * 
Chapter 3   
 
111 
 
         
                                                             
 
 
Figure 3.4 Immuno-detection of VSV-SNAP-hM2WT. Lysates prepared from cells 
treated with the indicated concentrations of doxycycline to express the receptor were 
immuno-blotted against the rabbit anti-SNAP antibody, which specifically detected the 
VSV-SNAP-hM2WT at 70 kDa (arrow). The expression of the receptor was increased with 
the increase in doxycycline concentration. Lysate samples prepared from cells not treated 
with doxycycline and those prepared from non-transfected Flp-In™ T-REx™-293 cells did 
not demonstrate receptor expression. The star indicates the presence of un-glucosylated 
receptor appearing as a lower molecular mass band. 10 μg of protein lysate were loaded 
per well. 
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Figure 3.5 Treatment with tunicamycin inhibits receptor N-linked glycosylation. Flp-
In™ T-REx™-293 cells stably expressing the HA-CLIP-hM3RASSL (upon addition of 10 
ng∙ml-1 dox) or VSV-SNAP-hM2WT (upon addition of 5 ng∙ml-1 dox), were treated with 6 
μM tunicamycin, for 16 hours. These cells were used to prepare the lysate samples that 
were subjected to SDS-PAGE and were immuno-blotted against the rabbit anti-SNAP 
antiserum. The glycosylated versions of HA-CLIP-hM3RASSL (upper arrow) appeared to 
be of higher molecular mass compared to the non-glycosylated form of the receptor (upper 
star). The same pattern was seen in the glycosylated (lower arrow) and non-glycosylated 
(lower star) form of the VSV-SNAP-hM2WT. Lanes 1 and 4 contain samples from non-
induced Flp-In™ T-REx™-293 cells.    
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C.                                                       D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Fluorescence measurements at 620 nm showed that receptor expression at 
cell surface is doxycycline dependent. The expression of HA-CLIP-hM3RASSL (A) was 
increased with the increase in doxycycline concentration, in live cells labelled with 20 nM 
CLIP-Lumi4 Tb. (B) The expression of the VSV-SNAP-hM2WT was increased in the 
same fashion when cells were labelled with 10 nM SNAP-Lumi4 Tb. Increasing 
concentrations of the Lumi4 Tb substrates were used to label cells expressing (C) HA-
CLIP-hM3RASSL and (D) VSV-SNAP-hM2WT, but without saturating the receptors, even 
at the higher concentrations used.  (Data presented as Means ± Range, n=2 for A, C and D 
and Means ± SEM, n=3 for B, all experiments performed in triplicates). 
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Figure 3.7 Live cell epi-fluorescence imaging demonstrates cell-surface receptor 
expression. Cells capable of expressing each of the receptors individually were grown on 
cover slips and were treated with doxycycline for 24 hours to induce receptor expression. 
Labelling of live cells was performed with cell impermeable fluorescent dyes that 
specifically recognised the SNAP or CLIP tags. (A) VSV-SNAP-hM2WT labelled with 5 
μM SNAP-Surface 488 (Green) and (B) HA-CLIP-hM3RASSL labelled with 5 μM CLIP-
Surface 547 (Red) were used for the labelling and fluorescence was monitored on an epi-
fluorescence microscope. The expression of the VSV-SNAP-hM2WT and HA-CLIP-
hM3RASSL was localised at the cell surface in cells treated with doxycycline (+Dox), but 
no fluorescence was seen in the cells grown in the absence of the antibiotic (-Dox).  
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C. D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.8 Total receptor expression determined by radioligand binding. Near 
saturating concentrations of [3H]-QNB were used against membranes prepared from cells 
treated with doxycycline to induce expression of (A) HA-CLIP-hM3RASSL (Data 
presented as Means ± Range, n=2, experiments in triplicates, radioligand concentration 
range 14-20 nM) and (B) VSV-SNAP-hM2WT (Data presented as Means ± SEM, n=3, 
experiments in triplicates, radioligand concentration  range 0.16-0.45 nM). (C) A 
representative example (n=1, experiment in triplicates) of an attempt to plot the saturation 
isotherm of the HA-CLIP-hM3RASSL enriched membranes prepared from the cell line 
expressing the receptor upon treatment with 10 ng∙ml-1 doxycycline failed to allow the 
calculation of KD for the receptor. (D) Saturation isotherm of the VSV-SNAP-hM2WT 
enriched membranes upon treatment with 5 ng∙ml-1 doxycycline. A representative 
experiment is shown, as data from radioligand binding assays should not be pooled 
together due to differences in radioactivity added. The KD and Bmax were calculated from 
the pooled data from four independent experiments (n=4). The affinity of the radioligand 
as calculated by the dissociation constant (KD= 0.32 ± 0.07 nM) and the expression levels 
(Bmax= 3.07 ± 0.52 pmol∙mg-1 protein) were determined as Means ± SEM, n=4, 
experiments in triplicates). 
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Figure 3.9 Competition binding data determined the Ki values of carbachol and 
atropine for the VSV-SNAP-hM2WT receptor expressed in single stable cell line.  The 
three figures are representative examples for the competition binding experiments carried 
out using 5 μg membrane protein per reaction and a set concentration of [3H]-QNB, while 
adding increasing concentrations of the ligands Cch, CNO and atropine. (A) Carbachol 
competed with the added 3.2 nM [3H]-QNB with a pKi of 6.37 ± 0.13 calculated from this 
experiment. (B) The synthetic ligand CNO did not bind to hM2WT receptor and therefore 
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could not compete with the added 3.7 nM [3H]-QNB. (C) Atropine decreased the specific 
binding of the 4.3 nM [3H]-QNB by displacing the radioligand with pKi = 8.74 ± 0.05. 
Data in the figure represent individual experiments carried out in triplicates. The pKi 
values shown in Table 3.1 (see page 98) represent the pooled data ffrom four different 
experiments and are presented as Means ± SEM, n=4 with each experiment carried out in 
triplicates. 
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Figure 3.10 G protein coupling and signalling pathways of M2 and M3 receptors. M3 
receptor upon agonist mediated activation shows preference to Gq/11 coupling and this 
leads to activation of phospholipase Cβ (PLCβ), which in turns catalyses the formation of 
IP3 and DAG)from PIP2. IP3 acts on IP3 receptors in the ER and induces release of calcium 
ions. DAG while still bound on the membrane works to activate PKC. On the other hand, 
M2 receptor, once activated by ligand, it binds to and activates the Gi/o protein dependent 
pathway. Gi/o acts by inhibiting the enzyme adenylate cyclase which catalyses the 
conversion of ATP to cAMP. Inhibition of adenylate cyclase, thus, leads to reduced 
intracellular cAMP levels.   
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Figure 3.11 Accumulation of inositol monophosphate (IP1) upon CNO mediated 
activation of hM3RASSL receptor. The HA-CLIP-hM3RASSL receptor expressed in 
cells treated with 10 ng∙ml-1 doxycycline was able to respond to the synthetic ligand CNO, 
which activated the receptor leading to Gq/11 protein coupling that potently resulted in the 
accumulation of IP1 (pEC50=7.7 ± 0.18). The muscarinic agonist carbachol was unable to 
induce a Gq/11 coupling response, since it does not bind to the hM3RASSL receptor. Data 
presented as Means ± SEM, n=4 and normalised to percentage, experiments carried out in 
triplicates. 
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Figure 3.12 cAMP inhibition upon carbachol mediated activation of hM2WT 
receptor. The VSV-SNAP-hM2WT receptor expressed in cells treated with 5 ng∙ml-1 
doxycycline responded to carbachol by coupling to Gi/o protein, and in turn inhibiting 
adenylate cyclase, resulting in a decrease in the cAMP levels (pEC50= 5.62 ± 0.46). Cells 
not treated with doxycycline also showed a decrease in cAMP levels at the highest 
carbachol concentration, probably due to the low levels of endogenous muscarinic 
receptors present. VSV-SNAP-hM2WT did not respond to the synthetic ligand CNO. 
Forskolin (1 μM) was used in the assay to initially activate adenylyl cyclase. IBMX at 0.5 
mM was used to prevent degradation of cAMP to AMP. Data was normalised to 
percentage for the maximal forskolin response and presented as Means ± SEM, n=3, 
experiments in triplicates. 
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Figure 3.13 Immuno-detection of VSV-SNAP-hM2WT and HA-CLIP-hM3RASSL in 
the different clonal cell lines using anti-SNAP/CLIP antibody. (A) Lysate samples 
prepared from the four different clonal cell lines were immuno-blotted against the anti-
SNAP/CLIP antiserum to allow detection of both receptors and to compare expression 
levels of receptors between the different cell lines. In the absence of doxycycline only the 
constitutive receptor HA-CLIP-hM3RASSL was expressed with the glycosylated version 
seen just below 140 kDa (upper arrow) and un-glycosylated at 100 kDa (upper star).  When 
cells were treated with 5 ng∙ml-1 doxycycline the VSV-SNAP-hM2WT expression was 
induced, allowing the detection of the glycosyoated polypeptide at around 80 kDa (lower 
arrow) and the un-glycosylated polypeptide with lower molecular mass (lower star). (B) 
The intensity of the doxycycline-induced VSV-SNAP-hM2WT and the constitutively 
expressed HA-CLIP-hM3RASSL polypeptide bands was calculated and plotted for the 
different cell lines. 
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Figure 3.14 Radioligand binding to quantify total receptor expression using a single 
[3H]-QNB concentration. Membrane preparations from the different clonal cell lines 
(treated or not with 5ng·ml-1 doxycycline for 24 hours) were used to determine specific 
binding of 16 nM [3H]-QNB.  Total receptor expression of HA-CLIP-hM3RASSL and 
VSV-SNAP-hM2WT was determined. (This is a representative experiment carried out in 
triplicates)  
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Figure 3.15 Fluorescence measurements at 620 nm detected expression of VSV-
SNAP-hM2WT and HA-CLIP-hM3RASSL in the clonal cell lines.  (A) 20 nM CLIP-
Lumi4 Tb was used to label the different clonal cell lines in the presence and absence of 
doxycycline. The fluorescence readings at 620 nm corresponded to the expression levels of 
the CLIP-tagged constitutively expressed hM3RASSL. (B) 10 nM SNAP-Lumi4 Tb was 
used to label the same clonal cell lines, in separate wells, and the increase in fluorescence 
measurements from the wells with cells treated with doxycycline compared to the 
untreated ones, corresponded to the induction of theVSV-SNAP-hM2WT receptor 
expression. (Data presented as Means ± SEM, n=3, experiments carried out in triplicates) 
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Figure 3.16 Immuno-detection of HA-CLIP-hM3RASSL and VSV-SNAP-hM2WT 
receptors in the cell line co-expressing the receptors. Lysates prepared from cells un-
treated or treated with varying concentrations of doxycycline were resolved by SDS-PAGE 
and immuno-blotted with three different antisera. 10 μg of protein were loaded per well. 
The anti-HA antibody detected the non-glycosylated form of HA-CLIP-hM3RASSL at 
around 100 kDa (arrow pointing rightwards). The anti-VSV antibody detected the non-
glycosylated form of VSV-SNAP-hM2WT at just above 70 kDa (blue star) and the anti-
SNAP detected both the receptors, HA-CLIP-hM3RASSL (arrow pointing leftwards) and 
VSV-SNAP-hM2WT (star), in the two forms, glycosylated and non-glycosylated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
Chapter 3   
 
125 
 
 
 
0 1 2.5 5
0
1.0104
2.0104
3.0104 CLIP-Lumi4 Tb
SNAP-Lumi4 Tb
Dox ngml
-1
F
lu
o
re
s
c
e
n
c
e
 @
 6
2
0
 n
m
 
 
 
3.17 Detection of cell surface expression of HA-CLIP-hM3RASSL and VSV-SNAP-
hM2WT receptors by monitoring fluorescence at 620 nm. Cells able of expressing both 
receptors were treated with varying concentrations of doxycycline and were labelled with 
CLIP-Lumi4 Tb (20 nM) or SNAP-Lumi4 Tb (10 nM) and fluorescence at 620 nm were 
measured. Data are Means ± SEM from n=8, except for 2.5 ng·ml-1 dox where n=6, 
experiments in duplicates).  
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Figure 3.18 Detection of receptors at cell surface using epi-fluorescence imaging. Cells 
capable of expressing both receptors were grown on cover slips, in the absence or presence 
of 5 ng·ml-1 doxycycline for 24 hours. The HA-CLIP-hM3RASSL (CLIP-Surface 488, 
Green) was expressed in cells untreated or treated with doxycycline. The VSV-SNAP-
hM2WT (SNAP-Surface 549, Red) expression was initiated only upon doxycycline 
addition. When both receptors were co-expressed the receptors displayed co-localisation at 
the cells surface as the merging of the two channels suggest.   
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Figure 3.19 Quantification of total HA-CLIP-hM3RASSL expression by radioligand 
binding. Membranes prepared cells capable of expressing both receptors were treated with 
various concentrations of doxycycline and were employed in determining the specific 
binding to a single saturating concentration of the muscarinic radioligand [3H]-QNB 
(radioligand range used was between 16 nM-21.6 nM. Data are Means ± SEM for n=4, 
experiments in triplicates).   
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     C.                                                      D. 
 
 
 
 
 
 
 
 
 
 
 
     E.                                                       F. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 Competition binding determined the affinity of ligands for the receptors. 
Data shown in A-F are individual experiments using 5 μg protein per reaction and a single 
near saturating concentration of [3H]-QNB (28.1 nM). Ligands were added to the reactions 
at increasing concentrations in samples prepared from cells either treated or not with 5 
ng∙ml-1 doxycycline. In samples where only the HA-CLIP-hM3RASSL is expressed (A) 
CNO successfully out-competed the radioligand with pKi = 6.12 ± 0.21. (B) In the 
presence of both receptors CNO showed a slightly different affinity with pKi = 5.68 ± 0.39. 
(C) Carbachol did not bind to the HA-CLIP-hM3RASSL receptor, (D) but only to the 
doxycycline inducedVSV-SNAP-hM2WT with pKi = 6.38 ± 0.27. (E) The antagonist 
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atropine could bind to the HA-CLIP-hM3RASSL when expressed alone with a high affinity 
(pKi = 8.13 ± 0.12) and (F) atropine also demonstrated binding to both receptors when they 
were co-expressed. This led to the observation of two different affinity measurements for 
atropine; one that corresponded to the M3 (pKi =7.68 ± 0.05) and a second that 
corresponded to the M2 (pKi = 8.56 ±0.05). The data from the competition binding assays 
were analysed using a two-site fit analysis for samples that contained both receptor 
populations and one-site fit analysis for the samples with only one receptor on Graph Pad 
software. 
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Figure 3.21 CNO-mediated hM3RASSL activation results in IP1 accumulation in cells 
co-expressing HA-CLIP-hM3RASSL and VSV-SNAP-hM2WT. Cells treated with 
doxycycline to allow co-expression of VSV-SNAP-hM2WT alongside the constitutive HA-
CLIP-hM3RASSL were employed to measure the levels of IP1. The synthetic ligand CNO 
potently increased the IP1 levels in the absence of VSV-SNAP-hM2WT (0 ng∙ml-1 dox) 
with pEC50 (-dox) = 8.2 ± 0.3. The potency of CNO remained unaltered in the presence of 
both receptors (+5 ng∙ml-1 dox) with pEC50= 8.2± 0.27. There was a trend towards an 
increase in the efficacy of CNO but it was not statistically significant (P>0.5). Data 
presented as Means ± SEM, n=5, experiments in triplicates. P value was obtained by 
comparing the –dox to the +dox data upon treatment with CNO, using a two-paired t-test. 
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Figure 3.22 Intracellular calcium ion mobilisation in response to CNO-mediated 
activation of HA-CLIP-hM3RASSL.  Cells seeded in 96 well plates were treated or not 
with doxycycline to allow co-expression of VSV-SNAP-hM2WT and HA-CLIP-
hM3RASSL. Cells were then labelled with 3μM fura 2 AM before addition of ligands and 
intracellular calcium concentration was measured after treatment with varying 
concentrations of carbachol (Cch) or CNO. The CNO mediated activation of HA-CLIP-
hM3RASSL receptor was responsible for the potent release of calcium ions (pEC50 = 8.4± 
0.08). The presence of VSV-SNAP-hM2WT (+dox) did not affect neither the efficacy nor 
the potency of CNO in inducing calcium release through Gq/11 coupling activation (pEC50 = 
8.3 ± 0.06). Data presented as Means ± Range, n=2, experiments in triplicates. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-11 -10 -9 -8 -7 -6 -5
0
1
2
3
4
0 ngml -1 dox  CNO
5 ngml -1 dox  CNO
0 ngml -1 dox  Cch
5 ngml -1 dox  Cch
log[agonist] M
[c
a
lc
iu
m
+
2
] i
 r
e
le
a
s
e
fu
ra
 2
 r
a
ti
o
Chapter 3   
 
132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23 Reduction of cellular cAMP levels in response to carbachol-mediated 
activation of VSV-SNAP-hM2WT through Gi/o coupling. Cells able of co-expressing 
both receptors were treated or not with 5 ng∙ml-1 doxycycline and were employed to 
measure the carbachol-mediated inhibition of forskolin-induced activation of adenylyl 
cyclase. Carbachol was able to potently (pEC50= 6.9 ± 0.1, Means ± SEM, n=3, 
experiments in triplicates) inhibit the activation of adenylyl cyclase and thus, reduce the 
levels of cAMP in cells treated with 5 ng∙ml-1 doxycycline. Carbachol showed no effect in 
the absence of the VSV-SNAP-hM2WT receptor. No adenylyl cyclase inhibition was 
detected in response to CNO treatment and thus levels of cAMP were maintained 
unaltered.  
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Chapter 4 
Analysis of hM2WT and hM3RASSL 
receptor complexes at the surface of 
live cells 
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4.1 Introduction  
Class A GPCRs, in their monomeric form, may bind to and activate their corresponding G 
proteins (Whorton et al., 2008), but there is accumulation of evidence suggesting that they 
may also exist and function as oligomers (Milligan, 2009; Javitch, 2004). There is growing 
evidence that supports the important role of oligomerisation in signalling, pharmacology 
and function of class A GPCRs (Milligan, 2013; Milligan et al., 2004; Angers et al., 2002; 
Ferre et al., 2014; Herrick-Davis, 2013). 
 M2 and M3 muscarinic acetylcholine receptors, members of class A family of GPCRs, are 
co-expressed and they demonstrate a pattern of co-localisation at the cell membrane of 
native tissues of the central nervous system, such as striatum, hippocampus, cerebral 
cortex, thalamus, hypothalamus and cranial nerve nuclei (Pan et al., 2008; Levey et al., 
1991; Wess, 2004), supporting the role of muscarinic receptors in cognition, memory and 
learning. M2 and M3 receptor subtypes are also co-expressed in the smooth muscle of the 
intestine, ileum, airway, iris, and bladder (Eglen et al., 1994; Uchiyama and Chess-
Williams, 2004; Wess, 2004), a fact that implies an important role of muscarinic receptors 
in the contraction of smooth muscle (Eglen et al., 1996; Caulfield, 1993). M2 receptor is 
also expressed in the heart, where it appears to play a role in controlling cardiac myocyte 
contraction (Caulfield, 1993; Wess, 2004). Saliva secretion (Matsui et al., 2000) and 
insulin secretion (Gautam et al., 2007) are functions that are thought to be mediated by the 
M3 receptor. Any possible interactions between the two muscarinic subtypes, M2 and M3, 
could be of therapeutic importance.  Therefore, a more thorough insight into the 
heteromerisation between M2 and M3 could be useful in terms of drug discovery. The 
interaction between M2 and M3 receptors has been demonstrated previously, by saturation 
BRET experiments, in live transfected HEK 293 cells (Goin and Nathanson, 2006). The 
analysis of BRET50 values, obtained from BRET saturation curves, also showed the 
existence of high affinity homomers of M1, M2 and M3 as well as a population of M1-M2, 
M1-M3 heteromers alongside with the M2-M3 heteromers, in the same cells (Goin and 
Nathanson, 2006). Other examples of muscarinic receptors in dimeric, or even higher 
oligomeric, forms have been reported (Hu et al., 2013, Alvarez-Curto et al., 2010, 
Patowary et al., 2013, Herrick-Davis et al., 2015). The existence of predominant tetrameric 
rhomboidal complex structures of the M3 receptor has been demonstrated by spectrally 
resolved FRET (Patowary et al., 2013). The oligomeric profile of the M3 receptor was also 
supported by BRET data and structural /modelling studies (McMillin et al., 2011), by 
disulphide cross-linking (Hu et al., 2013), as well as by FRET assays (Alvarez-Curto et al., 
2010). The M2 receptor was also shown to predominantly exist in tetrameric form, 
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determined by a quantitative FRET assessment (Pisterzi et al., 2010). The existence of the 
tetrameric form of M2 was supported by radioligand binding experiments, using 
reconstituted monomeric and tetrameric forms of the receptor (Redka et al., 2014).   
The focus of this chapter was to study the oligomerisation of muscarinic acetylcholine M2 
and M3 receptors. More specifically, the interest was focused on using htrFRET to detect 
the formation of M2 and M3 homomers, in live cells, expressing one of the receptors, in a 
doxycycline inducible manner, and the co-existence of receptor homomers with M2-M3 
heteromers, in cells expressing both the receptors.  The co-existence of M2 and M3 
heteromers alongside with the corresponding homomers has been demonstrated here, using 
htrFRET in combination with Tag-lite® technology, involving the SNAP/CLIP specific 
labelling of the N-terminally tagged receptors. 
The lack of subtype selective ligands, due to the high sequence homology in the orthosteric 
binding pocket of muscarinic receptors, directed my approach towards the use of a 
genetically engineered version of M3 receptor, which is unresponsive to the classical 
orthosteric muscarinic agonists, but is activated by the synthetic ligand CNO (Armbruster 
et al., 2007; Alvarez-Curto et al., 2011). The use of the hM3RASSL allowed the 
differential activation of the two receptors in question, hM2WT and hM3RASSL, when 
these were co-expressed at the surface of the same cells. In addition, the simultaneous 
activation of the two receptors enabled the assessment of the possible effects of 
oligomerisation on receptor signalling, via monitoring the inhibition of cyclic adenosine 
monophosphate (cAMP) levels (due to Gi coupling of M2) and the accumulation of inositol 
monophosphates (IP-1) levels, as well as the mobilisation of intracellular calcium ions (due 
to Gq coupling of M3).  
Aims of this chapter 
 Detection of VSV-SNAP-hM2WT and HA-CLIP-hM3RASSL homomers at the 
surface of cells expressing each of the receptors, by htrFRET. 
 Simultaneous detection of homomers and heteromers of VSV-SNAP-hM2WT and 
HA-CLIP-hM3RASSL receptors, in cells expressing both the receptors, by 
htrFRET. 
 Evidence of oligomerisation by biochemical approaches such as Blue Native PAGE 
and co-immunoprecipitation.  
 Consequences of receptor oligomerisation on receptor pharmacology and function. 
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4.2 Homomers of hM2WT and hM3RASSL receptors at the surface of live cells 
Flp-In™ T-REx™-293 stable cell lines expressing either VSV-SNAP-hM2WT or HA-
CLIP-hM3RASSL were characterised and the doxycycline concentrations at which the 
receptor expression levels were similar between the different cell lines were determined 
(see Table 4.1 summarising the doxycycline concentrations derived from results in Chapter 
3). htrFRET experiments were performed that allowed the detection of VSV-SNAP-
hM2WT and HA-CLIP-hM3RASSL homomers.  
Cell line expressing: [Doxycycline] (ng∙ml-1) 
VSV-SNAP-hM2WT 5 
HA-CLIP-hM3RASSL 10 
VSV-SNAP-hM2WT(i)/ 
HA-CLIP-hM3RASSL(c) 
5 
 
Table 4.1 Doxycycline concentrations used to induce receptor expression in the 
different cell lines. 5 ng∙ml-1 doxycycline was added to one cell line to induce VSV-
SNAP-hM2WT expression. Similar levels of HA-CLIP-hM3RASL expression were 
achieved with 10 ng∙ml-1 doxycycline in the second cell line. The concentration of 
doxycycline that allowed the co-expression of the inducible VSV-SNAP-hM2WT and the 
constitutively expressed HA-CLIP-hM3RASSL, in similar levels, was 5 ng∙ml-1. 
Doxycycline concentrations were determined by radioligand binding, fluorescence 
measurements and immuno-detection of the receptors as described in Chapter 3. 
 
Labelling of live cells with cell impermeant htrFRET compatible substrate pairs (donor and 
acceptor) was carried out and the protein-protein interactions were determined by 
monitoring the FRET signal at 665 nm. The combination of htrFRET donor and acceptor 
pair was selected according to the tagged-receptor fusion being expressed from each cell 
type. A schematic representation explaining the labelling approach and detection of the 
665 nm signal is shown in Figure 4.1. The detection of oligomers was carried out by 
monitoring the FRET signal at 665 nm, upon excitation of the donor at 337 nm. The 
terbium cryptate donors, upon excitation at 337 nm, emit at 620 nm which can in turn 
excite the red acceptor species and these subsequently emit at 665 nm.  
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The cells inducibly expressing VSV-SNAP-hM2WT upon treatment with 5 ng∙ml-1 
doxycycline, were labelled with 5 nM SNAP-Lumi4 Tb (donor) and varying 
concentrations of SNAP-Red (acceptor) and homomers of VSV-SNAP-hM2WT were 
detected (Figure 4.2). The cells inducibly expressing HA-CLIP-hM3RASSL upon 
treatment with 10 ng∙ml-1 doxycycline were labelled with 10 nM CLIP-Lumi4 Tb (donor) 
and varying concentrations of CLIP-Red (acceptor) and homomers were detected (Figure 
4.3).   
When examining homomer formation, the substrates used for the labelling bind to the same 
receptor species, therefore, when analysing the FRET results, the data at 665 nm were 
plotted against a logarithmic scale of acceptor concentration, to allow fitting the data to a 
Gaussian equation and the generation of a bell-shaped curve. The position of the peak of 
the bell shaped curve corresponded to the optimum donor/acceptor ratio that allowed the 
detection of the homomers. Theoretically, the peak of the curve indicates that 50 % of the 
labelled cell surface receptors were labelled with the donor species and 50 % were labelled 
with the acceptor species.  
 Homomers were not detected at the surface of cells that were not treated with doxycycline 
i.e. when receptors were not expressed. The minus doxycycline control was a very helpful 
way of determining homomer formation and allowing the determination of specific FRET 
signal, by subtracting the non- specific signal (-Dox) from the total FRET signal (+Dox). 
In order to determine the bystander FRET a different approach was followed that involved 
the use of a cell line inducibly expressing the VSV-SNAP-CD86 receptor. The use of the 
cell surface receptor CD86 that is naturally expressed on antigen presenting cells and only 
exists in a monomeric state (James et al., 2007; Girard et al., 2014) was found very useful 
as a negative control for oligomerisation, despite the structural differences compared to 7 
TM receptors such as muscarinic acetylcholine receptors. A cell line able to inducibly 
express a modified version of the CD86 receptor was employed in htrFRET experiments. 
The VSV-SNAP-CD86 receptor fusion was used alongside the VSV-SNAP-hM2WT to 
allow me to distinguish between real homomeric VSV-SNAP-hM2WT interactions and 
bystander FRET signal obtained from the strictly monomeric CD86 receptor (Figure 4.4). 
The VSV-SNAP-CD86 receptor was expressed at the cell surface when cells were treated 
with doxycycline. The total expression profile of the VSV-SNAP-CD86 was demonstrated 
by subjecting lysates prepared from cells treated with varying doxycycline concentrations, 
by SDS-PAGE analysis and Western blot using an anti-SNAP antiserum (4.4 A). Cell 
surface expression of the receptor was measured by monitoring the fluorescence at 620 nm, 
of doxycycline treated cells, labelled with 5 nM of SNAP-Lumi4 Tb (Figure 4.4 B). A 
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comparison between the expression profiles of the VSV-SNAP-hM2WT and VSV-SNAP-
CD86 receptors is shown in Figure 4.4 C, demonstrating the concentration of doxycycline 
used to achieve similar expression levels between the two receptors in the two cell lines i.e. 
2 ng∙ml-1 doxycycline led to expression of CD86 at levels similar to hM2WT when the 
VSV-SNAP-hM2WT expressing cell line was treated with 5 ng∙ml-1 doxycycline. 
Achieving similar expression levels was essential in comparing the htrFRET at 665 nm 
results obtained from the two receptors i.e. their ability to form oligomers (Figure 4.4 D). 
The two cell lines, expressing each of the receptors, were labelled with the same 
combination of htrFRET compatible donor/acceptor pair e.g. 5 nM SNAP-Lumi4 Tb and 
varying concentrations of SNAP-Red. The VSV-SNAP-CD86 did not seem to generate a 
bell-shaped curve comparable to that obtained from VSV-SNAP-hM2WT. This suggested 
the lack of oligomer formation in CD86 receptor, as expected, and confirmed the bell 
shaped curve obtained from hM2WT was not due to artefacts or random collision, but due 
to actual receptor oligomerisation.  
 
4.3 Co-existence of homomers and heteromers of hM2 and hM3 when both receptors 
are co-expressed 
Having established the formation of receptor homomers in Flp-In™ T-REx™-293   cell 
lines expressing each receptor individually, an important question to be addressed was 
whether the homomers of hM2 and hM3 receptors co-existed with the hM2/hM3 heteromers, 
when the two receptors were co-expressed. The htrFRET approach was employed, using 
cells able to express both receptors. Characterisation of this cell line enabled the 
determination of the doxycycline concentration (5 ng∙ml-1) that allowed the expression of 
both the inducibly expressed VSV-SNAP-hM2WT receptor with the constitutive expressed 
HA-CLIP-hM3RASSL in amounts relatively close to the physiological ones (see Chapter 3, 
section 3.3). 
To assess the formation of homomers of VSV-SNAP-hM2WT and HA-CLIP-hM3RASSL 
at the surface of this cell line, cells were either co-labelled with 5 nM SNAP-Lumi4 Tb and 
varying concentrations of SNAP-Red (Figure 4.5 A) or 10  nM CLIP-Lumi4 Tb and 
varying concentrations of CLIP-Red (Figure 4.5 B), respectively. These cells, labelled with 
SNAP-Lumi4 Tb/SNAP-Red in the absence of doxycycline treatment did not demonstrate 
formation of hM2WT homomers, which were only observed after treatment with 5 ng∙ml-1 
dox, detected as htrFRET signal at 665 nm (Figure 4.5 A). On the other hand, when the 
same cells were used for detection of hM3RASSL homomers, following CLIP-Lumi4 Tb/ 
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CLIP-Red co-labelling, without treatment with doxycycline, hM3RASSL homomeric 
interactions were detected, and were maintained unchanged, in cells treated with 
doxycycline (Figure 4.5 B).  Neither the signal at 665 nm nor the shape of the curve had 
changed, suggesting that the HA-CLIP-hM3RASSL homomers remained unaffected by the 
presence of the inducible receptor VSV-SNAP-hM2WT homomers.  
To allow detection of heteromers between the VSV-SNAP-hM2WT and HA-CLIP-
hM3RASSL, when both receptors were co-expressed at the surface of the same cells upon 
addition of doxycycline, a different combination of the htrFRET labelling donor/acceptor 
substrates was utilised (Figure 4.6). SNAP-Lumi4 Tb was used as a donor and CLIP-Red 
was used as an acceptor. An increase in fluorescence emission at 665 nm was detected, 
consistent with the presence of hM2WT/hM3RASSL heteromers. Equivalent results were 
obtained when the reverse combination of donor/acceptor was used. Heteromers were also 
detected when cells were labelled with CLIP-Lumi4 Tb as a donor and SNAP-Red as an 
acceptor. The htrFRET experiments to detect co-existence of homomers and heteromers in 
the same cell line when both receptors were co-expressed were carried out simultaneously.  
 
4.4 Oligomeric complexes detected by Blue Native (BN) - PAGE and co-
immunoprecipitation (Co-IP).  
In addition to the htrFRET experiments, other more classic biochemical approaches were 
utilised to assess the formation of oligomeric complexes of the receptors in question. These 
included BN-PAGE and Co-IP. Various possibilities for oligomeric arrangements between 
the receptors may exist, either homomeric or heteromeric. Some of the possible 
arrangements, with their estimated sizes, are included in Figure 4.7, showing mostly 
dimers and tetramers. The reason mostly dimers and tetramers were taken into account was 
the reported preference of both receptors to exist in a tetrameric arrangement as homomers, 
with pharmacology data supporting M2 tetramer formation (Redka et al., 2014) and the 
suggested tetrameric rhomboidal homomeric arrangement of M3 (Patowary et al., 2013).  
Blue Native PAGE was carried out (Figure 4.8) using lysates prepared from the cell line 
able to express both the receptors. Cells were treated or not with doxycycline to allow co-
expression of both receptors or expression of only the constitutive HA-CLIP-hM3RASSL. 
This allowed the detection of a number of potential oligomeric complexes with their 
estimated molecular masses, using anti-SNAP/CLIP and anti-VSV antibodies.  Lysates 
prepared from cells not treated with doxycycline demonstrated HA-CLIP-hM3RASSL 
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polypeptide appearing at about 400-480 kDa, consistent with a tetrameric arrangement of 
the receptor, as detected with the anti-SNAP/CLIP antibody. Upon treatment with 
doxycycline, the VSV-SNAP-hM2WT receptor was expressed, and the appearance of much 
more intense polypeptide bands ranging from around 100-480 kDa were detected (although 
not clear) using an anti-SNAP/CLIP antibody. A polypeptide band above 240 kDa that was 
detected using the anti-VSV antibody, could suggest interactions between hM2WT and 
hM3RASSL receptors in a tetrameric arrangement. A second band seen at above 146 kDa 
could correspond to the homodimeric arrangement of VSV-SNAP-hM2WT or a hetero-
dimeric formation between hM2WT/hM3RASSL, while a more intense band at around 100 
kDa could represent the monomers of VSV-SNAP-hM2WT.   Combinations such as 3 x 
hM3RASSL/ 1 x hM2WT (estimated size at 380 kDa) or 2 x hM3RASSL/ 2 x hM2WT 
(estimated size at 360 kDa) or even 1 x hM3RASSL/ 3 x hM2WT (estimated size at 340 
kDa) could exist, but are not easily detected by the anti-SNAP/CLIP antibody.  Treatment 
of the lysates with 1% SDS (reducing conditions) resulted in lower molecular mass 
polypeptide bands that could correspond to existence of monomers of HA-CLIP-
hM3RASSL and monomers of VSV-SNAP-hM2WT. The anti-SNAP antiserum was not 
able to distinguish between the two receptors but the use of anti-VSV antibody managed to 
locate VSV-SNAP-hM2WT presence at the polypeptides seen at 480 kDa and between 
480-240 kDa, an observation that could be consistent with the presence of hM2WT in a 
heteromeric complex with hM3RASSL, in various combinations e.g. 3 x hM3RASSL/1 x 
hM2WT (estimated at 380 kDa), 2 x hM3RASSL/ 2 x hM2WT (estimated at 360 kDa), 1 x 
hM3RASSL/ 3 x hM2WT (estimated at 340 kDa) and in a homo-tetrameric form e.g. 4 x 
hM2WT (estimated at 320 kDa). The polypeptide band seen at around 146 kDa could 
possibly suggest the existence of the hM2WT in a homo-dimer (2 x hM2WT, estimated at 
160 kDa) or a hetero-dimer 1 x hM3RASSL/ 1 x hM2WT (estimated at 180 kDa). 
Treatment with 1% SDS resulted in the reduction of the sizes of the polypeptides to an 
intense band seen using either anti-SNAP/CLIP or anti-VSV antibodies, at just above 146 
kDa, possibly suggesting the dissociation of the tetrameric forms to dimeric ones. In 
addition, a less intense polypeptide band was seen at above 66 kDa possibly corresponding 
to the monomers of hM2WT (expected molecular mass approximately 80 kDa). Although, 
the sizes of the polypeptide bands seen on the blot were close to the estimated sizes of 
some of the expected oligomeric arrangements, we have to take into consideration the 
expected error in protein size estimation, when carrying out a BN-PAGE (Ward et al., 
2013; Wittig et al., 2006).  
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The use of VSV and HA tag-receptor fusions allowed the performance of co-
immunoprecipitation experiments, to assess potential VSV-SNAP-hM2WT/HA-CLIP-
hM3RASSL heteromeric interactions in cells able to co-express both receptors (Figure 4.9). 
Cells were treated with 5 ng∙ml-1 doxycycline and 6 μM tunicamycin and the treatments 
were stopped at several time points. Tunicamycin is a mixture of antibiotics that inhibit N-
glycosylation in early stages of protein synthesis. Cells treated with tunicamycin are 
expected to express only the non-glycosylated version of proteins/receptors synthesised 
after tunicamycin treatment, and these appear as lower molecular mass bands when 
analysed on a Western blot, compared to the N-glycosylated version of the proteins 
synthesised prior to tunicamycin addition (see Chapter 3, section 3.2 and Figure 3.5). Cells 
were lysed using a relatively mild detergent dodecyl maltoside (DDM) containing lysis 
buffer that allows solubilisation of the proteins whilst preserving protein-protein 
interactions.  
Lysates of cells were immuno-precipitated with anti-VSV. Immuno-precipitated samples 
were then resolved by SDS-PAGE and immuno-blotted with an anti-HA antibody to detect 
co-immunoprecipitation of HA-CLIP-hM3RASSL. As induction of expression of VSV-
SNAP-hM2WT requires a significant period of time after addition of doxycycline, co-
immunoprecipitation was only observed at the later time points (after 8 hours). As shown 
in Figure 3.3 (see Chapter 3), anti-HA is only able to identify the non-N-glycosylated form 
of HA-CLIP-hM3RASSL. This is why experiments were performed in tunicamycin-treated 
cells. 
 
The immunoprecipitation of VSV-SNAP-hM2WT with anti-VSV antibodies resulted in the 
co-immunoprecipitation of anti-HA immuno-reactivity, corresponding to HA-CLIP-
hM3RASSL, only after treatment with doxycycline, thus when both receptors were co-
expressed (Figure 4.9). The co-immunoprecipitation data do not demonstrate the existence 
of direct interactions but only imply the interaction of hM3RASSL with hM2WT. The 
inability of anti-HA antibody to efficiently detect the glycosylated version of HA-CLIP-
hM3RASSL is the reason that a band was not detected in the sample prepared from cells 
expressing both receptors in the absence of tunicamycin.  
The biochemical results support the presence of oligomeric complexes, both homomeric 
and heteromeric in nature, and support the data obtained from the htrFRET experiments, 
suggesting that the htrFRET signal at 665 nm demonstrates the proximity of hM2WT and 
hM3RASSL within either homomeric or heteromeric interactions. 
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4.5 Oligomerisation in signalling and function 
Once the existence of heteromers between VSV-SNAP-hM2WT and HA-CLIP-
hM3RASSL at the surface of live cells was confirmed and once the conditions in which 
heteromerisation was achieved were established, it was important to assess whether 
heteromerisation affected the signalling and/or the function of the receptors. The key 
signalling pathways of the hM2WT and hM3RASSL receptors were described in Chapter 3 
(see section 3.3). Briefly, hM2WT, upon agonist-mediated activation, binds to and activates 
Gi/0 protein-dependent signalling pathways which involve inhibition of adenylate cyclase 
that leads to decreased levels of cAMP.  On the other hand, the hM3RASSL, upon CNO-
mediated activation, binds to and activates Gq/11 proteins in a way similar to that of the 
hM3WT receptor. Activation of Gq/11 dependent pathways involve the sequential activation 
of phospholipase Cβ (PLCβ), which in turns catalyses the formation of inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG) from phosphatidylinositol 4,5-bisphosphate 
(PIP2). IP3 acts on IP3 receptors in the Endoplasmic reticulum (ER) and induces release of 
calcium ions. DAG while still bound on the membrane acts to activate protein kinase C 
(PKC) (see Chapter 3, Figure 3.10).  
In order to assess the role of oligomerisation in receptor function and signalling, the data 
already obtained from functional experiments (Figures 3.21, 3.22 and 3.23) were re-
examined and discussed, while taking into consideration the existence of 
hM2WT/hM3RSSL heteromers. Cells able to co-express both receptors were treated or not 
with doxycycline and were employed to measure CNO-mediated increase in levels of 
inositol monophosphates (IP-1). There was a trend towards an increase in the efficacy of 
CNO in the presence of heteromers (+Dox), but it was not significant. The potency of 
CNO remained unaltered either in the absence of heteromers with pEC50 (-dox) = 8.2 ± 0.3 
or in the presence of heteromers pEC50 (+dox) = 8.2 ± 0.27 (see Figure 3.21). Cells treated 
or not with doxycycline, were employed to measure the carbachol-mediated inhibition of 
forskolin mediated cAMP levels. Carbachol was able to potently (pEC50=6.9 ±0.1) inhibit 
the levels of cAMP, in live cells, at conditions where the existence of heteromers was 
confirmed (+Dox). The presence of hM2WT/hM3RASSL heteromers did not seem to affect 
the hM2WT mediated inhibition of cAMP levels (Figure 3.23).  
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4.6 Discussion 
One of the main aims of this chapter was to detect the existence of oligomeric interactions 
of VSV-SNAP-hM2WT and HA-CLIP-hM3RASSL receptors that exist either in a 
homomeric or heteromeric arrangement. In cells stably expressing one of the receptors, 
upon treatment with the antibiotic doxycycline, detection of VSV-SNAP-hM2WT or HA-
CLIP-hM3RASSL homomers was monitored by htrFRET. Homomeric interactions were 
not detected from cells in the absence of doxycycline, suggesting that the bell shaped 
curves obtained from doxycycline treated cells were due to receptor homomers. Although, 
that was a useful assay control, a negative oligomerisation control was required. For this 
reason the CD86 receptor that exists in a monomeric state at the surface of live cells 
(Girard et al., 2014, James et al., 2007), was used as a negative oligomerisation control. 
The cell line inducibly expressing the VSV-SNAP-CD86 upon treatment with doxycycline 
was used for labelling with 10 nM SNAP-Lumi4 Tb and varying concentrations of SNAP-
Red and the FRET signal at 665 nm was monitored. The characteristic bell-shaped curve 
suggesting oligomerisation was absent in the case of CD86 receptor, when the data were 
compared to those obtained for the hM2WT receptor. The result obtained from cells 
expressing the CD86 receptor clearly demonstrated the lack of oligomer formation and 
thus allowed the determination of bystander FRET levels. In conclusion, the bell-shaped 
curves obtained from VSV-SNAP-hM2WT expressing cells were due to oligomerisation 
rather than random receptor-receptor interactions. The presence of VSV-SNAP-hM2WT 
and HA-CLIP-hM3RASSL homomers was consistent with previous reports on formation of 
M2/M3 heteromers from the literature (Goin and Nathanson, 2006).  
The existence of the htrFRET signal at 665 nm indicated the close proximity between the 
receptors and this was interpreted as receptor oligomerisation. The nature of resonance 
energy transfer techniques does not allow concluding on the order of the receptor 
interactions (e.g. dimeric, tetrameric or higher order oligomeric) but only supports the 
existence of receptors being in close proximity that could be organised in an oligomeric 
complex.  
The concentrations of the substrates used in the htrFRET experiments were not enough to 
fully saturate the tagged receptors. One of the main reasons for using sub-saturation 
concentrations had to do with high cost of the substrates. Although, only part of the cell 
surface expressed receptors was labelled using sub-saturation concentrations (nano molar 
level) of the substrates, FRET signals that corresponded to oligomeric interactions between 
the receptors were efficiently detected.  Similar experiments carried out by others, using 
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the same technology and labelling substrates to monitor htrFRET as a means to detect 
homomers and heteromers of receptors in live cells, included use of higher concentrations 
of the donors and acceptors at the micro molar level (Doumazane et al., 2011). Despite the 
use of sub-saturating substrate concentrations, the main idea was to have a population of 
the cell surface expressed receptors labelled, and theoretically by using the same 
doxycycline concentrations to achieve equal receptor expression between the experiments, 
and by using the same substrate concentrations to allow relatively equal labelling, allowed 
the assumption that the labelled receptor population was relatively equal between the 
experiments. Thus, detection of oligomers was considered consistent throughout the 
experiments.   
Confirmation of the existence of oligomeric interactions between the co-expressed VSV-
SNAP-hM2WT and HA-CLIP-hM3RASSL receptors was offered by a set of biochemical 
experiments, such as BN-PAGE and co-IP. In summary, co-existence of oligomers when 
both receptors were present was in agreement with the literature on muscarinic receptors 
and other GPCRs (Pou et al., 2012; Maggio et al., 1993; Goin and Nathanson, 2006). The 
htrFRET and biochemical data supported the formation of oligomers of muscarinic 
receptors are in agreement with the notion that class A GPCRs may form constitutive 
oligomers (Bouvier and Hebert, 2014).  
The last important matter that was assessed in this chapter concerned the possible effects of 
oligomerisation on receptor signalling and function. There is evidence that propose that 
GPCR oligomerisation can affect the pharmacology and/or signalling transduction 
(Gonzalez-Maeso, 2011; Milligan, 2013). Data supporting the signalling cross-talk 
between the muscarinic M2 and M3 receptors were presented previously, suggesting a 
synergistic activation of ERK 1/2 signalling, following agonist-mediated co-activation of 
M2 and M3 when both receptors were co-expressed, in CHO cells (Hornigold et al., 2003). 
In order to assess the role of oligomerisation in receptor signalling, the activation of G-
proteins and downstream signalling was examined, upon agonist treatment, in the presence 
of heteromers in the cell line that co-expressed both receptors. There was a trend towards 
an increase in the efficacy of CNO in increasing the hM3RASSL mediated inositol 
phosphate (IP1) levels, in the presence of heteromers while the efficacy of CNO was not 
affected. The potency of CNO remained unaltered in the absence of heteromers. Carbachol 
activation of the doxycycline induced VSV-SNAP-hM2WT, in the presence of the 
constitutively expressed HA-CLIP-hM3RASSL, demonstrated the expected inhibition of 
forskolin-induced cAMP levels that follows activation of Gi/o coupling.  Therefore, we can 
conclude that oligomerisation did not affect the signalling of the receptors in question. The 
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possible reason we did not detect a synergistic effect on signalling similar to that seen by 
Hornigold et al., (2003) has to do with the different approaches followed in terms of 
receptor activation. Signalling cross-talk was observed when M2 and M3 receptors were co-
activated by an agonist, whereas, in the functional assays carried out during this project, 
each receptor was activated separately and each signalling pathway was assessed 
individually. Another reason may involve the use of different cell lines and more 
importantly the use of a mutated version of hM3 receptor, the hM3RASSL. The 
hM3RASSL, although, it binds to and activates the Gq/11 dependent pathway, it might be 
demonstrating a different behaviour, in terms of signalling cross-talk, compared to the wild 
type receptor. 
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Figure 4.1 Schematic representation of hM2 and hM3 oligomers. Tag-lite® technology 
combines the use of SNAP and CLIP tags fused to the N-terminus of the receptor, together 
with htrFRET. The SNAP and CLIP tags are specifically and covalently labelled with 
benzyl guanine/cytosine derivative substrates such as SNAP-Lumi4 Tb and CLIP-Lumi4 
Tb, respectively, which emit at 620 nm, following excitation at 337 nm and are used as 
donors. SNAP-Red and CLIP-Red which emit at 665 nm, following excitation at 620 nm, 
are used as acceptors. The use of an engineered version of the hM3 receptor (hM3RASSL), 
modified within the 3rd and 5th transmembrane domains (●Y149C and ●A239G) allowed 
the selective activation of the hM3RASSL with the synthetic ligand clozapine-N-oxide 
(CNO), independently from the hM2WT receptor, when co-expressed. The receptors are 
also N-terminally tagged with HA and VSV-G.  
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Figure 4.2 Homomers of VSV-SNAP-hM2WT at the surface of live cells expressing 
the receptor. Cells able to express VSV-SNAP-hM2WT in a doxycycline induced manner, 
were untreated (no dox) or treated with 5 ng∙ml-1 dox, for 24 hours. After cells were plated 
in 96 well FRET-compatible plates, they were subjected to co-labelling with a combination 
of 5 nM SNAP Lumi4 Tb (energy donor) and varying concentrations of SNAP-Red 
(energy acceptor). Following excitation at 337 nm, fluorescence emission at 665 nm was 
monitored, which corresponded to the htrFRET signal. The non-specific signal obtained 
from doxycycline untreated cells was used as the basal signal, and was subtracted from the 
total (obtained from doxycycline treated cells), to calculate the specific htrFRET. The peak 
signal indicated the optimal energy donor/acceptor ratio concentrations e.g. 5 nM SNAP 
Lumi4 Tb (donor)/ 100 nM SNAP-Red (acceptor).  
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Figure 4.3 Homomers of HA-CLIP-hM3RASSL at the surface of live cells expressing 
the receptor. Cells able to express the HA-CLIP-hM3RASSL in a doxycycline dependent 
manner, were untreated (0 ng∙ml-1 doxycycline) or treated (with 10 ng∙ml-1 doxycycline), 
for 24 hours. After cells were plated in a 96 well FRET-compatible plate, they were 
subjected to co-labelling with 10 nM CLIP Lumi4Tb (energy donor) and varying 
concentrations of CLIP-Red (energy acceptor). Following excitation at 337 nm, the 
fluorescence emission at 665 nm, corresponding to the htrFRET signal was monitored. The 
non-specific signal obtained from doxycycline untreated cells was used as the basal signal, 
and was subtracted from the total (obtained from doxycycline treated cells), to calculate the 
specific htrFRET. The peak signal indicated the optimal energy donor/acceptor ratio 
concentrations e.g. 10 nM CLIP Lumi4 Tb (donor)/ 100 nM CLIP-Red (acceptor).  
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D. 
 
 
 
 
 
 
 
 
 
Figure 4.4 Negative control for oligomerisation (A) Total expression of VSV-SNAP-
CD86, detected as 80 kDa polypeptide bands (arrow) using anti-SNAP/CLIP antiserum 
against lysates prepared from cells inducibly expressing the receptor upon treatment with 
varying concentrations of doxycycline. The non-glycosylated poypeptides appear at just 
belw 80 kDa (star). (B) VSV-SNAP-CD86 cell surface expression, by measuring 
fluorescence at 620 nm, following labelling of live doxycycline induced cells with 10 nM 
SNAP-Lumi4 Tb.  (C) Comparison of the expression profiles between VSV-SNAP-
hM2WT and VSV-SNAP-CD86. (D) VS-SNAP-CD86 acting as a negative oligomerisation 
control, based on the inability to form a bell shape curve, compared to the VSV-SNAP-
hM2WT forming homomers in Figure 4.2. 
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A. 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Homomers of VSV-G-SNAP-hM2WT and HA-CLIP-hM3RASSL co-exist 
at the surface of live cells expressing both receptors. Cells able to express the VSV-
SNAP-hM2WT receptor in a doxycycline dependent manner while constitutively 
expressing the HA-CLIP-hM3RASSL receptor, were untreated (0 ng∙ml-1 doxycycline) or 
treated(with 5 ng∙ml-1 doxycycline) for 24 hours. (A) Cells were co-labelled with 5 nM 
SNAP Lumi4 Tb (energy donor) and varying concentrations of SNAP-Red (energy 
acceptor). (B) A different set of the same cell line was co-labelled with 10 nM CLIP 
Lumi4 Tb (energy donor) and varying concentrations of CLIP-Red (energy acceptor) and 
after excitation at 337 nm, the 665 nm htrFRET signal obtained, demonstrated the co-
existence of VSV-SNAP-hM2WT homomers and  HA-CLIP-hM3RASSL homomers at the 
cell surface when both receptors are co-expressed.  
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Figure 4.6 Heteromers between co-expressed HA-CLIP-hM3RASSL and VSV-SNAP-
hM2WT receptors at the surface of live cells expressing both the receptors. Cells 
expressing both receptors were co-labelled with combinations of either SNAP Lumi4 
Tb/CLIP-Red (circles) or CLIP Lumi4 Tb/SNAP-Red (squares). After excitation at 337 nm 
htrFRET signal at 665 nm was obtained. The htrFRET analysis suggested that heteromers 
between HA-CLIP-hM3RASSL and VSV-SNAP-hM2WT exist at the surface of live cells, 
when both receptors are co-expressed.  
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Figure 4.7 Sizes of the possible hM2WT or hM3RASSL homomeric and heteromeric 
complexes that may be formed. Some of the possible combinations of the oligomeric 
complexes were considered in this figure, and the possible molecular masses were 
estimated, to allow easier identification of any oligomeric complexes demonstrated on a 
Blue Native PAGE.  
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Figure 4.8 Blue Native PAGE demonstrating the different oligomeric complexes 
between the co-expressed HA-CLIP-hM3RASSL and VSV-SNAP-hM2WT. Cells 
expressing the HA-CLIP-hM3RASSL (constitutively) and the VSV-SNAP-hM2WT (in a 
doxycycline dependent manner), were treated with 5 ng∙ml-1 doxycycline (+ Dox) or 
without (-Dox). Lysates prepared from these cells were extracted with dodecyl maltoside 
(DDM) and were subjected to Blue Native PAGE, either directly or following addition of 
1% SDS, which were further processed to allow immune-detection using anti-SNAP/CLIP 
and anti-VSV antibodies.The upper arrow (pointing rightwards) at approximately 480 kDa 
indicates a possible tetrameric organisation of the HA-CLIP-hM3RASSL.The middle arrow 
indicates possible dimeric arrangement of HA-CLIP-hM3RASSL homomers or 
hM3RASS/hM2WT heteromers, that were not reduced to their monomeric forms upon 
addition of SDS. The lower arrow indicates the monomeric form of VSV-SNAP-hM2WT. 
The stars at the second panel aim to point out the presence of VSV-SNAP-hM2WT 
receptor in various heteromeric, homomeric or monomeric forms of the receptor. 
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Figure 4.9 Co-immunoprecipitation confirms interaction between VSV-SNAP-
hM2WT and HA-CLIP-hM3RASSL receptors when co-expressed. Cells treated or not 
with 5 ng∙ml-1 doxycycline, were subjected to lysate preparation after co-treatment with 6 
µM tunicamycin. The VSV-SNAP-hM2WT receptor was immuno-precipitated from the 
lysate by incubation with VSV-conjugated agarose beads, and co-precipitation of HA-
CLIP-hM3RASSL was assessed by using anti-HA antiserum and Western blotting. Co-
immunoprecipitation of the two receptors was observed (arrow indicating the presence of 
HA-CLIP-hM3RASSL interacting with VSV-SNAP-hM2WT) in the samples from cells 
treated with both doxycycline and tunicamycin for at least 8 h, with the intensity of the 
bands increasing with time of treatment. No specific polypeptide bands were observed in 
the samples treated only with doxycycline but not with tunicamycin. 
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5.1 Introduction 
 
The co-existence of hM2WT/hM3RASSL heteromers with individual receptor homomers 
of hM2WT and hM3RASSL, at the surface of live cells expressing both receptors, was 
demonstrated by htrFRET and biochemical experiments as described in Chapter 4. These 
observations were in agreement with previous studies in which muscarinic receptors had 
been demonstrated to have a capacity to form oligomers (Goin and Nathanson, 2006; 
Alvarez-Curto et al., 2010; Hu et al., 2012; Patowary et al., 2013). Other class A GPCRs 
have also been shown to form oligomers, e.g. dopamine receptors (Pou et al., 2012) and 
opioid receptors (Gomes et at., 2013).  
An important question that remains to be addressed involves the potential of ligands to 
regulate the oligomeric state of muscarinic receptors. This may provide information that 
can be useful in drug discovery, in terms of drug selectivity improvement. Targeting 
receptor oligomers rather than the monomeric form of receptors (Angers et al., 2002; 
Milligan, 2013) is a concept arising from the suggestion that oligomerisation may confer 
novel pharmacology to the receptors, resulting from binding site interactions within an 
oligomeric complex (Smith and Milligan, 2010; Chun et al., 2013).  
Several observations have been previously reported in terms of ligand regulation of GPCR 
oligomerisation. The first BRET-based assay that documented the existence of homomers 
of β2-adrenoceptors, demonstrated an increase in the energy transfer upon addition of the 
selective agonist isoproterenol, which was interpreted as an increase in oligomeric receptor 
interactions (Angers et al., 2000). In another BRET-based study, constitutive δ-opioid 
receptor homomers were unaltered upon agonist treatment, implying a lack of agonist 
mediated regulation of this oligomer (McVey et al., 2001). Studies on the CXCR1 and 
CXCR2 receptors forming homomers and heteromers as detected by FRET, demonstrated 
that upon ligand (CXCL8) activation of the receptors, the heteromeric complexes were 
altered whereas the homomeric profile of both receptors was stabilised (Martinez-Muñoz 
et al., 2009). By contrast, a BRET-based approach used to study CXCL8-mediated 
regulation of CXCR1 and CXCR2 did not show any changes either in homomerisation or 
heteromerisation (Wilson et al., 2005). The above examples point out the importance of the 
methodology used to study receptor oligomerisation and in addition, these examples 
suggest that different receptors may demonstrate different oligomerisation profiles and 
varied stability in the presence of ligands.  
The literature on muscarinic receptors offers contradictory observations in terms of ligand 
regulation of oligomerisation. Specifically, the M1 receptor was shown to exist as a 
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monomer, dimer or higher order oligomer (Marquer et al., 2010). Hern et al., (2010) 
demonstrated that about 30% of the M1 receptor exists as a dimer, at any given time, and 
there is a dynamic interchange between monomers and dimers, detected by total internal 
reflection fluorescence imaging (TIRFM) at single cell level (Hern et al., 2010). 
Constitutive M1 receptor dimers seem to be stabilised upon treatment with the M1- 
selective allosteric ligand, MT7, as demonstrated by Western blotting and native PAGE 
electrophoresis as well as by FRET and BRET based assays (Marquer et al., 2010). In an 
in vitro study using insect cells and isolated membranes the orthosteric muscarinic 
antagonist QNB was shown to confer stability to pre-existing M2 oligomers (Park and 
Wells, 2003). In addition, the muscarinic antagonist pirenzepine promoted M1 dimerisation 
in live cells as observed by fluorescence correlation spectroscopy (Ilien et al., 2009). Ilien 
et al., (2009) suggested that in the absence of ligand, the M1 predominantly existed as a 
monomer and it formed oligomers upon addition of pirenzepine (Ilien et al., 2009). 
Detection of M3 homo-dimers was enabled by using cysteine substituted mutants of the rat 
M3 receptor in disulphide cross-linking experiments and Western blotting, where an 
increase in the formation of M3 oligomeric complexes was observed upon addition of 
carbachol (Hu et al., 2012). Quantitative BRET analysis using cells expressing M1, M2 or 
M3 receptors showed the existence of homomers and saturation BRET analysis in cells co-
expressing two of the receptors at a time demonstrated the presence of heteromers between 
M1-M2, M2-M3 and M1-M3. No effect was detected in the oligomeric status of homomers 
or heteromers upon carbachol treatment (Goin and Nathanson, 2006). Lack of significant 
effect of agonist induced receptor stimulation on M3 receptor oligomerisation was shown 
by SDS-PAGE and Western blot analysis of membrane extracts from COS-7 cells 
expressing a mutant  M3 lacking most of the third intracellular loop  domain (Zeng and 
Wess, 1999). In a more recent study, carbachol modified the homomeric status of M3 
receptor as detected by an increase in the htrFRET signal upon addition of agonist, 
possibly due to carbachol-mediated conformational change in the receptor (Alvarez-Curto 
et al., 2010).  
The detection of ligand-mediated changes in the oligomeric profile of GPCRs is a debated 
field of research and no conclusions have been reached for the overall GPCR family, since 
each member has demonstrated a unique oligomeric profile that is not easily applied to 
another member of the GPCR group (Pfleger and Eidne, 2005). 
 
The approach described in this chapter in order to detect possible ligand-mediated effects 
on oligomerisation, involved a kinetic htrFRET method following addition of various 
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muscarinic ligands and the monitoring of the FRET signal at several time points. The 
donor/acceptor ratio was calculated and was plotted against time. SNAP- or CLIP-Lumi4 
Tb was used as a donor in combination with the corresponding Red acceptor, in the dual 
labelling experiments. Combinations of red and green acceptors were used in the multiplex 
(triple) labelling of live cells, which allowed for the simultaneous detection of changes in 
homomer and heteromer status. 
 
 
Aims of this chapter 
To: 
 Utilise htrFRET to assess whether muscarinic ligands can regulate homomeric and 
heteromeric profile of VSV-SNAP-hM2WT and HA-CLIP-hM3RASSL receptors. 
 Use multiplex labelling to simultaneously detect more than one change in the 
system. 
 Examine the role of receptor internalisation in oligomerisation upon agonist-
mediated receptor activation. 
 
 
5.2 Carbachol mediates a decrease in M2/M3 heteromers with a simultaneous increase 
in M2/M2 homomerisation. 
To assess the regulation of receptor oligomerisation by ligands, kinetic htrFRET 
experiments were carried out using a selection of muscarinic ligands on the previously 
described cell lines expressing the SNAP/CLIP tagged receptors.  
A summary of the donor/ acceptor concentrations that allowed for detection of oligomers 
are listed in Table 5.1.  
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Donor/ acceptor concentrations (nM) Oligomer detected 
SNAP-Lumi4 Tb (5 nM) / SNAP-Red (100 nM) hM2WT/hM2WT homomer 
CLIP-Lumi4 Tb (10 nM) / CLIP-Red (100 nM) hM3RASSL/hM3RASSL homomer 
SNAP-Lumi4 Tb (5 nM) / CLIP-Red (100 nM) hM2WT/hM3RASSL heteromer 
CLIP-Lumi4 Tb (10 nM) / SNAP-Red (125 nM) hM2WT/hM3RASSL heteromer 
 
Table 5.1 Optimum donor/acceptor concentrations that allowed detection of 
oligomers.  The concentrations of substrates were obtained from the bell shape Gaussian 
curves (for homomers) and saturation curves (for heteromers) following co-labelling of 
live cells with a fixed concentration of donor and varying concentrations of acceptor. The 
concentrations of the donors and acceptors were determined by the peaks of the bell shaped 
curves in the case of homomers and the saturation point in the case of heteromers, where 
the optimum observation of oligomers was detected (see Chapter 4). 
 
The selection of ligand concentrations used in the kinetic htrFRET assays was based on the 
Ki values for each ligand obtained from competition binding experiments in the presence of  
[3H]-QNB (see Chapter 3, Tables 3.1 and 3.2). Following labelling of live cells with the 
htrFRET compatible substrates, set concentrations of the ligands were added to the assay 
one minute after performing the first reading on the plate reader. Measurements were 
recorded at several time points, over a 60 minute period. The 665/620 ratio was calculated 
and changes in this ratio were monitored in response to the different ligands added.  
Live cells expressing both the receptors after treatment with 5 ng∙ml-1 doxycycline, were 
labelled with CLIP-Lumi4 Tb and SNAP-Red. This substrate pair combination allowed 
detection of heteromers between VSV-SNAP-hM2WT and HA-CLIP-hM3RASSL. This 
showed a decrease in htrFRET, potentially reflective of a decrease in heteromers, in 
response to 1 mM carbachol and a decrease in response to the combination of 1 mM 
carbachol and 100 μM CNO but not to 100 μM CNO alone. Atropine (10 μM) had no 
effect on the heteromeric status of the receptors, as the profile of the kinetic htrFRET was 
similar to the one where no ligand was added (Vehicle: labelling medium containing 
0.33% DMSO to maintain consistency between treatments) (Figure 5.1 A). A subsequent 
recording of the htrFRET on cells labelled with SNAP-Lumi4 Tb/SNAP-Red, 
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demonstrated an increase in the FRET signal and potentially in the formation of hM2WT 
homomers in response to 1 mM carbachol or the combination of carbachol and CNO, but 
not to CNO alone, or to the antagonist atropine (Figure 5.1 B). Combining the two 
observations, a conclusion can be reached suggesting that carbachol-mediated occupation 
of hM2WT receptor may disturb the oligomeric balance by causing an increase in the 
hM2WT homomers and a simultaneous decrease in the heteromers i.e. a transition from 
heteromeric to homomeric organisation of the receptors. Interestingly, the kinetics of each 
change were found to be rather slow. The half time (t1/2) of carbachol in decreasing the 
heteromer was 5.6 ± 3.2 minutes and the t1/2 in increasing the homomers was 14.0 ± 3.8 
minutes (Table 5.2). The synthetic ligand CNO did not lead to any alterations in the 
hM2WT/hM3RASSL heteromer formation.  
The reverse donor/acceptor combination (SNAP-Lumi4 Tb/CLIP-Red) was also used to 
allow detection of changes within the hM2WT/hM3RASSL heteromer following ligand 
addition. Surprisingly, although this combination was successful in detecting VSV-SNAP-
hM2WT/HA-CLIP-hM3RASSL heteromers, no significant changes were detected in the 
kinetic htrFRET upon carbachol addition, or upon addition of the combination of carbachol 
and CNO (Figure 5.1 C). The window was too small for any significant changes to be 
detected. The reason for this observation could be explained by the composition and size of 
the heteromer that could be affecting the orientation of the fluorophores within the 
complex. An example that points out the difference in the outcome on the kinetic htrFRET 
between the two sets of donor/acceptor pair combinations is shown in Figure 5.1 D with 
the CLIP-Lumi4 Tb/SNAP-Red pair resulting in a significant change in 665/620 ratio upon 
carbachol treatment (P=0.0013, two-paired t-test comparing ratio at time 0 minute versus 
time 40 minutes, upon treatment, n=3).  
The homomeric profile of HA-CLIP-hM3RASSL was also monitored in the cell line 
expressing both receptors. Cells treated or not with doxycycline were co-labelled with 
CLIP-Lumi4 Tb and CLIP-Red and the 665/620 ratio was monitored following ligand 
addition. There were no changes detected in the hM3RASSL homomeric status, in response 
to any of the ligands, either in the absence (-Dox) or presence (+Dox) of hM2WT (Figure 
5.2 A and B, respectively). Overall, CNO did not have any effect on the oligomeric status 
of the receptors. There was an overall decline in the 665/620 ratio over time, even in the 
absence of ligands. This trend was observed in all kinetic experiments that involved the use 
of Tag-lite® technology, and it is considered to be the result of photo-bleaching of the 
substrates. Photo-bleaching was not detected in single point readings since the cells are 
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exposed to laser once, but it was detectable in sequential readings that involved multiple 
exposures of the substrates to light. Once the ligand-mediated changes on the 
oligomerisation profile of the receptors were observed by kinetic htrFRET it was important 
to address whether these changes were concentration dependent. Therefore, cells labelled 
with CLIP-Lumi4 Tb/SNAP-Red (detecting hM2WT/hM3RASSL heteromers) and SNAP-
Lumi4 Tb/SNAP-Red (detecting hM2WT homomers) were subjected to treatments with 
varying concentrations of carbachol, to allow the determination of the concentration-
dependent fashion of oligomerisation changes (Figure 5.3). The choice of the 40 min time 
point to carry out the measurements was based on the fact that the changes were 
established at 40 min and were maintained for up to one hour. Carbachol potently 
decreased the formation of hM2WT/hM3RASSL heteromers (pIC50= 5.2 ± 0.3) (Figure 5.3 
A) and increased the formation of hM2WT homomers (pEC50= 5.5 ± 0.2) (Figure 5.3 B). 
Co-incubation with 10 μM atropine blocked the effects of carbachol in both cases. 
Incubation at 4˚C also inhibited the carbachol mediated decrease in heteromerisation and 
the increase in hM2WT homomerisation, suggesting a possible involvement of receptor 
internalisation in the regulation of receptor oligomerisation.  
The fluorescence at 620 nm was monitored using cells labelled only with Lumi4 Tb donor, 
to assess whether there were any changes at the cell surface receptor population in 
response to the ligand treatments (Figure 5.4).  Cells treated with doxycycline to allow co-
expression of both receptors, were labelled with 5 nM SNAP-Lumi4 Tb and were then 
subjected to ligand treatments while fluorescence at 620 nm was monitored for up to 60 
minutes. There was a trend towards reduction in 620 nm signal upon treatment with 1 mM 
carbachol and with the combination of carbachol and CNO, but it was not significant 
(Figure 5.4 A). This small decline in the 620 nm signal could suggest a limited extend of 
internalisation of the hM2WT receptors due to agonist-mediated activation. Cells labelled 
with 10 nM CLIP-Lumi4 Tb did not demonstrate any changes in the cell surface 
population of HA-CLIP-hM3RASSL either when hM3RASSL was expressed alone (-Dox) 
or when co-expressed with hM2WT (+Dox) (Figure 5.4 B and C, respectively). 
One limitation of the cellular system used to study the co-expressed receptors was that it 
did not allow the assessment of hM2WT receptor alone, since VSV-SNAP-hM2WT was 
only studied in the presence of the constitutively expressed HA-CLIP- hM3RASSL. 
Therefore, a cell line inducibly expressing the VSV-SNAP-hM2WT receptor was 
employed to carry out similar kinetic htrFRET experiments, offering a view of the 
behaviour of hM2WT homomers in response to ligands in the absence of hM3RASSL. 
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Cells capable of expressing VSV-SNAP-hM2WT upon treatment with doxycycline were 
labelled with SNAP-Lumi4 Tb/SNAP-Red substrate pair, to allow detection of hM2WT 
homomers and the 665/620 ratio was monitored over time (Figure 5.5). Carbachol (1 mM) 
produced an increase in the hM2WT homomeric profile of the receptor with a t1/2 =12.2 ± 
0.8 minutes (Table 5.2). The combination of carbachol (1 mM) and CNO (100 μM) also 
led to an increase in hM2WT homomerisation (Figure 5.5.A). The kinetics of this change 
were also relatively slow with a t1/2 =22.0 ±7.0 minutes (Table 5.2), suggesting that the 
change might not be due to a conformational change, but  rather due to recruitment of 
partners, or due to potential receptor internalisation. The fluorescence at 620 nm was also 
monitored, upon ligand addition, using cells labelled only with SNAP-Lumi 4 Tb. 
Treatment with carbachol demonstrated a trend towards a decrease in the 620 nm, 
suggesting a limited decrease in the cell surface population of the labelled VSV-SNAP-
hM2WT, potentially due to internalisation (Figure 5.5 B). The potent increase in the 
hM2WT homomer formation caused by carbachol was also found to be concentration 
dependent with pEC50= 5.20 ± 0.08. The agonist-mediated effect was inhibited by 
incubation at 4˚C (Figure 5.5 C).  
 
 
Oligomer affected 
t1/2 (minutes) 
(1mM Cch) 
t1/2 (minutes) 
 (Cch +CNO) 
 
hM2WT/hM3RASSL 
in cells co-expressing both 
receptors 
 
5.6 ± 3.2 
 
14.0 ± 3.8 
 
hM2WT/hM2WT 
in cells co-expressing both 
receptors 
 
10.5 ± 2.5 
 
24.5 ± 4.5 
 
hM2WT/hM2WT  
in cells expressing hM2WT 
 
12.2 ± 0.8 
 
22.0 ± 7.0 
 
Table 5.2 Half time analysis of the kinetic htrFRET data. The half times (t1/2) of 
agonists were calculated in order to measure the time required for each treatment to reduce 
the hM2WT/hM3RASSL heteromeric population to half its initial value or to double 
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hM2WT homomers in cells that co-express the receptors and in cells that only express the 
VSV-SNAP-hM2WT. The t1/2 values were obtained from one phase decay analysis of 
kinetic htrFRET data. Data presented as Mean ± SEM, n=3.  
 
Despite the changes observed in the hM2WT/hM3RASSL heteromer and hM2WT homomer 
formation, there was no change observed within the hM3RASSL homomers in response to 
ligands. In order to rule out the possibility of inefficient CLIP labelling (compared to the 
SNAP labelling) and any other interference originating from the cell line used, a different 
cell line was employed to assess ligand regulation of hM3RASSL homomerisation (Figure 
5.6). A cell line able to express VSV-SNAP-hM3RASSL, in a doxycycline dependent 
manner (Figure 5.6 A) was used. Cells expressing the receptor were labelled with SNAP-
Lumi4 Tb/SNAP-Red and homomers of VSV-SNAP-hM3RASSL were detected at the 
surface of live cells (Figure 5.6 B).  The synthetic ligand CNO was added but there were 
no significant changes detected in the hM3RASSL homomer formation in kinetic htrFRET 
experiments (Figures 5.6 C and D). In conclusion, the hM3RASSL homomer detected 
either using CLIP or SNAP tag labelling, in both cell lines used, remained unaffected by 
ligand mediated activation. Neither the increase in hM2WT homomerisation nor the 
simultaneous decrease in the heteromers, when the two receptors were co-expressed, 
affected the profile and stability of hM3RASSL homomers.  
 
5.3 Multiplex labelling htrFRET confirms oligomerisation regulation mediated by 
carbachol and shows an effect of CNO on hM3 homomeric arrangement. 
The dynamics of oligomerisation is a term used to describe the formation of oligomers and 
dissociation into monomers, a process that is of great interest.  The approach described in 
this section was intended to investigate the dynamics of oligomerisation between hM2WT 
and hM3RASSL receptors, using an agonist-mediated activation of receptors, in 
combination with the simultaneous measurement of htrFRET signal at two distinct 
wavelengths. The cell line able to express both receptors was treated with doxycycline to 
allow co-expression of VSV-SNAP-hM2WT with the constitutively expressed HA-CLIP-
hM3RASSL at the surface of live cells. The receptors were labelled with one donor (Lumi4 
Tb) and two different acceptors (green and red). The two different acceptors once excited, 
emitted at distinguishable wavelengths with the green emitting at 520 nm and the red at 
Chapter 5                                                                                                                                  
 
 
165 
 
665 nm (see diagram in Figure 4.1 B and Figure 5.7). This method allowed for the 
simultaneous detection of changes in two different sets of oligomeric arrangements i.e. 
heteromers and homomers, by utilising three different substrates to label a cell population. 
By using SNAP-Lumi4 Tb as donor and CLIP-Red with SNAP-Green as acceptors the 
changes in VSV-SNAP-hM2WT/HA-CLIP-hM3RASSL heteromers and VSV-SNAP- 
hM2WT homomers were detected, respectively. Replacing the SNAP-Lumi4 Tb donor 
with CLIP-Lumi4 Tb while maintaining the same acceptors, CLIP-Red and SNAP-Green, 
allowed for changes in HA-CLIP-hM3RASSL homomers and hM2WT/hM3RASSL 
heteromers to be detected, respectively (Figure 5.7). 
Cells labelled with 5 nM SNAP-Lumi4 Tb/ 100 nM CLIP-Red / 100 nM SNAP-Green 
were subjected to ligand treatments for 40 minutes. Two measurements were taken, one at 
time 0 minute (prior to ligand addition) and one at 40 minutes (post ligand treatment). The 
665/620 and 520/620 ratios, indicative of hM2WT/hM3RASSL heteromers and hM2WT 
homomers, respectively, were calculated at both time points, for each treatment and 
statistics were performed to determine whether changes observed were significant. The P 
values were obtained by carrying out a two paired t-test comparing the ratio at time 0 
minutes (untreated) versus time at 40 minutes (treated), for n=3 with each experiment 
carried out in triplicates. 
The donor/acceptor ratio at time 0 min of each treated cell population was compared to the 
donor/acceptor ratio at time 40 minutes of the same treated cell set and a two tailed, paired 
t-test was performed for each set. The decrease in 665/620 ratio, corresponded to a 
significant reduction (P= 0.04) in the hM2WT/hM3RASSL heteromeric arrangement, in 
response to 1 mM carbachol (Figure 5.8 A). A significant increase in the 520/620 ratio (P< 
0.0001) corresponded to an increase in the hM2WT homomers, in response to carbachol. A 
significant decrease (P= 0.006) in the formation of hM2WT homomers was also detected in 
response to 100 μM CNO, a change that was not previously observed in the dual labelling 
kinetic htrFRET experiments.  
In a similar set of experiments the SNAP-Lumi4 Tb donor was replaced with 10 nM CLIP-
Lumi4 Tb. The donor/acceptor ratio of 665/620 allowed the detection of an increase in the 
hM3RASSL homomeric arrangement (P= 0.03), in response to the synthetic ligand CNO 
(Figure 5.9 A). This increase was only observed in cells that were not treated with 
doxycycline, thus in the absence of hM2WT receptor and therefore in the absence of 
heteromers (Figure 5.9 A). There was no effect detected due to CNO- mediated activation 
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of hM3RASSL, in the presence of hM2WT (Figure 5.9 B). The changes in the 
hM2WT/hM3RASSL heteromeric arrangement, when CLIP-Lumi4 Tb was used as donor 
were monitored by measuring the 520/620 ratio, in the presence of both receptors. The 
heteromeric organisation was significantly reduced (P= 0.0001) in response to 1 mM 
carbachol as shown in Figure 5.9 C.  
 
 5.4 Internalisation of receptors in response to agonists 
The decrease in the heteromeric arrangement between hM2WT/hM3RASSL and the 
simultaneous increase in the hM2WT homomerisation, in response to carbachol, along with 
the relatively slow kinetics of those changes, had led to the hypothesis that receptor 
internalisation might be playing a role in ligand-mediated oligomerisation. In addition, 
htrFRET experiments performed at 4˚C, which should inhibit receptor internalisation, 
blocked the ligand mediated changes in both homomers and heteromers (see Figure 5.4 A 
and B), suggesting receptor internalisation might be implicated in this process. 
To explore receptor internalisation, the cell line co-expressing both the receptors was 
employed in epi-fluorescence imaging experiments. Cells were grown on cover-slips and 
were either treated or not with doxycycline. Cells were then co-labelled with cell 
impermeable fluorescent dyes and internalisation was monitored over a 40 minute period, 
in the presence of a set concentration of the ligands/treatments. The labelling was 
performed at least 16 hours post doxycycline induction by co-incubating the cells with 5 
μM of each fluorescent dye, CLIP-Surface 488 (green) and SNAP-Surface 549 (red) for 30 
minutes. Cells without pre-treatment with doxycycline were only labelled with CLIP-
Surface 488, to label the constitutively expressed HA-CLIP-hM3RASSL.  
Carbachol did not have any effect on the hM3RASSL receptor (green), but seemingly led 
to hM2WT (Red) internalisation (Figure 5.10). When the two channels were merged, the 
co-localisation of the two receptors was observed at the cell surface before the addition of 
ligand (with a calculated Pearson’s correlation co-efficient r2= 0.815, derived from scatter 
plot) and then co-localisation was lost as hM2WT was internalised due to carbachol-
mediated activation. The Pearson’s correlation coefficient calculated at 40 minutes was 
decreased to r2= 0.533.  
Addition of 100 μM CNO did not lead to either hM3RASSL or hM2WT receptor 
internalisation (Figure 5.11) with both the receptors remaining at the cell surface. 
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Similarly, addition of vehicle (HBSS containing 0.33% DMSO to maintain consistency) 
demonstrated the lack of internalisation for both receptors (Figure 5.12). In an attempt to 
study hM3RASSL internalisation, in the absence of hM2WT, cells not treated with 
doxycycline were used.  In those cells neither addition of CNO nor carbachol showed any 
signs of receptor internalisation (Figure 5.13).  
An alternative approach to assess the extent of receptor internalisation, in response to 
ligand treatment in live cells, involved the combination of SNAP/CLIP-Lumi4 Tb labelling 
of the receptors and the Tag-lite® internalisation buffer containing the ligand treatments. 
The internalisation buffer possesses spectral properties (able to emit at 520 nm upon 
excitation at 490 nm) compatible with the Lumi4 Tb donors and can be used as an energy 
acceptor for the internalisation FRET assay. Cells inducibly expressing the VSV-SNAP-
hM2WT and the HA-CLIP-hM3RASSL in a constitutive manner were labelled with SNAP-
Lumi4 Tb or CLIP-Lumi4 Tb for an hour, prior to application of the ligand treatments. The 
FRET signal between the Lumi4 Tb and internalisation buffer was monitored. The ratio 
was calculated as (donor/acceptor channel) x 104 with any changes observed in the 
620/520 ratio corresponded to changes in receptor internalisation. The percentage of 
maximal internalisation was calculated. 
Internalisation of VSV-SNAP-hM2WT was mediated upon stimulation with 1 mM 
carbachol and also when 1mM carbachol was co-added with 100 μM CNO, in cells 
expressing both receptors. Vehicle and addition of 10 μM atropine did not result in 
receptor internalisation, as expected (Figure 5.14 A). In another set of cells, not treated 
with doxycycline, thus expressing only the constitutive HA-CLIP-hM3RASSL, 
internalisation was observed in response to 100 μM CNO, but also when CNO was used in 
combination with 1 mM carbachol. The HA-CLIP-hM3RASSL demonstrated some level of 
internalisation in the absence of ligands, and in the presence of the antagonist atropine 
(Figure 5.14 B). This could probably correspond to the basal signal or it could be 
originating from constitutive receptor internalisation. In cells expressing both receptors, 
HA-CLIP-hM3RASSL internalised upon CNO stimulation, but when CNO was co-added 
with carbachol, the internalisation level dropped to values close to basal (Figure 5.14 C).  
The contradicting results concerning hM3RASSL internalisation between epi-fluorescence 
microscopy and Tag-lite® internalisation approaches were probably due to the difference 
in sensitivity between the two methods. The Tag-lite® internalisation is a more sensitive 
technique, allowing detection of changes more efficiently than epi-fluorescence 
Chapter 5                                                                                                                                  
 
 
168 
 
microscopy. The more efficient labelling of the receptors with the Lumi4 Tb substrates, 
using relative high concentrations reaching 100 nM for SNAP-Lumi4 Tb and 200 nM for 
CLIP-Lumi4 Tb (20 fold more than those used in the rest of htrFRET experiments) also 
contributed to the sensitivity of the internalisation assay compared to the epi-fluorescence 
microscopy. 
5.5 Discussion 
The key points of this chapter include the observation of the agonist mediated changes in 
oligomerisation organisation of the receptors demonstrated by dual and triple labelling 
kinetic htrFRET approaches. The decrease in the hM2WT/hM3RASSL heteromer and the 
simultaneous increase in the hM2WT homomer, leaving the hM3RASSL homomer 
unaffected, in response to the agonist carbachol, were detected using both the dual and 
triple labelling htrFRET. In cells inducibly expressing the VSV-SNAP-hM2WT receptor 
alone, a similar increase in homomer formation was detected, demonstrating similar 
kinetics, in response to carbachol. In order to rule out the possibility of inefficient CLIP-
labelling (compared to the very efficient SNAP labelling as suggested by Pou et al., 2010) 
that may be interfering with the detection of changes in the hM3RASSL homomerisation, a 
cell line expressing the VSV-SNAP-hM3RASSL receptor alone was employed for dual 
labelling with SNAP-specific substrates and subsequent kinetic htrFRET experiments. This 
had led to the suggestion that CNO did not affect the homomerisation of hM3RASSL. 
Surprisingly, when using the multiplex labelling approach, employing CLIP-Lumi4 Tb as 
an energy donor to study the simultaneous changes in the system, a significant increase in 
the hM3RASSL homomer was detected in response to CNO, in the absence of hM2WT. 
This increase in hM3RASSL homomers was not detected in the presence of 
hM2WT/hM3RASSL heteromers. Another novel observation offered by the multiplex 
labelling approach, using SNAP-Lumi4 Tb as an energy donor, involved the detection of 
an increase in the hM2WT homomer in response to CNO (Figure 5.8 B) that could be due 
to down-regulation of the heteromer organisation. A possible explanation for the more 
efficient detection of agonist mediated changes in oligomerisation, with multiplex 
labelling, could relate to the more efficient labelling of the receptors as more substrate was 
added to the receptors being studied, making the approach more sensitive in detecting 
those changes.  
Resonance energy transfer methods allow the detection of the real time interactions 
between donor and acceptor species and suggest possible receptor-receptor interactions 
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without being able to distinguish between dimers or higher order oligomers. The changes 
in the htrFRET signals or the ratios upon ligand treatment could be due to conformational 
changes within pre-existing oligomers, rather than alterations in the number of oligomers 
or due to formation of new oligomeric complexes or breaking of pre-existing ones. Those 
conformational rearrangements mediated by ligands could be modifying the distance 
between the donor and acceptor species, without rearranging the oligomeric complex as a 
whole. That could explain the increase in hM2WT homomers and the simultaneous 
decrease in the hM2WT/hM3RASSL heteromers, leaving the hM3RASSL unaffected. The 
CNO mediated stimulation of hM3RASSL may be modifying the distance between the 
donor/acceptor but not in an extent as to allow detection of changes in the homomer.  
The carbachol mediated heteromer decrease and the simultaneous hM2WT homomer 
increase were reversed upon incubation at 4˚C, suggesting possible involvement of 
receptor internalisation in the regulation of oligomerisation. The changes that were initially 
thought to be due to ligand-mediated actions could be a consequence of the hM2WT 
internalisation rather than hM2WT/hM3RASSL heteromer down-regulation. According to 
the epi-fluorescence microscopy based internalisation experiments the hM2WT receptor 
was readily internalised in response to carbachol treatment, leaving the hM3RASSL at the 
cell surface. The hM3RASSL demonstrated some degree of internalisation in response to 
CNO, detected by the Tag-lite® internalisation assay, possibly due to the higher sensitivity 
of the method compared to the low spatial resolution of light microscopy. These 
observations were in agreement with the suggestion by Zeng and Wess, (1999) that M2 
receptor undergoes agonist induced down-regulation to a higher extent than M3 and that 
M2 internalisation could be involved in the M2/M3 heteromer down-regulation (Zeng and 
Wess, 1999). The agonist mediated internalisation and down-regulation of hM2WT 
receptor has also been suggested previously (Tsuga et al., 1998; Schlador et al., 2000), 
whereas the hM3WT or hM3RASSL receptor did not demonstrate a great degree of 
internalisation upon agonist treatment (Alvarez-Curto et al., 2010).  
To assess the role of internalisation in regulating receptor oligomerisation, a whole set of 
experiments could be planned for future work. An example could include the use of 
receptors that have been modified in order to develop non-internalising mutants, and those 
could be then used in combination with the Tag-lite® technology and htrFRET method, in 
a similar manner described in this chapter. A receptor modified in such a way as to confer 
inability to internalise could be useful in studying the role of internalisation in oligomer 
formation.   Assessing the role of oligomerisation in trafficking and endoplasmic reticulum 
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(ER) export would also be advantageous in answering key questions on the receptor 
oligomerisation mechanism.  In addition, assessing the conformational modifications 
within the oligomeric structure could be useful by performing intramolecular FRET 
experiments that could detect possible changes in the intramolecular domains in response 
to receptor activation in a similar manner that was described in Alvarez-Curto et al., 
(2011). 
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Figure 5.1 Carbachol mediated decrease in hM2WT/hM3RASSL heteromers and a 
simultaneous increase in hM2WT homomers, by kinetic htrFRET.  Cells expressing 
the VSV-SNAP-hM2WT in a doxycycline inducible manner and the HA-CLIP-hM3RASSL 
constitutively, were treated with 5 ng∙ml-1 doxycycline for 24 hours and then subjected to 
co-labelling with (A) 10 nM CLIP-Lumi4 Tb and 125 nM SNAP-Red, and treated with a 
series of muscarinic ligands with the FRET ratio being monitored for 60 minutes. The 
heteromeric arrangement of VSV-SNAP-hM2WT/HA-CLIP-hM3RASSL was reduced in 
response to 1 mM carbachol and to the combination treatment of carbachol (1 mM) with 
CNO (100 μM). CNO alone did not have any effect on the heteromerisation nor did 
atropine and Vehicle (no ligand treatment; labelling medium containing 0.33% DMSO to 
maintain consistency). (B) Another set of doxycycline treated cells were co-labelled with 5 
nM SNAP-Lumi4 Tb and 100 nM SNAP-Red to allow detection of VSV-SNAP-hM2WT 
homomers. Treatment with 1 mM carbachol showed an increase in the homomer 
formation. The treatment combining both carbachol and CNO also resulted in an increase 
inVSV-SNAP-hM2WT homomers. (C) Cells co-expressing the receptors were co-labelled 
with 5 nM SNAP-Lumi4 and 100 nM CLIP-Red to allow detection of VSV-SNAP-
hM2WT/HA-CLIP-hM3RASSL heteromers. No significant changes in the kinetic htrFRET 
were detected upon ligand addition when using this donor/acceptor combination. Data in 
A, B and C are form a represenatative experiment carried out in triplicates. the experiment 
was repeated two more times but data could not be pooled together due to differences in 
620 fluorescence.  (D) Comparison between changes detected in VSV-SNAP-hM2WT/HA-
CLIP-hM3RASSL heteromer in response to 1 mM Cch, of cells labelled with SNAP-
Lumi4 Tb as donor and CLIP-Red as acceptor (pink bars) versus cells labelled with CLIP-
Lumi4 Tb as donor and SNAP-Red as acceptor (grey bars). The reduction in VSV-SNAP-
hM2WT/HA-CLIP-hM3RASSL heteromeric arrangement in response to 1 mM Cch was 
statistically significant (** P= 0.0013) when CLIP-Lumi4 Tb was used as donor and that 
was the reason for the choice of this donor/acceptor combination for the kinetic htrFRET 
experiments. P values were calculated by performing a two paired t-test, comparing the 
ratio at time 0 minutes(untreated) to time 40 minutes(treated), for n=3 (each experiment 
was carried out in triplicates). 
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Figure 5.2 hM3RASSL homomeric organisation is not affected by ligands either in the 
presence or absence of heteromers or hM2WT homomers. (A) Cells either not treated 
with doxycycline or (B) treated with 5 ng∙ml-1 doxycycline were labelled with 10 nM 
CLIP-Lumi4 Tb and 100 nM CLIP-Red to assess any changes within the HA-CLIP-
hM3RASSL homomers, upon addition of ligands. There was not a significant change 
observed in the 665/620 ratio, in response to any of the ligands added. There was a overall 
decline in the 665/620 ratio, that probably corresponds to the decrease in the 665 nm signal 
due to photo-bleaching.  
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Figure 5.3 Effects of carbachol on oligomerisation are concentration dependent. 
Experiments involving addition of carbachol dose response concentrations were performed 
using cells treated with 5 ng∙ml-1 doxycycline to allow co-expression of both VSV-SNAP-
hM2WT with the constitutively expressed HA-CLIP-hM3RASSL.  Measurements carried 
out twice, one at 0 minutes- before drug addition and one at 40 minutes-after drug addition. 
(A) The reduction in hM2WT/hM3RASSL heteromer in response to increasing 
concentrations of carbachol after 40 minutes treatment of cells co-labelled with 10 nM 
CLIP-Lumi4 Tb and  125 nM SNAP-Red led to an estimation of  pIC50= 5.3± 0.3. (B) 
Increase in the hM2WT homomeric arrangement using cells co-labelled with 5 nM SNAP-
Lumi4 Tb and 100 nM SNAP-Red, with calculated pEC50= 5.5± 0.2. (Mean +/- SEM, n=4 
for all treatments and n=2 for the treatments at 4˚C, experiments carried out in triplicate 
wells). The carbachol mediated effects were reversed when ligand treatments were carried 
out at 4˚C (open triangles). Co-incubation of carbachol with the muscarinic antagonist 
atropine reversed the increase in hM2WT homomers.  
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Figure 5.4 Monitoring cell surface receptor population upon ligand treatments. (A) 
Cells treated with 5 ng∙ml-1 doxycycline to express both receptors were labelled with 10 
nM SNAP-Lumi4 Tb and were then treated with ligands. A non- significant (P>0.05) trend 
towards a reduction in 620 nm fluorescence, corresponding to hM2WT receptors was 
detected in response to carbachol. (B) Cells not treated with doxycycline and thus, 
expressing only the constitutive hM3RASSL were labelled with 20 nM CLIP-Lumi4 Tb. 
Ligand treatments did not affect 620 nm signal. (C) Cells treated with 5 ng∙ml-1 
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doxycycline to express both receptors were labelled with 20 nM CLIP-Lumi4 Tb. No 
change in the 620 nm signal was detected upon ligand treatments.  
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Figure 5.5 Ligand regulation of hM2WT homomers in the absence of hM3RASSL. 
Cells expressing VSV-SNAP-hM2WT receptor alone upon doxycycline induction were 
used to assess the regulation of hM2WT homomerisation in the absence of heteromers (A) 
Cells co-labelled with 5 nM SNAP-Lumi4 Tb and 100 nM SNAP-Red were employed in a 
kinetic htrFRET assay.  There was an increase in homomeric profile in response to 
carbachol and in response to combination treatment of carbachol and CNO, with similar 
kinetics, while CNO alone had no effect on hM2WT homomerisation. (B) Monitoring the 
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620 nm fluorescence after labelling of cells with 10 nM SNAP-Lumi4 Tb detected a trend 
towards a decrease in the cell surface hM2WT population. (C)  Cells co-labelled with 5 nM 
SNAP-Lumi4 Tb and 100 nM SNAP-Red demonstrated an increase in the homomerisation 
of VSV-SNAP-hM2WT in response to carbachol which was concentration dependent 
(pEC50= 5.28 ± 0.08) (Mean +/- SEM, n=4 for all treatments and Mean +/- Range, n=2 for 
treatments at 4˚C), and was completely abolished by incubation at 4˚C. 
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Figure 5.6 Assessing VSV-SNAP-hM3RASSL receptor homomerisation. In order to 
assess the possible effect of the SNAP or CLIP tags on receptor oligomerisation a cell line 
was used able of expressing VSV-SNAP-hM3RASSL after doxycycline induction. (A) 
Labelling of live cells stably expressing VSV-SNAP-hM3RASSLdemonstrated an increase 
in receptor expression at the cell surface with increasing doxycycline concentrations. (B) 
Detection of VSV-SNAP-hM3RASSL homomers at the cell surface of live cells following 
co-labelling with 5 nM SNAP-Lumi4 Tb and varying concentrations of SNAP-Red was in 
agreement with the existence of HA-CLIP-hM3RASSL homomers. (C) The kinetic 
htrFRET showed no significant change in the homomerisation of the SNAP-tagged 
receptor, which is similar to that seen with the CLIP-tagged receptor. (D) No effect was 
detected following addition of increasing concentrations of CNO while monitoring the 
665/620 ratio at set time points of 0 and 40 minutes. 
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Figure 5.7 Schematic representation of multiplex (triple) labelling approach to detect 
simultaneous changes in receptor oligomerisation. This method utilises labelling of live 
cells with three different substrates, one donor (Lumi4 Tb) and two acceptor species (green 
and red). Lumi4 Tb donor emits at four different wavelengths, upon excitation at 337 nm. 
Emission at 490 nm excites the green acceptors which in turns emit at 520 nm. Emission at 
620 nm excites the red acceptors that subsequently emit at 665 nm. The multiplex labelling 
was followed using (A) CLIP-Lumi4 Tb as a donor in combination with CLIP-Red and 
SNAP-Green acceptors to detect simultaneous changes in M3/M3 homomeric and M2/M3 
heteromeric arrangements, respectively. (B) SNAP-Lumi4 Tb as donor with SNAP-Green 
and CLIP-Red acceptors to detect M2/M2 homomers and M2/M3 heteromers, respectively.  
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Figure 5.8 Triple labelling with SNAP-Lumi4 Tb as donor. Cells treated with 
doxycycline to enable co-expression of both VSV-SNAP-hM2WT and HA-CLIP-
hM3RASSL receptors were labelled with three substrates; SNAP-Lumi4 Tb as donor and 
SNAP-Green and CLIP-Red as acceptors. Treatments with ligands were carried out for 40 
minutes and the signal originating from the red emitting acceptor (A) was monitored at 665 
nm, with the 665/620 ratio showing a decrease in the heteromer formation in response to 1 
mM carbachol (* P= 0.04 ). (B) The signal from the green emitting acceptor was read at 
520 nm and the 520/620 ratio was increased in response to 1 mM carbachol (*** 
P<0.0001), corresponding to an increase in the hM2WT homomers, with a simultaneous 
decrease upon treatment with CNO (** P=0.006) suggesting a decrease in the homomeric 
arrangement of hM2WT when the co-expressed hM3RASSL was stimulated. (Mean +/- 
SEM, n=3, all experiments were carried out in triplicate points). 
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C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 Triple labelling with CLIP-Lumi4 Tb as donor. Cells able of expressing 
both the receptors were either treated or not with doxycycline and were then labelled with 
three different substrates with CLIP-Lumi4 Tb acting as energy donor and SNAP-Green 
and CLIP-Red as acceptors. (A) Cells not treated with doxycycline, thus only expressing 
the constitutive HA-CLIP-hM3RASSL, were labelled with the three substrates and then 
treated with ligands for 40 minutes with the signal at 665 nm being monitored. The 
treatment with CNO resulted in a significant increase in the hM3RASSL homomeric 
arrangement (* P= 0.03). (B) Cells treated with 5 ng∙ml-1 doxycycline, thus in the presence 
of VSV-SNAP-hM2WT/HA-CLIP-hM3RASSL heteromers did not demonstrate any 
changes in hM3RASSL homomeric arrangement.  (C) The simultaneous monitoring of 520 
nm fluorescence originating from the green acceptor, using cells treated with doxycycline 
demonstrated a decrease in the heteromeric profile of the receptors in response to 
carbachol (** P=  0.0001). P values were calculated by performing a two-paired t-test, 
comparing the ratios obtained from vehicle treated cells versus drug treated cells, 40 
minutes after treatments. (Mean +/- SEM, n=3, all experiments were carried out in 
triplicate wells).  
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Figure 5.10 VSV-SNAP-hM2WT receptor internalised in response to carbachol as 
detected by epi-fluorescence imaging. Live cells were plated on glass cover slips and 
treated with 5 ng∙ml-1 doxycycline for at least 16 hours, thus able to express both the 
receptors, VSV-SNAP-hM2WT and HA-CLIP-hM3RASSL. Cells were co-labelled with 
cell impermeant fluorescent dyes, CLIP-Surface 488 and SNAP-Surface 549. Cells were 
then treated with 1 mM carbachol and images were captured to detect internalisation of the 
receptors. The green labelled hM3RASSL did not show any internalisation, in response to 
carbachol, but the red labelled hM2WT internalised upon stimulation with the agonist 
carbachol. Merging of the images allowed the detection of co-localisation of the two 
receptors that was lost upon stimulation and internalisation of hM2WT. The Pearson’s 
correlation coefficient was calculated from the scatter plots, demonstrating the initial co-
localisation of the two differentially tagged receptors (r2= 0.815) prior to treatment with the 
agonist and loss of co-localisation due to internalisation after 40 minutes of agonist 
treatment (r2= 0.533).   
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Figure 5.11 CNO does not mediate receptor internalisation. Live cells were plated on 
cover slips and treated with 5 ng∙ml-1 doxycycline for at least 16 hours, to allow co-
expression of both receptors. Cells were then co-labelled with cell impermeant fluorescent 
dyes, CLIP-Surface 488 and SNAP-Surface 549. Treatments with 100 μM CNO followed 
and images were captured at several time points to detect potential receptor internalisation. 
The green fluorescing hM3RASL did not internalise upon stimulation with the synthetic 
ligand CNO, although it seemed that intensity was lost, possibly due to photo-bleaching. 
The red fluorescing hM2WT receptor did not internalise upon addition of CNO.  
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Figure 5.12 Epi-fluorescence microscopy using Vehicle as a control for internalisation 
experiments.  Live cells were plated on cover slips and treated with 5 ng∙ml-1 doxycycline 
for at least 16 hours, to allow co-expression of both receptors. Cells were then co-labelled 
with cell impermeable fluorescent dyes, CLIP-Surface 488 and SNAP-Surface 549, and 
were treated with HBSS (with 0.33% DMSO to maintain the consistency between 
treatments) acting as a vehicle for the assay. Addition of vehicle did not demonstrate any 
constitutive internalisation of either receptor.  
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Figure 5.13 HA-CLIP-hM3RASSL receptor does not internalise. Live cells were plated 
on cover slips, and were grown in the absence of doxycycline therefore cells were only 
constitutively expressing the HA-CLIP-hM3RASSL receptor. Cells were labelled with 
CLIP-Surface 488 and images were captured prior and post treatments with either CNO or 
carbachol. The constitutively expressed HA-CLIP-hM3RASSL did not demonstrate 
internalisation in response to either of the agonists.  
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Figure 5.14 Tag-lite® internalisation assay to assess ligand-mediated receptor 
internalisation. (A) Cells treated with 5 ng∙ml-1 doxycycline to induce expression of both 
VSV-SNAP-hM2WT and HA-CLIP-hM3RASSL, were labelled with 100 nM SNAP-
Lumi4 Tb and subsequently incubated with a mixture of Tag-lite® internalisation buffer 
and each of the ligand treatments. Fluorescence was monitored for up to 60 minutes. 
Carbachol and the combination of carbachol with CNO treatment promoted hM2WT 
receptor internalisation which increased with time. (B) Cells not treated with doxycycline, 
able to express only the HA-CLIP-hM3RASSL in a constitutive manner, were labelled with 
200 nM CLIP-Lumi4 Tb and subsequently incubated with a mixture of Tag-lite® 
internalisation buffer with each of the treatments. CNO and the combination of CNO with 
carbachol treatment led to hM3RASSL internalisation. (C) Cells expressing both the 
receptors were labelled with 200 nM CLIP-Lumi4 Tb and were then subjected to 
treatments. Internalisation of hM3RASSL was detected in response to CNO, but not in 
response to the combination of CNO with carbachol. (Data shown as % of maximum 
internalisation, Mean ± Range, n=2). 
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6. Discussion 
The work presented in the context of this thesis confirms the previously demonstrated 
formation of homomers and heteromers between muscarinic receptor subtypes, in this case 
M2 and M3, at the surface of intact cells. A genetically engineered version of the human M3 
(HA-CLIP-hM3RASSL) that was unable to bind and to respond to the endogenous 
muscarinic ligand acetylcholine or chemical analogues (i.e. carbachol) was used in 
combination with a form of the wild type human M2 (VSV-SNAP-hM2WT) to describe the 
receptor-receptor interactions, either homomeric or heteromeric, by htrFRET in 
combination with SNAP/CLIP tagging technology. The existence of oligomeric complexes 
was also confirmed by biochemical methods, such as Blue Native-PAGE and co-
immunoprecipitation, using antibodies specific for the epitope VSV- and HA- tags that 
were fused at the N-termini of the receptors.  
The most original finding here was the observation of ligand-induced alterations in the 
oligomeric profile of the receptors. Namely, upon VSV-SNAP-M2WT specific stimulation 
with carbachol, pre-existing VSV-SNAP-hM2WT/HA-CLIP-hM3RASSL heteromeric 
organisation was reduced. At the same time, an increase in VSV-SNAP-hM2WT 
homomeric profile was detected. These changes were ligand concentration-dependent and 
consistent with the extent of ligand occupancy of the receptor. Selective activation of HA-
CLIP-hM3RASSL with the synthetic ligand CNO did not result in significant changes in 
the oligomeric profile of either receptor homomers or heteromers. An alternative approach 
included triple labelling of the receptors i.e. one energy donor and two energy acceptors 
emitting at distinct wavelengths, provided interesting insight into the dynamics of 
interchange between homomers and heteromers upon ligand-mediated receptor 
stimulation. Ligand addition switched the balance from M2/M3 heteromers to M2/M2 
homomers, but has left the M3/M3 homomers largely unaffected. Dissociation of the 
heteromers may have enhanced formation of M2/M2 oligomerisation and M2 internalisation 
upon carbachol treatment. The inability to observe any changes in the M3 homomeric 
arrangement could be due to the fact that M3 receptors dissociating from the relatively 
transient heteromeric interaction remained at the plasma membrane and possibly interacted 
with other cellular components. It is known that the M3 is able of forming tetramers that 
exist in a rhomboidal arrangement at the cell surface (Patowary et al., 2013) and it could be 
that this is a more stable complex than the M2/M3 heteromeric arrangement.  
According to the data obtained it may be proposed that ligand-mediated changes in the 
oligomeric profiles of the mAChRs favour heteromer-to-homomer transitions and this may 
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in general be a feature of homomers vs heteromers. Ligand-induced conformational 
changes in the muscarinic receptor M2 activation possibly result in a more stable M2/M2 
homomer that readily internalises. The dynamics of interchange between homomers and 
heteromers as observed by utilising a multiplex labelling approach and htrFRET detection 
of the oligomeric changes was helpful in confirming the simultaneous ligand-induced 
effects on oligomerisation. However, this approach was not sufficient to quantify the 
percentage of monomers/dimers/higher order oligomers in the system or to determine the 
exact arrangement of each oligomeric complex (dimer, tetramer or higher order oligomer), 
due to the limitations of RET-based techniques. In addition, there is still a need to resolve 
whether heteromers formed between M2 and M3 consist of heteromers of homodimers or 
other combinations of the receptors.  
It is generally appreciated that identifying a consensus dimer interface or a common 
mechanism for dimer/oligomer formation could support the biological and functional 
relevance of GPCR oligomerisation (Lambert and Javitch, 2014). This seems to be very 
difficult given the diversity of observations in the field. Alternatively, it could be possible 
that different GPCRs act differently and that there is no consensus mechanism for 
oligomerisation. Investigation of oligomerisation could be focused on one GPCR type or a 
group of GPCRs. It is a possibility that every GPCR uses a unique mechanism, despite the 
obvious structural and functional similarities. It could as well be the case that every GPCR-
GPCR complex, either homomeric or heteromeric, is behaving in a self-defined manner, 
and it could be this variation that defines the divergence in GPCR oligomerisation 
implications in receptor’s functional and biological diversity, in a given cellular system or 
tissue/organ.  
A common theme of receptor oligomerisation is the diversity of functions and ligand 
specificities that oligomerisation provides. The physical interactions between receptors 
result in an enlarged surface area that can have beneficial effects on the rate of reactions 
and orientation of the binding site through conformational changes conferred upon the 
receptors that enable ligand binding or promote subsequent interactions with other cellular 
components (Klemm et al., 1998). Oligomerisation can result in altered signalling and 
pharmacology (Hiller et al., 2013). Understanding the pharmacology of 
dimerisation/oligomerisation may lead to the development of ligands capable of selective 
targeting of GPCR dimers, thus providing an alternative approach in the treatment of 
diseases or conditions where GPCR oligomerisation is implicated. Initial attempts have led 
to the identification of certain ligands that possess two pharmacophores (bivalent ligands) 
able to interact at the binding sites of a receptor dimer (Hiller et al., 2013). Development 
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and use of such ligands may provide new insight into the physiological importance of 
GPCR heteromerisation in vivo.  
The lack of selective ligands for each muscarinic receptor subtype is a substantial 
limitation when it comes to selective receptor activation. This reflects the highly conserved 
orthosteric binding site between muscarinic receptor subtypes and it makes it very difficult 
to pharmacologically differentiate between muscarinic receptor sub-types. The generation 
of RASSLs and DREADDs offers great advantages in overcoming this drawback. The use 
of a RASSL version of M3 receptor that can only be activated by the synthetic ligand, 
CNO, allowed the differential activation of the two receptors M2 and M3, when studying 
oligomerisation in a heterologous cellular system where both receptors were co-expressed.  
Data collected from functional assays, in an attempt to investigate the role of receptor 
oligomerisation in signalling, suggested that formation of heteromers between VSV-
SNAP-hM2WT and HA-CLIP-hM3RASSL did not affect the Gi/o coupling-mediated 
pathway or Gq/11 coupling-dependent signalling. Interestingly, there was a trend towards an 
increase in the efficacy of CNO (not statistically significant) in increasing the IP1 levels 
upon M3 stimulation, in the presence of heteromers, while at the same time the potency of 
the ligand remained unaffected. It could be explained as a result of receptor 
heteromerisation affecting the pharmacology of the protomers, or it could have resulted 
from signalling cross-talk that is independent of any physical interactions between the 
receptors. Signalling cross-talk between M2 and M3 receptors at the level of second 
messenger and ERK activation has been described previously. Hornigold et al., (2003), 
reported that co-activation of M2 and M3 receptor sub-types in CHO cells resulted in a 
synergistic activation of ERK and also in increased IP3 production compared to that seen in 
cells expressing only M3 receptor (Hornigold et al., 2003). 
The use of htrFRET and SNAP/CLIP technology offers several advantages in the study of 
GPCR oligomerisation. Firstly, there is no disruption of the natural environment where 
oligomerisation takes place. Secondly, it allows detection of oligomerisation with the 
simultaneous monitoring of ligand-induced regulation of oligomerisation. Finally, htrFRET 
offers high signal-to-noise ratio. One of the main disadvantages of the htrFRET approach 
used in this project involves the high cost of the SNAP/CLIP technology reagents.  In 
addition, the inability to estimate the exact size and composition of an oligomer is a 
limiting factor in the understanding of the oligomeric organisation of receptors. Another 
drawback involves the existence of ‘bystander’ FRET signal that originates from proteins 
that do not interact but still result in a FRET signal, which could be falsely interpreted as 
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real receptor-receptor interactions. An approach that can be used to confirm the 
dimerisation results obtained from an htrFRET based assay may involve the use of a 
negative oligomerisation control. Such a control could be a receptor that is known to be 
unable to form oligomeric complexes, existing in a monomeric form at the cell surface. 
Such a control could be used to determine bystander FRET signal and help distinguish real 
receptor -receptor interactions from random collisions. The cluster of differentiation 86 
(CD86) receptor, a protein that is expressed on the surface of T cells and is implicated in 
numerous autoimmune diseases (Chang et al., 2002) exists as a monomer (James et al., 
2007; Girard et al., 2014) and this observation has been further validated by dual-colour 
fluorescence recovery after photo-bleaching (FRAP) microscopy, in live cells (Dorsch et 
al., 2009). The tagging of the N-terminus of the CD86 receptor with SNAP tag has 
generated a fusion that was stably expressed in single stable Flp-In™ T-REx™-293 cells. 
Labelling of the expressed fusion at the surface of live cells with SNAP-Lumi4 Tb as 
donor and SNAP-Red as acceptor demonstrated the inability of CD86 receptor to 
dimerise/oligomerise. This observation suggests that the htrFRET signal originating from 
M2 labelled receptors corresponds to real receptor interactions rather than random 
collisions (Aslanoglou et al., 2015).   
The use of Flp-In™ T-REx™-293 cells as a heterologous expression system offered 
certain advantages. Firstly, it ensured the trafficking and localisation of the expressed 
functional receptors at the cell surface and secondly, it allowed the manipulation of 
receptor expression, i.e. VSV-SNAP-hM2W expression was induced by addition of 
doxycycline, while the HA-CLIP-hM3RASSL was constitutively expressed at the cell 
surface. Expression of HA-CLIP-hM3RASSL was unaffected by the presence or absence of 
doxycycline.  
Reversal of the tagging of receptors could be a useful strategy to confirm the results 
obtained. Namely, the generation of a double stable cell line expressing both the VSV-
SNAP-hM3RASSL and HA-CLIP-hM2WT receptors could be used in similar htrFRET 
experiments as future work.   
The role of internalisation can be further investigated, as there was evidence that suggested 
receptor internalisation followed the ligand-mediated regulation of oligomerisation. The 
dissociation of M2/M3 heteromers was followed by an increase in M2/M2 homomers that 
internalised shortly after carbachol treatment. Further questions that still remain 
unanswered include whether the htrFRET signal obtained from the internalised M2 
receptors was due to the receptors being internalised as homomers or due to the close 
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proximity of M2 protomers in endocytic vesicles. It has been suggested that the M2 
undergoes agonist-induced internalisation at a higher extent than M3 receptor, proposing 
that most of the M3 receptor population remains at the cell surface following ligand 
addition (Schlador et al., 2000). 
Experiments that would offer functional relevance of the M2/M3 heteromerisation in vivo 
could be advantageous in understanding the role of the heteromers in native tissues, organ 
or even whole organisms. M2 and M3 receptor sub-types are found in CNS and periphery, 
and they are co-expressed in smooth muscle cells (e.g. of the intestine and airway) with M3 
playing a direct role in smooth muscle contraction, while, M2 affects smooth muscle 
contraction in an indirect manner, possibly through inhibiting the action of relaxants 
(Eglen et al., 1996). The involvement of the two receptors in numerous disorders such as 
Alzheimer’s disease, schizophrenia and cognitive impairment, makes them ideal targets for 
therapeutics. The understanding of the heteromerisation mechanism between these two 
receptors may lead to the development of novel therapeutic compounds able of recognising 
and binding to the oligomeric arrangement of the two receptors, rather than to the 
individual protomers, thereby regulating the oligomer-related signalling and function.  
The work presented in this thesis could enhance the understanding in the field of ligand-
mediated regulation of muscarinic acetylcholine receptors and provide a starting point that 
could potentially lead to the future development of novel therapeutics for the treatment of 
conditions where muscarinic receptor oligomerisation might be implicated.  
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